<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2712200368
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TYKODAS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DASATINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        5219.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSN LABORATORIES PRIVATE LIMITED " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSN LABORATORIES PRIVATE LIMITED 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XE06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tykodas Tablets contains the active substance Tykodas. This medicine is used to treat chronic myeloid leukaemia (CML) in adults, adolescents and children at least 1 year of age. Leukaemia is a cancer of white blood cells. These white cells usually help the body to fight infection. In people with CML, white cells called granulocytes start growing out of control. Tykodas Tablets inhibits the growth of these leukaemic cells.</p><p>Tykodas Tablets is also used to treat Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) in adults, adolescents, and children at least 1 year of age, and lymphoid blast CML in adults who are not benefiting from prior therapies. In people with ALL, white cells called lymphocytes multiply too quickly and live too long. Tykodas Tablets inhibits the growth of these leukemic cells.</p><p>&nbsp;</p><p>If you have any questions about how Tykodas Tablets works or why this medicine has been</p><p>prescribed for you, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Tykodas Tablets</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to Tykodas or any of the other ingredients of this medicine (listed in section 6). If you could be allergic, ask your doctor for advice.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before using Tykodas Tablets</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking medicines to thin the blood or prevent clots (see &quot;Other medicines and Tykodas Tablets &quot;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a liver or heart problem, or used to have one</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you start having difficulty breathing, chest pain, or a cough when taking Tykodas Tablets: this may be a sign of fluid retention in the lungs or chest (which can be more common in patients aged 65 years and older), or due to changes in the blood vessels supplying the lungs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had or might now have a hepatitis B infection. This is because Tykodas Tablets could cause hepatitis B to become active again, which can be fatal in some cases. Patients will be carefully checked by their doctor for signs of this infection before treatment is started.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience bruising, bleeding, fever, fatigue and confusion when taking Tykodas Tablets, contact your doctor. This may be a sign of damage to blood vessels known as thrombotic microangiopathy (TMA).</p><p>Your doctor will regularly monitor your condition to check whether Tykodas Tablets is having the desired effect. You will also have blood tests regularly while you are taking Tykodas Tablets.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children younger than one year of age. There is limited experience with the use of Tykodas Tablets in this age group. Bone growth and development will be closely monitored in children taking Tykodas Tablets.</p><p>&nbsp;</p><p><strong>Other medicines and Tykodas Tablets</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>Tykodas Tablets is mainly handled by the liver. Certain medicines may interfere with the effect of Tykodas Tablets when taken together.</p><p>&nbsp;</p><p><strong>These medicines are not to be used with Tykodas Tablets:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ketoconazole, itraconazole - these are antifungal medicines</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erythromycin, clarithromycin, telithromycin - these are antibiotics</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ritonavir - this is an antiviral medicine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin, carbamazepine, phenobarbital - these are treatments for epilepsy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin - this is a treatment for tuberculosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; famotidine, omeprazole - these are medicines that block stomach acids</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s wort - a herbal preparation obtained without a prescription, used to treat depression and other conditions (also known as Hypericum perforatum)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take medicines that neutralize stomach acids (antacids such as aluminum hydroxide or magnesium hydroxide) in the 2 hours before or 2 hours after taking Tykodas Tablets.</p><p>&nbsp;</p><p>Tell your doctor if you are taking medicines to thin the blood or prevent clots.</p><p>&nbsp;</p><p><strong>Tykodas Tablets with food and drink</strong></p><p>Do not take Tykodas Tablets with grapefruit or grapefruit juice.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or think you may be pregnant, tell your doctor immediately. Tykodas Tablets is not to be used during pregnancy unless clearly necessary. Your doctor will discuss with you the potential risk of taking Tykodas Tablets during pregnancy.</p><p>Both men and women taking Tykodas Tablets will be advised to use effective contraception</p><p>during treatment.</p><p>If you are breast-feeding, tell your doctor. You should stop breast-feeding while you are taking Tykodas Tablets.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Take special care when driving or using machines in case you experience side effects such as dizziness and blurred vision.</p><p>&nbsp;</p><p><strong>Tykodas Tablets contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tykodas Tablets will only be prescribed to you by a doctor with experience in treating leukaemia. &nbsp;</p><p>&nbsp;</p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Tykodas Tablets is prescribed for adults and children at least 1 year of age.</p><p>&nbsp;</p><p>The starting dose recommended for adult patients with chronic phase CML is 100 mg once a day.</p><p>&nbsp;</p><p>The starting dose recommended for adult patients with accelerated or blast crisis CML or Ph+ ALL is 140 mg once a day.</p><p>Dosing for children with chronic phase CML or Ph+ ALL is on the basis of body weight.</p><p>&nbsp;</p><p>Tykodas Tablets is administered orally once daily in the form of either Tykodas Tablets or Tykodas Tablets powder for oral suspension. Tykodas Tablets are not recommended for patients weighing less than 10 kg. The powder for oral suspension should be used for patients weighing less than 10 kg and patients who cannot swallow tablets. A change in dose may occur when switching between formulations (i.e., tablets and powder for oral suspension), so you should not switch from one to the other.</p><p>&nbsp;</p><p>Your doctor will decide the right formulation and dose based on your weight, any side effects and response to treatment. The starting dose of Tykodas Tablets for children is calculated by body weight as shown below:</p><p>&nbsp;</p><p>Body Weight (kg)a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Daily Dose (mg)</p><p>10 to less than 20 kg &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;40 mg</p><p>20 to less than 30 kg &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;60 mg</p><p>30 to less than 45 kg &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;70 mg</p><p>at least 45 kg &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100 mg</p><p><sub>a </sub>The tablet is not recommended for patients weighing less than 10 kg; the powder for oral suspension should be used for these patients.</p><p>There is no dose recommendation for Tykodas Tablets with children under 1 year of age.</p><p>Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose, or even stopping treatment briefly. For higher or lower doses, you may need to take combinations of the different tablet strengths.</p><p>The tablets may come in packs with calendar blisters. These are blisters showing the days of the week. There are arrows to show the next tablet to be taken according to your treatment schedule.</p><p>&nbsp;</p><p><strong>How to take Tykodas Tablets</strong></p><p>Take your tablets at the same time every day. Swallow the tablets whole. Do not crush, cut or chew them. Do not take dispersed tablets. You cannot be sure you will receive the correct dose if you crush, cut, chew or disperse the tablets. Tykodas Tablets can be taken with or without a meal.</p><p>&nbsp;</p><p><strong>Special handling instructions for Tykodas Tablets</strong></p><p>It is unlikely that the Tykodas Tablets will get broken. But if they do, persons other than the patient should use gloves when handling Tykodas Tablets.</p><p>&nbsp;</p><p><strong>How long to take Tykodas Tablets</strong></p><p>Take Tykodas Tablets daily until your doctor tells you to stop. Make sure you take Tykodas</p><p>Tablets for as long as it is prescribed.</p><p>&nbsp;</p><p><strong>If you take more Tykodas Tablets than you should</strong></p><p>If you have accidentally taken too many tablets, talk to your doctor immediately. You may require medical attention.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take Tykodas Tablets</strong></p><p>Do not take a double dose to make up for a forgotten tablet. Take the next scheduled dose at the regular time.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following can all be signs of serious side effects:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have chest pain, difficulty breathing, coughing and fainting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience unexpected bleeding or bruising without having an injury</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you find blood in your vomit, stools or urine, or have black stools</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get signs of infections such as fever, severe chills</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get fever, sore mouth or throat, blistering or peeling of your skin and/or mucous membranes <strong>Contact your doctor immediately </strong>if you notice any of the above.</p><p>&nbsp;</p><p><strong>Very common side effects (may affect more than 1 in 10 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections (including bacterial, viral and fungal)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart and lungs: shortness of breath</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digestive problems: diarrhoea, feeling or being sick (nausea, vomiting)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin, hair, eye, general: skin rash, fever, swelling around the face, hands and feet, headache, feeling tired or weak, bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain: pain in the muscles (during or after discontinuing treatment), tummy (abdominal) pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tests may show: low blood platelet count, low white blood cells count (neutropaenia), anaemia, fluid around the lungs</p><p>&nbsp;</p><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections: pneumonia, herpes virus infection (including cytomegalovirus - CMV), upper respiratory tract infection, serious infection of the blood or tissues (including uncommon cases with fatal outcomes)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart and lungs: palpitations, irregular heartbeat, congestive heart failure, weak heart muscle, high blood pressure, increased blood pressure in the lungs, cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digestive problems: appetite disturbances, taste disturbance, bloated or distended tummy(abdomen), inflammation of the colon, constipation, heartburn, mouth ulceration, weight increase, weight decrease, gastritis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin, hair, eye, general: skin tingling, itching, dry skin, acne, inflammation of the skin, persistent noise in ears, hair loss, excessive perspiration, visual disorder (including blurred vision and disturbed vision), dry eye, bruise, depression, insomnia, flushing, dizziness, contusion (bruising), anorexia, somnolence, generalised oedema</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain: pain in joints, muscular weakness, chest pain, pain around hands and feet, chills, stiffness in muscles and joints, muscle spasm</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tests may show: fluid around the heart, fluid in the lungs, arrhythmia, febrile neutropaenia, gastrointestinal bleeding, high uric acid levels in the blood</p><p>&nbsp;</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart and lungs: heart attack (including fatal outcome), inflammation of the lining (fibrous sack) surrounding the heart, irregular heartbeat, chest pain due to lack of blood supply to the heart (angina), low blood pressure, narrowing of airway that may cause breathing difficulties, asthma, increased blood pressure in the arteries (blood vessels) of the lungs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digestive problems: inflammation of the pancreas, peptic ulcer, inflammation of the food pipe, swollen tummy (abdomen), tear in the skin of the anal canal, difficulty in swallowing, inflammation of the gallbladder, blockage of bile ducts, gastro-oesophageal reflux (a condition where acid and other stomach contents come back up into the throat)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin, hair, eye, general: allergic reaction including tender, red lumps on the skin (erythema nodosum), anxiety, confusion, mood swings, lower sexual drive, fainting, tremor, inflammation of the eye which causes redness or pain, a skin disease characterized by tender, red, well-defined blotches with the sudden onset of fever and raised white blood cell count (neutrophilic dermatosis), loss of hearing, sensitivity to light, visual impairment, increased eye tearing, disturbance in skin colour, inflammation of fatty tissue under the skin, skin ulcer, blistering of the skin, nail disorder, hair disorder, hand-foot disorder, renal failure, urinary frequency, breast enlargement in men, menstrual disorder, general weakness and discomfort, low thyroid function, losing balance while walking, osteonecrosis (a disease of reduced blood flow to the bones, which can cause bone loss and bone death), arthritis, skin swelling anywhere in the body</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain: inflammation of vein which can cause redness, tenderness and swelling, inflammation of the tendon</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brain: loss of memory</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tests may show: abnormal blood test results and possibly impaired kidney function caused by the waste products of the dying tumour (tumour lysis syndrome), low levels of albumin in the blood, low levels of lymphocytes (a type of white blood cell) in the blood, high level of cholesterol in the blood, swollen lymph nodes, bleeding in the brain, irregularity of the electrical activity of the heart, enlarged heart, inflammation of the liver, protein in the urine, raised creatine phosphokinase (an enzyme mainly found in the heart, brain and skeletal muscles), raised troponin (an enzyme mainly found in the heart and skeletal muscles), raised gamma-glutamyltransferase (an enzyme mainly found in the liver)</p><p>&nbsp;</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart and lungs: enlargement of the right ventricle in the heart, inflammation of the heart muscle, collection of conditions resulting from blockage of blood supply to the heart muscle (acute coronary syndrome), cardiac arrest (stopping of blood flow from the heart), coronary (heart) artery disease, inflammation of the tissue covering the heart and lungs, blood clots, blood clots in the lungs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digestive problems: loss of vital nutrients such as protein from your digestive tract, bowel obstruction, anal fistula (an abnormal opening from the anus to the skin around the anus), impairment of kidney function, diabetes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin, hair, eye, general: convulsion, inflammation of the optic nerve that may cause a complete or partial loss of vision, blue-purple mottling of the skin, abnormally high thyroid function, inflammation of the thyroid gland, ataxia (a condition associated with lack of muscular coordination), difficulty walking, miscarriage, inflammation of the skin blood vessels, skin fibrosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brain: stroke, temporary episode of neurologic dysfunction caused by loss of blood flow, facial nerve paralysis, dementia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immune system: severe allergic reaction</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Musculoskeletal and connective tissue: delayed fusion of the rounded ends that form joints (epiphyses); slower or delayed growth</p><p>&nbsp;</p><p><strong>Other side effects that have been reported with frequency not known (cannot be estimated from</strong></p><p><strong>the available data)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the lungs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding in the stomach or bowels that can cause death</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrence (reactivation) of hepatitis B infection when you have had hepatitis B in the past (a liver infection)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A reaction with fever, blisters on the skin, and ulceration of the mucous membranes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disease of the kidneys with symptoms including oedema and abnormal laboratory test results such as protein in the urine and low protein level in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Damage to blood vessels known as thrombotic microangiopathy (TMA), including decreased red blood cell count, decreased platelets, and formation of blood clots</p><p>&nbsp;</p><p>Your doctor will check for some of these effects during your treatment.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]--></p><p>Do not store above 30<sup>0</sup>C. Keep out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the bottle label, blister or carton after EXP. The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]--></p><p><!--[if !supportLists]--></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is Dasatinib.</p><p>Each film coated tablet contains Tykodas --------- 50 mg/ 70mg/ 100mg</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p><u>Tablet core:</u></p><p>Microcrystalline Cellulose PH 101, Microcrystalline Cellulose PH 102, Lactose monohydrate, Hydroxypropyl Cellulose, Croscarmellose sodium, Magnesium Stearate and Purifed water.</p><p><u>Tablet coat:</u></p><p>Opadry white 03O18646 (HPMC 2910/Hypromellose, Titanium dioxide, Triethyl citrate.)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tykodas Tablets 50 mg
White to off white, oval, biconvex, film coated tablets debossed with “DAS” on one side and “50” on the other side.
Tykodas Tablets 70 mg
White to off white, round, biconvex, film coated tablets debossed with “DAS” on one side and “70” on the other side.
Tykodas Tablets 100 mg
White to off white, round, biconvex, film coated tablets debossed with “DAS” on one side and “100” on the other side.

Tykodas Tablets 50 mg or 70 mg or 100 mg are available in 10's Blister Pack
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MAH and Secondary packaging:</p><p>Boston Oncology Arabia</p><p>Sudair Industrial City,</p><p>Sudair, Saudi Arabia</p><p>&nbsp;</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Full Manufacturing and Primary Packaging:</p><p>MSN Laboratories Pharma Limite</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 07/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تحتوي أقراص <strong>تايكوداس</strong> على المادة الفعالة داساتينِب. يُستخدم هذا الدواء لمعالجة سرطان الدم النخاعي المزمن (CML) لدى البالغين، المراهقين والأطفال بعمر سنة واحدة على الأقل. سرطان الدم هو سرطان خلايا الدم البيضاء. هذه الخلايا البيضاء عادة ما تساعد الجسم على مكافحة العدوى. في الأشخاص الذين يعانون من (CML)، تبدأ الخلايا البيضاء المسماة المحببة في النمو خارج نطاق السيطرة. تمنع أقراص <strong>تايكوداس</strong> نمو خلايا السرطان هذه.</p><p dir="RTL">تُستخدم أقراص <strong>تايكوداس</strong> أيضاً لمعالجة كروموسوم فيلادلفيا الإيجابي (Ph<sup>+</sup>) سرطان الدم اللمفاوي الحاد (ALL) لدى البالغين، المراهقين والأطفال بعمر سنة واحدة على الأقل، والهجمة اللمفاوية (CML) لدى البالغين الذين لم يستفيدوا من المعالجات السابقة. في الأشخاص الذين يعانون من (ALL)، تسمى الخلايا البيضاء الخلايا اللمفاوية التي تتكاثر بسرعة كبيرة وتعيش لفترة طويلة. أقراص <strong>تايكوداس</strong> تمنع نمو خلايا السرطان هذه.</p><p dir="RTL">إذا كان لديك أية أسئلة حول كيفية عمل أقراص <strong>تايكوداس </strong>أو لماذا تم وصف هذا الدواء لك، اسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تأخذ أقراص تايكوداس</strong></p><p dir="RTL">- إذا كنت تعاني من حساسية تجاه <strong>تايكوداس </strong>أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">إذا كنت تعاني من الحساسية، اطلب مشورة طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل استخدام أقراص <strong>تايكوداس.</strong></p><p dir="RTL">- إذا كنت تأخذ أدوية لتمييع الدم أو لمنع الجلطات (انظر &quot;أدوية أخرى وأقراص <strong>تايكوداس</strong> &quot;).</p><p dir="RTL">- إذا كنت تعاني من مشكلة في الكبد أو القلب، أو حدث لك أحدها.</p><p dir="RTL">- إذا بدأت تواجه صعوبة في التنفس، ألم في الصدر، أو سعال عند تناول أقراص <strong>تايكوداس</strong>: قد يكون هذا علامة على احتباس السوائل في الرئتين أو الصدر (والتي قد تكون أكثر شيوعاً في المرضى بعمر 65 سنة أو أكبر)، أو بسبب التغيرات في الأوعية الدموية التي تزود الرئتين.</p><p dir="RTL">- إذا حصل معك سابقاً أو ربما حصل لديك الآن التهاب الكبد B. ذلك لأن أقراص <strong>تايكوداس</strong> قد تسبب تجدد نشاط التهاب الكبد B مرة أخرى، والذي قد يكون قاتلاً في بعض الحالات. سوف يتم فحص المرضى بعناية من قبل أطبائهم لمعرفة علامات هذه العدوى قبل بدء المعالجة.</p><p dir="RTL">- إذا واجهت كدمات، نزيف، حمى، إرهاق وارتباك عند تناول أقراص <strong>تايكوداس</strong>، اتصل بطبيبك. قد يكون هذا علامة على تلف الأوعية الدموية المعروف باسم اعتلال الأوعية الدموية الخثاري (TMA).</p><p dir="RTL">سيقوم طبيبك بمراقبة حالتك بانتظام لمعرفة ما إذا كانت أقراص <strong>تايكوداس</strong> تؤدي المفعول المطلوب. وعليك أن تُجري أيضاً فحوصات الدم بانتظام أثناء تناول أقراص <strong>تايكوداس</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا تعطي هذا الدواء للأطفال دون السنة الواحدة من العمر. ذلك لوجود خبرة محدودة حول استخدام أقراص <strong>تايكوداس</strong> لدى هذه الفئة من العمر. سيتم عن كثب مراقبة نمو العظام والتطور لدى الأطفال الذين يتناولون أقراص <strong>تايكوداس</strong>.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أدوية أخرى وأقراص تايكوداس</strong></p><p dir="RTL">أخبر طبيبك إذا كنت تتناول، أو قد تناولت مؤخراً أو قد تتناول أية أدوية أخرى.</p><p dir="RTL">تتم معالجة أقراص <strong>تايكوداس</strong> بشكل رئيسي من قبل الكبد. وقد تتداخل بعض الأدوية في تأثير أقراص <strong>تايكوداس</strong> عند تناولها معاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا ينبغي استخدام هذه الأدوية مع أقراص تايكوداس:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p dir="RTL">- كيتوكونازول، إتراكونازول - وهي أدوية مضادة للفطريات.</p><p dir="RTL">- إريثرومايسين، كلاريثرومايسين، تيليثرومايسين - وهي مضادات حيوية.</p><p dir="RTL">- ريتوناڤير - دواء مضاد للفيروسات</p><p dir="RTL">- فينيتوئين، كاربامازيبين، فينوباربيتال - أدوية معالجة الصرع</p><p dir="RTL">- ريفامبيسين - دواء لمعالجة مرض السل</p><p dir="RTL">- فاموتيدين، أوميبرازول - أدوية صادة لأحماض المعدة</p><p dir="RTL">- نبتة القديس جون - مستحضر عشبي يتم الحصول عليه بدون وصفة طبية، ويُستخدم لمعالجة الاكتئاب وغيره من الحالات (ويُعرف أيضاً باسم عشبة القديس يوحنا)</p><p dir="RTL">لا تأخذ الأدوية التي تُحيِّد أحماض المعدة (مضادات الحموضة مثل هايدروكسايد الألمنيوم أو هايدروكسايد المغنيسيوم) خلال ساعتين قبل أو بعد تناولك أقراص <strong>تايكوداس</strong>.</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أدوية لتمييع الدم أو لمنع الجلطات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أقراص تايكوداس مع الطعام والشراب</strong></p><p dir="RTL">لا تأخذ أقراص <strong>تايكوداس</strong> مع الجريب فروت أو عصير الجريب فروت.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو تظنينَ أنكِ قد تكونين حاملاً، أخبري طبيبك فوراً. لا ينبغي استخدام أقراص <strong>تايكوداس</strong> أثناء الحمل ما لم تستدع الضرورة ذلك. سيبحث طبيبكِ معكِ المخاطر المحتملة عند تناول أقراص <strong>تايكوداس </strong>أثناء الحمل.</p><p dir="RTL">سيٌنصح كلاً من الرجال والنساء الذين يتناولون أقراص <strong>تايكوداس </strong>باستخدام وسائل منع الحمل الفعالة أثناء المعالجة.</p><p dir="RTL">إذا كنت تُرضعينَ طفلكِ، أخبري طبيبكِ. يجب أن تتوقفي عن الرضاعة الطبيعية أثناء تناول أقراص <strong>تايكوداس</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يجب توخي الحذر عند القيادة أو استخدام الآلات في حال مواجهتك لتأثيرات جانبية مثل الدوخة وعدم وضوح الرؤية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحتوي أقراص تايكوداس على اللاكتوز</strong></p><p dir="RTL">إذا أخبرك طبيبك أن لديك حساسية مفرطة لبعض السكريات، تحدث إلى طبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ستوصف إليك أقراص <strong>تايكوداس </strong>فقط من قبل طبيب ذو خبرة في معالجة سرطان الدم.</p><p dir="RTL">تناول هذا الدواء دائماً كما أخبرك طبيبك تماماً. تحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد. تُوصف أقراص <strong>تايكوداس </strong>للبالغين والأطفال بعمر سنة واحدة على الأقل.</p><p dir="RTL">جرعة البداية الموصى بها للمرضى البالغين الذين يعانون من مرحلة مزمنة (CML) هي 100 ملغ مرة واحدة باليوم.</p><p dir="RTL">جرعة البداية الموصى بها للمرضى البالغين الذين يعانون من أزمــة متسارعة أو هبّـات (CML) أو (Ph<sup>+</sup> ALL) هي 140 ملغ مرة واحدة باليوم.</p><p dir="RTL">جرعات الأطفال الذين يعانون من مرحلة مزمنة (CML) أو (Ph<sup>+</sup> ALL) تعتمد على وزن الجسم.</p><p dir="RTL">تُعطى أقراص <strong>تايكوداس</strong> عن طريق الفم مرة واحدة باليوم إما بشكل أقراص <strong>تايكوداس</strong> أو بشكل مسحوق لأجل شراب معلَّق عن طريق الفم. لا يُنصح بإعطاء أقراص <strong>تايكوداس</strong> للمرضى الذين يقل وزنهم عن 10 كغ. يجب استخدام مسحوق الشراب المعلَّق عن طريق الفم للمرضى الذين هم بوزن أقل من 10 كغ وللمرضى الذين لا يستطيعون ابتلاع الأقراص. قد يحدث تغيُّر بالجرعة عند التبديل بين شكلي الدواء (مثل، الأقراص والمسحوق للتعليق الفموي)، لذلك يجب عليك ألا تنتقل من واحد لآخر.</p><p dir="RTL">سيقرر طبيبك الشكل الصحيح للدواء والجرعة بناءً على وزنك، وعلى التأثيرات الجانبية وعلى استجابتك للمعالجة. يتم احتساب جرعة البداية من أقراص <strong>تايكوداس</strong> للأطفال وفقاً لوزن الجسم كما هو مبين أدناه:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>وزن الجسم (كغ)<sup>(*)</sup></strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة اليومية (ملغ)</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">10 إلى أقل من 20 كغ</p><p dir="RTL">20 إلى أقل من 30 كغ</p><p dir="RTL">30 إلى أقل من 45 كغ</p><p dir="RTL">ما لا يقل عن 45 كغ</p></td><td style="vertical-align:top"><p dir="RTL">40 ملغ</p><p dir="RTL">60 ملغ</p><p dir="RTL">70 ملغ</p><p dir="RTL">100 ملغ</p></td></tr></tbody></table><p dir="RTL"><strong><sup>(*)</sup></strong><sup> </sup>لا يوصى باستخدام الأقراص للمرضى بوزن أقل من 10 كغ، وينبغي استخدام مسحوق الشراب المعلَّق لهؤلاء المرضى.</p><p dir="RTL">لا توجد توصيات حول جرعة أقراص <strong>تايكوداس</strong> للأطفال دون السنة الواحدة من العمر.</p><p dir="RTL">اعتماداً على كيفية استجابتك للمعالجة، قد يقترح طبيبك جرعة أعلى أو أقل، أو حتى وقف المعالجة لفترة وجيزة. بالنسبة للجرعات الأعلى أو الأقل، قد تحتاج إلى أخذ مجموعة مشتركة من الأقراص بعيارات مختلفة.</p><p dir="RTL">قد تأتي الأقراص في عبوات بليستر عليها تقويم. هذه البليسترات&nbsp; تظهر عليها أيام الأسبوع. وهناك أسهم تدل على القرص التالي الذي يجب أخذه وفقاً لجدول معالجتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف تأخذ أقراص تايكوداس</strong></p><p dir="RTL">خذ أقراصك بنفس الوقت كل يوم. ابتلع الأقراص كاملة. لا تسحقهم، أو تقطعهم أو تمضغهم. لا تأخذ الأقراص المفتتة. لا يمكنك التأكد أنك قد تلقيت الجرعة الصحيحة إذا أنت سحقت أو قطعت أو مضغت أو فتَّتَّ الأقراص. يمكن أخذ أقراص <strong>تايكوداس </strong>مع أو بدون الوجبات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات خاصة للتعامل مع أقراص تايكوداس</strong></p><p dir="RTL">من المُستبعد أن تتكسر أقراص <strong>تايكوداس</strong>. ولكن إذا تكسَّرت، فإن أشخاص آخرين غير المريض يجب عليهم استخدام القفازات عند التعامل مع أقراص <strong>تايكوداس</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إلى متى ستأخذ أقراص تايكوداس</strong></p><p dir="RTL">خذ أقراص <strong>تايكوداس</strong> كل يوم إلى أن يُخبرك طبيبك بالتوقف. تأكد من أنك تأخذ أقراص <strong>تايكوداس</strong> طوال الفترة الموصوفة لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أخذت أقراص تايكوداس أكثر مما يجب</strong></p><p dir="RTL">إذا تناولت خطأً الكثير جداً من الأقراص، تحدث إلى طبيبك فوراً. فقد تحتاج إلى عناية طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول أقراص تايكوداس</strong></p><p dir="RTL">لا تأخذ جرعة مضاعفة لتعويض قرصٍ منسيٍّ. خذ الجرعة التالية كما وردت في الجدول بوقتها العادي.</p><p dir="RTL">إذا كان لديك أية أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء تأثيرات جانبية، ولو أنها لا تحصل لدى كل شخص.</p><p dir="RTL">يمكن أن يكون كل ما يلي علامات على تأثيرات جانبية خطيرة:</p><p dir="RTL">- إذا كان عندك ألم في الصدر، صعوبة في التنفس، سعال وإغماء.</p><p dir="RTL">- إذا واجهت نزيفاً غير متوقع أو كدمات دون التعرض لإصابة.</p><p dir="RTL">- إذا وجدت دماً في القيء، البراز أو البول، أو لديك براز أسود.</p><p dir="RTL">- إذا حصل عندك علامات عدوى مثل حمى، قشعريرة شديدة.</p><p dir="RTL">- إذا حصل عندك حمى، التهاب فم أو حلق، تقرحات أو تقشير في جلدك و/أو الأغشية المخاطية.</p><p dir="RTL"><strong>اتصل بطبيبك في الحال </strong>إذا لاحظت أيّاً مما سبق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية شائعة جداً (قد تؤثر في أكثر من 1 من كل 10 أشخاص)</strong></p><p dir="RTL">- الالتهابات (بما في ذلك البكتيرية، والفيروسية والفطرية).</p><p dir="RTL">- القلب والرئتين: ضيق التنفس.</p><p dir="RTL">- مشاكل في الجهاز الهضمي: إسهال، شعور بالمرض (غثيان، قيء).</p><p dir="RTL">- الجلد، الشعر، العين، وبشكل عام: طفح جلدي، حمى، تورُّم حول الوجه، اليدين والقدمين، صداع، شعور بالتعب أو الضعف، نزيف.</p><p dir="RTL">- الألم: ألم في العضلات (أثناء أو بعد وقف المعالجة)، ألم بطن (البطن).</p><p dir="RTL">- قد تظهر الفحوصات: انخفاض عدد الصفائح الدموية، انخفاض عدد خلايا الدم البيضاء (قلة العدلات)، فقر دم، سوائل حول الرئتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية شائعة (قد تؤثر حتى في 1 من كل 10 أشخاص)</strong></p><p dir="RTL">- الالتهابات: التهاب رئوي، عدوى فيروس الهربس (بما في ذلك الفيروس المضخم للخلايا - CMV))، عدوى الجهاز التنفسي العلوي، عدوى خطيرة في الدم أو الأنسجة (بما في ذلك حالات غير مألوفة بنتائج مميتة).</p><p dir="RTL">- القلب والرئتين: خفقان، عدم انتظام ضربات القلب، قصور القلب الاحتقاني، ضعف عضلة القلب، ضغط دم عالٍ، زيادة ضغط الدم في الرئتين وسعال.</p><p dir="RTL">- مشاكل في الجهاز الهضمي: اضطرابات الشهية، اضطراب التَّذوق، بطن متضخم أو منتفخ (البطن)، التهاب القولون، إمساك، حرقة، تقرح الفم، زيادة الوزن، انخفاض الوزن، التهاب المعدة.</p><p dir="RTL">- الجلد، الشعر، العين، وبشكل عام: وخز الجلد، حكة، جلد جاف، حب الشباب، التهاب الجلد، ضجيج مستمر في الأذنين، تساقط الشعر، تعرُّق مفرط، اضطراب الرؤية (بما في ذلك عدم وضوح الرؤية ورؤية مضطربة)، عين جافة، كدمات، كآبة، أرق، توهُّج، دوخة، رضوض (كدمات)، فقدان شهية، نعاس، وذمة معمَّمة.</p><p dir="RTL">- الألم: ألم في المفاصل، ضعف عضلي، ألم في الصدر، ألم حول اليدين والقدمين، قشعريرة، تصلب في العضلات والمفاصل، تشنج عضلي.</p><p dir="RTL">- قد تظهر الفحوصات: سائل حول القلب، سائل في الرئتين، عدم انتظام ضربات القلب، قلة العدلات الحموية، نزيف الجهاز الهضمي، ارتفاع مستويات حمض البول في الدم،</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية غير شائعة (قد تؤثر حتى في 1 من كل 100 شخص)</strong></p><p dir="RTL">- القلب والرئتين: نوبة قلبية (بما في ذلك النتائج المميتة)، التهاب بطانة (كيس ليفي) يحيط بالقلب، عدم انتظام ضربات القلب، آلم في الصدر بسبب نقص إمدادات الدم للقلب (الذبحة الصدرية)، انخفاض ضغط الدم، تضيُّق مجرى الهواء الذي قد يسبب صعوبات في التنفس، ربو، زيادة ضغط الدم في الشرايين (الأوعية الدموية) في الرئتين.</p><p dir="RTL">- مشاكل في الجهاز الهضمي: التهاب البنكرياس، قرحة هضمية، التهاب أنبوب الغذاء، تورُّم بطن (البطن)، تمزُّق في القناة الشرجية، صعوبة في البلع، التهاب المرارة، انسداد القنوات الصفراوية، ارتجاع معدي مريئي (حالة يعود فيها الحمض ومحتويات المعدة الأخرى إلى الحلق).</p><p dir="RTL">- الجلد، الشعر، العين، وبشكل عام: رد فعل تحسسي بما في ذلك الوهن، كتل حمراء على الجلد (حمامي عقدية)، قلق، ارتباك، تقلب مزاج، انخفاض الدافع الجنسي، إغماء، هزَّة، التهاب العين الذي يسبب الإحمرار أو الألم، مرض جلدي يتميز بالعقد، بقع حمراء واضحة المعالم مع بداية مفاجئة للحمى وارتفاع عدد خلايا الدم البيضاء (التهاب الجلد العدلي)، فقدان السمع، حساسية للضوء، ضعف البصر، زيادة دموع العين، اضطراب في لون الجلد، التهاب الأنسجة الدهنية تحت الجلد، قرحة الجلد، تقرحات الجلد، اضطراب الأظافر، اضطراب الشعر، اضطراب اليد والقدم، فشل كلوي، تكرار التبول، تضخم الثدي لدى الرجال، اضطراب الدورة الشهرية، ضعف عام وعدم ارتياح، انخفاض وظيفة الغدة الدرقية، فقدان التوازن أثناء المشي، تنخر العظم (مرض انخفاض تدفق الدم للعظام، الذي يمكن أن يسبب فقدان العظام وموت العظام)، التهاب المفاصل، تورُّم الجلد في أي مكان من الجسم.</p><p dir="RTL">- الألم: التهاب الوريد الذي يمكن أن يسبب احمرار، وهن وتورُّم، التهاب الوتر.</p><p dir="RTL">- الدماغ: فقدان الذاكرة.</p><p dir="RTL">- قد تظهر الفحوصات: نتائج فحص دم غير طبيعية وربما اختلال وظائف الكلى التي تسببها نفايات الورم الميتة (متلازمة تحلل الورم)، انخفاض مستويات الألبومين في الدم، انخفاض مستويات الخلايا الليمفاوية (نوع من خلايا الدم البيضاء) في الدم، ارتفاع مستوى الكوليسترول في الدم، تضخم الغدد الليمفاوية، نزيف في المخ، عدم انتظام النشاط الكهربي للقلب، تضخم القلب، التهاب الكبد، بروتين في البول، ارتفاع فوسفوكيناز الكرياتين (إنزيم موجود بشكل رئيسي في القلب والدماغ والعضلات الهيكلية)، ارتفاع تروبونين (إنزيم موجود بشكل رئيسي في القلب والعضلات الهيكلية)، ارتفاع غاما غلوتاميل ترانسفيراز (إنزيم موجود بشكل رئيسي في الكبد).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية نادرة (قد تؤثر حتى في 1 من كل 1000 شخص)</strong></p><p dir="RTL">- القلب والرئتين: تضخم البطين الأيمن في القلب، التهاب عضلة القلب، مجموعة من الحالات ناتجة عن انسداد تدفق الدم إلى عضلة القلب (متلازمة الشريان التاجي الحاد)، السكتة القلبية (وقف تدفق الدم من القلب)، مرض الشريان التاجي (القلب)، التهاب النسج الذي يغطي القلب والرئتين، جلطات دموية، جلطات دموية في الرئتين.</p><p dir="RTL">- مشاكل في الجهاز الهضمي: فقدان العناصر الغذائية الحيوية مثل البروتين من جهازك الهضمي، انسداد الأمعاء، ناسور شرجي (فتحة غير طبيعية من الشرج إلى الجلد حول فتحة الشرج)، فشل وظائف الكلى، مرض السكري.</p><p dir="RTL">- الجلد، الشعر، العين، وبشكل عام: تشنج التهاب العصب البصري الذي قد يسبب فقدان جزئي أو كامل للبصر، تبلد أزرق بنفسجي للجلد، ارتفاع وظيفة الغدة الدرقية بشكل غير طبيعي، التهاب الغدة الدرقية، ترنح (حالة مرتبطة بنقص توافق العضلات)، صعوبة المشي، إخفاق، التهاب الأوعية الدموية في الجلد، تليف الجلد.</p><p dir="RTL">- الدماغ: سكتة دماغية، حادثة عرضية من الخلل العصبي ناجمة عن فقدان تدفق الدم، شلل عصب الوجه، الخرف.</p><p dir="RTL">- الجهاز المناعي: رد فعل تحسسي شديد.</p><p dir="RTL">- النسيج العضلي الهيكلي والنسيج الضام: تأخر اندماج النهايات الدائرية التي تشكل المفاصل (المشاش)؛ نمو أبطأ أو متأخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية أخرى تم الإبلاغ عنها بتكرار غير معروف (لا يمكن تقديرها من البيانات المتاحة)</strong></p><p dir="RTL">- التهاب الرئتين.</p><p dir="RTL">- نزيف في المعدة أو الأمعاء يمكن أن يسبب الموت.</p><p dir="RTL">- تكرار (إعادة تنشيط) عدوى الالتهاب الكبدي B عندما تكون مصاباً في الماضي بالتهاب الكبد B (عدوى الكبد).</p><p dir="RTL">- رد فعل مع حمى، بثور على الجلد، وتقرح الأغشية المخاطية.</p><p dir="RTL">- مرض الكلى بأعراض منها الوذمة ونتائج الفحوصات المخبرية غير الطبيعية مثل البروتين في البول وانخفاض مستوى البروتين في الدم.</p><p dir="RTL">- تلف الأوعية الدموية المعروف باسم اعتلال الأوعية الدقيقة الخثاري (TMA)، بما في ذلك انخفاض عدد خلايا الدم الحمراء، انخفاض الصفائح الدموية، وتشكُّل جلطات الدم.</p><p dir="RTL">سيتحقق طبيبك من بعض هذه التأثيرات أثناء معالجتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن التأثيرات الجانبية</strong></p><p dir="RTL">إذا حصل عندك أية تأثيرات جانبية، تحدث إلى طبيبك أو الصيدلي. وهذا يشمل أية تأثيرات جانبية محتملة غير مذكورة في هذه النشرة. يمكنك أيضاً الإبلاغ عن التأثيرات الجانبية مباشرةً (انظر التفاصيل أدناه).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- لا تحفظ الدواء بدرجة حرارة أعلى من 30 مئوية. احفظ الدواء بعيداً عن رؤية ومتناول الأطفال.</p><p dir="RTL">- لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على لصاقة القارورة، البليستر أوالعلبة الكرتون بعد EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">- لا يتطلب هذا الدواء أية شروط تخزين خاصة.</p><p dir="RTL">- لا تتخلص من أية أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي كيف تتخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير سوف تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- المادة الفعالة هي داساتينب.</p><p dir="RTL">&nbsp; يحتوي كل قرص مغلف بالفلم على 50ملغ أو 70 ملغ أو 100ملغ من داساتينب.</p><p dir="RTL">- المكونات الأخرى هي:</p><p dir="RTL"><u>نواة القرص:</u></p><p dir="RTL">مايكروكريستالين سليلوز، لاكتوز مونوهايدرات، هايدروكسي بروبيل سليلوز، كروسكارميلوز الصوديوم، ومغنيسيوم ستيآرات.</p><p dir="RTL"><u>غلاف القرص:</u></p><p dir="RTL">هايبروميللوز، ثاني أوكسيد التيتانيوم، تري إيتيل سيترات).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>أقراص <strong>تايكوداس</strong> 50 ملغ</u></p><p dir="RTL">أقراص بلون أبيض إلى أبيض خفيف، بيضاوية الشكل، ثنائية التحدب، مغلفة بفلم ومحفورة بالأحرف &quot;DAS&quot; في أحد الجانبين و بالرقم &quot;50&quot; &nbsp;في الجانب الآخر.</p><p dir="RTL"><u>أقراص <strong>تايكوداس</strong> 70 ملغ</u></p><p dir="RTL">أقراص بلون أبيض إلى أبيض خفيف، دائرية الشكل، ثنائية التحدب، مغلفة بفلم ومحفورة بالأحرف &quot;DAS&quot; في أحد الجانبين و بالرقم &quot;70&quot; &nbsp;في الجانب الآخر.</p><p dir="RTL"><u>أقراص <strong>تايكوداس</strong> 100 ملغ</u></p><p dir="RTL">أقراص بلون أبيض إلى أبيض خفيف، دائرية الشكل، ثنائية التحدب، مغلفة بفلم ومحفورة بالأحرف &quot;DAS&quot; في أحد الجانبين و بالرقم &quot;100&quot; &nbsp;في الجانب الآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص <strong>تايكوداس</strong> 50ملغ أو70ملغ أو100ملغ متوفرة بعبوات بليستر من 10 أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>أ&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>مالك حقوق التسويق والتغليف الثانوي: </em></p><p dir="RTL"><em>شركة بوستن اونكولجي العربية </em></p><p dir="RTL">منطقة سدير الصناعية، سدير، المملكة العربية السعودية</p><p dir="RTL"><em>ب&zwnj;-&nbsp; </em><em>التصنيع الكامل والتغليف الأولي: </em></p><p dir="RTL">مختبرات إم إس إن الخاصة المحدودة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة آخر مرة في 08/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TYKODAS 50/ 70
Dasatinib Tablets 50 mg/ 70mg

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dasatinib Tablets 50 mg/ 70mg 
Each film coated tablet contains 
Dasatinib	50 mg/ 70mg
Product contains Lactose
For the full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dasatinib Tablets 50 mg
White to off white, oval, biconvex, film coated tablets debossed with “DAS” on one side and “50” on the other side.
Dasatinib Tablets 70 mg
White to off white, round, biconvex, film coated tablets debossed with “DAS” on one side and “70” on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Dasatinib&nbsp;Tablets&nbsp;is&nbsp;indicated&nbsp;for&nbsp;the&nbsp;treatment&nbsp;of&nbsp;adult&nbsp;patients&nbsp;with:</u></p><p><!--[if !supportLists]-->&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<!--[endif]-->newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->chronic,&nbsp;accelerated&nbsp;or&nbsp;blast&nbsp;phase&nbsp;CML&nbsp;with&nbsp;resistance&nbsp;or&nbsp;intolerance&nbsp;to&nbsp;prior&nbsp;therapy including imatinib.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Ph+&nbsp;acute&nbsp;lymphoblastic&nbsp;leukaemia&nbsp;(ALL)&nbsp;and&nbsp;lymphoid&nbsp;blast&nbsp;CML&nbsp;with&nbsp;resistance&nbsp;or intolerance to prior therapy.</p><p><u>Dasatinib&nbsp;Tablets&nbsp;is&nbsp;indicated&nbsp;for&nbsp;the&nbsp;treatment&nbsp;of&nbsp;paediatric&nbsp;patients&nbsp;with:</u></p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->newly diagnosed Ph+ CML in chronic phase (Ph+&nbsp;CML-CP) or Ph+ CML-CP resistant or&nbsp;intolerant to prior therapy including imatinib.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->newly&nbsp;diagnosed&nbsp;Ph+&nbsp;ALL&nbsp;in&nbsp;combination&nbsp;with&nbsp;chemotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy&nbsp;should&nbsp;be&nbsp;initiated&nbsp;by&nbsp;a&nbsp;physician&nbsp;experienced&nbsp;in&nbsp;the&nbsp;diagnosis&nbsp;and&nbsp;treatment&nbsp;of&nbsp;patients&nbsp;with&nbsp;leukaemia.</p><p><u>Posology</u></p><p><em><u>Adult&nbsp;patients</u></em></p><p>The&nbsp;recommended&nbsp;starting&nbsp;dose&nbsp;for&nbsp;chronic&nbsp;phase&nbsp;CML&nbsp;is&nbsp;100&nbsp;mg dasatinib once&nbsp;daily.</p><p>The recommended starting dose for accelerated, myeloid or lymphoid blast phase (advanced phase) CML or Ph+ALL is 140 mg once daily (see section 4.4).</p><p><em><u>Paediatric&nbsp;population&nbsp;(Ph+&nbsp;CML-CP&nbsp;and&nbsp;Ph+&nbsp;ALL)</u></em></p><p>Dosing for children and adolescents is on the basis of body weight (see Table 1). Dasatinib is administered orally once daily in the form of either Dasatinib Tablets film-coated tablets or Dasatinib Tablets powder for oral suspension (see Summary of Product Characteristics for&nbsp;Dasatinib Tablets powder for oral suspension). The dose should be recalculated every 3 months based on changes in body weight, or more often if necessary. The tablet is not recommended for patients weighing less than 10 kg; the powder for oral suspension should be used for these patients. Dose increase or reduction is recommended based on individual patient response and tolerability. There is no experience with Dasatinib&nbsp;Tablets treatment in children under 1 year of age.</p><p>Dasatinib Tablets film-coated tablets and Dasatinib Tablets powder for oral suspension are not bioequivalent. Patients who are able to swallow tablets and who desire to switch from Dasatinib Tablets powder for oral suspension to Dasatinib Tablets tablets or patients who are not able to swallow tablets and who desire to switch from tablets to oral suspension, may do so, provided that the correct dosing recommendations for the dosage form are followed.</p><p>The recommended starting daily dosage of Dasatinib Tablets tablets in paediatric patients is shown in Table 1.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table&nbsp;1:&nbsp;Dosage&nbsp;of&nbsp;Dasatinib&nbsp;Tablets&nbsp;tablets&nbsp;for&nbsp;paediatric&nbsp;patients&nbsp;with&nbsp;Ph+&nbsp;CML-CP or Ph+&nbsp;ALL</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Body&nbsp;weight&nbsp;(kg)<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Daily&nbsp;dose&nbsp;(mg)</strong></p></td></tr><tr><td style="vertical-align:top"><p>10&nbsp;to less&nbsp;than&nbsp;20&nbsp;kg</p></td><td style="vertical-align:top"><p>40&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>20&nbsp;to less&nbsp;than&nbsp;30&nbsp;kg</p></td><td style="vertical-align:top"><p>60&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>30&nbsp;to less&nbsp;than&nbsp;45&nbsp;kg</p></td><td style="vertical-align:top"><p>70&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>at&nbsp;least 45&nbsp;kg</p></td><td style="vertical-align:top"><p>100&nbsp;mg</p></td></tr></tbody></table><p>a&nbsp;The&nbsp;tablet&nbsp;is&nbsp;not&nbsp;recommended&nbsp;for&nbsp;patients&nbsp;weighing&nbsp;less&nbsp;than&nbsp;10&nbsp;kg;&nbsp;the&nbsp;powder&nbsp;for&nbsp;oral&nbsp;suspension&nbsp;should&nbsp;be&nbsp;used&nbsp;for these patients.</p><p>&nbsp;</p><p><strong>Treatment&nbsp;duration</strong></p><p>In clinical studies, treatment with Dasatinib Tablets in adults with Ph+ CML-CP, accelerated, myeloid&nbsp;or&nbsp;lymphoidblast&nbsp;phase&nbsp;(advanced&nbsp;phase)&nbsp;CML,&nbsp;or&nbsp;Ph+&nbsp;ALL&nbsp;and&nbsp;paediatric&nbsp;patients&nbsp;with&nbsp;Ph+&nbsp;CML CP was&nbsp;continued until disease progression&nbsp;or until no longer tolerated by the&nbsp;patient.</p><p>The effect of stopping treatment on long-term disease outcome after the achievement of a cytogenetic or molecular response [including complete cytogenetic response (CCyR), major molecular response (MMR) and MR4.5] has not been investigated.</p><p>In clinical studies, treatment with Dasatinib Tablets in paediatric patients with Ph+ ALL was administered continuously, added to successive blocks of backbone chemotherapy, for a maximum duration of two years. In patients that receive a subsequent stem cell transplantation, Dasatinib Tablets can be administered for an additional year post-transplantation.</p><p>To achieve the recommended dose, Dasatinib Tablets is available as 20 mg, 50 mg, 70 mg, 80 mg, 100 mg and 140 mg filmcoated tablets and powder for oral suspension (10 mg/mL&nbsp;suspension upon constitution).&nbsp;Dose increase orreduction&nbsp;is&nbsp;recommended&nbsp;based&nbsp;on&nbsp;patient&nbsp;response&nbsp;and tolerability.&nbsp;</p><p>&nbsp;</p><p><strong><u>Dose escalation</u></strong></p><p>In clinical studies in adult CML and Ph+ ALL patients, dose escalation to 140 mg once daily (chronic phase CML) or 180 mg once daily (advanced phase CML or Ph+ ALL) was allowed in patients who did not achieve a haematologic or cytogenetic response at the recommended starting&nbsp;dose.</p><p>The following dose escalations shown in Table 2 are recommended in paediatric patients with Ph+ CML-CP who do not achieve a haematologic, cytogenetic and molecular response at the recommended time points, per current treatment guidelines, and who tolerate the treatment.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;2:&nbsp;Dose&nbsp;escalation&nbsp;for&nbsp;paediatric&nbsp;patients&nbsp;with&nbsp;Ph+&nbsp;CML-CP</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Dose&nbsp;(maximum&nbsp;dose&nbsp;per&nbsp;day)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Starting&nbsp;dose</p></td><td style="vertical-align:top"><p>Escalation</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Tablets</p></td><td style="vertical-align:top"><p>40&nbsp;mg</p></td><td style="vertical-align:top"><p>50&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>60&nbsp;mg</p></td><td style="vertical-align:top"><p>70&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>70&nbsp;mg</p></td><td style="vertical-align:top"><p>90&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>100&nbsp;mg</p></td><td style="vertical-align:top"><p>120&nbsp;mg</p></td></tr></tbody></table><p>Dose&nbsp;escalation&nbsp;is&nbsp;not&nbsp;recommended&nbsp;for&nbsp;paediatric&nbsp;patients&nbsp;with&nbsp;Ph+&nbsp;ALL,&nbsp;as&nbsp;Dasatinib&nbsp;Tablets&nbsp;is&nbsp;administered&nbsp;in combination&nbsp;with&nbsp;chemotherapy&nbsp;in these&nbsp;patients.</p><p>&nbsp;</p><p><u>Dose&nbsp;adjustment&nbsp;for&nbsp;adverse&nbsp;reactions</u>&nbsp;</p><p>Myelosuppression</p><p>In clinical studies, myelosuppression was managed by dose interruption, dose reduction, or discontinuation of study therapy. Platelet transfusion and red cell transfusion were used as appropriate.&nbsp;Haematopoietic&nbsp;growth&nbsp;factor&nbsp;hasbeen&nbsp;used&nbsp;in&nbsp;patients&nbsp;with&nbsp;resistant&nbsp;myelosuppression.</p><p>Guidelines for dose modifications in adults are summarised in Table 3 and in paediatric patients&nbsp;with Ph+ CML-CP in Table 4. Guidelines for paediatric patients with Ph+ ALL treated in combination with chemotherapy are in a separate paragraph following the tables.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;3:&nbsp;Dose&nbsp;adjustments&nbsp;for&nbsp;neutropaenia&nbsp;and&nbsp;thrombocytopaenia&nbsp;in&nbsp;adults</strong></p></td></tr><tr><td style="vertical-align:top"><p>Adults&nbsp;with&nbsp;chronic&nbsp;phase&nbsp;CML</p><p>(starting&nbsp;dose&nbsp;100&nbsp;mg once daily)</p></td><td style="vertical-align:top"><p>NC&nbsp;&lt; 0.5&nbsp;x&nbsp;10<sup>9</sup>/L</p><p>and/or</p><p>platelets&nbsp;&lt;&nbsp;50&nbsp;x&nbsp;10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p><!--[if !supportLists]--><strong>1.&nbsp;&nbsp;</strong><!--[endif]-->Stop&nbsp;treatment&nbsp;until&nbsp;ANC&nbsp;&ge;&nbsp;1.0&nbsp;x&nbsp;10<sup>9</sup>/L&nbsp;and platelets &ge; 50 x 10<sup>9</sup>/L.</p><p>&nbsp;</p><p><!--[if !supportLists]--><strong>2.&nbsp;&nbsp;</strong><!--[endif]-->Resume&nbsp;treatment&nbsp;at&nbsp;the&nbsp;original&nbsp;starting&nbsp;dose.</p><p>&nbsp;</p><p><!--[if !supportLists]--><strong>3.&nbsp;&nbsp;</strong><!--[endif]-->If&nbsp;platelets&nbsp;&lt;&nbsp;25&nbsp;x&nbsp;10<sup>9</sup>/L&nbsp;and/or&nbsp;recurrence&nbsp;of ANC &lt; 0.5 x 10<sup>9</sup>/L&nbsp;for &gt; 7 days, repeat step 1 and resume treatment at a reduced dose of 80 mg once daily for second episode. For third episode, further reduce dose to 50 mg once daily (for newly diagnosed patients) or discontinue (for patients resistant or intolerant to prior therapy including imatinib)</p></td></tr><tr><td style="vertical-align:top"><p>Adults with accelerated and&nbsp;blast&nbsp;phase&nbsp;CML&nbsp;and Ph+&nbsp;ALL</p><p>(starting&nbsp;dose&nbsp;140&nbsp;mg once daily</p></td><td style="vertical-align:top"><p>ANC&nbsp;&lt; 0.5&nbsp;x&nbsp;10<sup>9</sup>/L</p><p>and/or</p><p>platelets&nbsp;&lt;&nbsp;10&nbsp;x&nbsp;10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p><!--[if !supportLists]--><strong>1.&nbsp;&nbsp;</strong><!--[endif]-->Check&nbsp;if&nbsp;cytopaenia&nbsp;is&nbsp;related&nbsp;to&nbsp;leukaemia (marrow aspirate or biopsy).</p><p>&nbsp;</p><p><!--[if !supportLists]--><strong>2.&nbsp;&nbsp;</strong><!--[endif]-->If cytopaenia is unrelated to leukaemia, stop treatment&nbsp;until&nbsp;ANC&nbsp;&ge;&nbsp;1.0&nbsp;x&nbsp;10<sup>9</sup>/L&nbsp;and&nbsp;platelets</p><p>&ge;&nbsp;20&nbsp;x&nbsp;10<sup>9</sup>/L&nbsp;and&nbsp;resume&nbsp;at&nbsp;the&nbsp;original&nbsp;starting&nbsp;dose.</p><p>&nbsp;</p><p><!--[if !supportLists]--><strong>3.&nbsp;&nbsp;</strong><!--[endif]-->If recurrence of cytopaenia, repeat step 1 and&nbsp;resume&nbsp;treatment&nbsp;at&nbsp;a&nbsp;reduced&nbsp;dose&nbsp;of&nbsp;100 mg&nbsp;once&nbsp;daily&nbsp;(second&nbsp;episode)&nbsp;or&nbsp;80&nbsp;mg&nbsp;once daily (third episode).</p><p>&nbsp;</p><p><!--[if !supportLists]--><strong>4.&nbsp;&nbsp;</strong><!--[endif]-->If cytopaenia is related to leukaemia, consider&nbsp;dose&nbsp;escalation&nbsp;to&nbsp;180&nbsp;mg&nbsp;once&nbsp;daily.</p></td></tr></tbody></table><p>ANC:&nbsp;absolute&nbsp;neutrophil&nbsp;count</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Table&nbsp;4:&nbsp;Dose&nbsp;adjustments&nbsp;for&nbsp;neutropaenia&nbsp;and&nbsp;thrombocytopaenia&nbsp;in&nbsp;paediatric&nbsp;patients with Ph+ CML-CP</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>1.&nbsp;</strong>If&nbsp;cytopaenia persists&nbsp;for&nbsp;more</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Dose&nbsp;(maximum&nbsp;dose&nbsp;per&nbsp;day)</strong></p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>than&nbsp;3&nbsp;weeks,&nbsp;check&nbsp;if&nbsp;cytopaenia&nbsp;is related to leukaemia (marrow aspirate or biopsy).</p><p><!--[if !supportLists]--><strong>2.&nbsp;&nbsp;</strong><!--[endif]-->If cytopaenia is unrelated to leukaemia,&nbsp;stop&nbsp;treatment&nbsp;until&nbsp;ANC</p><p>&ge;1.0 &times; 10<sup>9</sup>/L and platelets &ge;75 &times; 10<sup>9</sup>/L and resume at the original starting&nbsp;dose&nbsp;or&nbsp;at a&nbsp;reduced&nbsp;dose.</p><p><!--[if !supportLists]--><strong>3.&nbsp;&nbsp;</strong><!--[endif]-->If cytopaenia recurs, repeat marrow&nbsp;aspirate/biopsy&nbsp;and&nbsp;resume treatment at a reduced dose.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Original&nbsp;</strong><strong>starting&nbsp;dose</strong></p></td><td style="vertical-align:top"><p><strong>One-level&nbsp;dosereduction</strong></p></td><td style="vertical-align:top"><p><strong>Two-level</strong><strong>&nbsp;</strong><strong>dose reduction</strong></p></td></tr><tr><td style="vertical-align:top"><p>Tablets</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>*</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>20</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>70</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>70</p></td></tr></tbody></table><p>ANC:&nbsp;absolute&nbsp;neutrophil&nbsp;count</p><p>&nbsp;</p><p>*lower&nbsp;tablet&nbsp;dose&nbsp;not&nbsp;available</p><p>For paediatric patients with Ph+ CML-CP, if Grade &ge;3 neutropaenia or thrombocytopaenia recurs during completehaematologic&nbsp;response (CHR), Dasatinib&nbsp;Tablets should be&nbsp;interrupted, and may&nbsp;be subsequently&nbsp;resumedat&nbsp;a&nbsp;reduced&nbsp;dose.&nbsp;Temporary&nbsp;dose&nbsp;reductions&nbsp;for&nbsp;intermediate&nbsp;degrees&nbsp;of cytopaenia and disease response should be implemented as needed.</p><p>For paediatric patients with Ph+ ALL, no dose modification is recommended in cases of haematologic Grade 1 to 4 toxicities. If neutropaenia and/or thrombocytopaenia result in delay of&nbsp;the next block of treatment by more than 14 days, Dasatinib Tablets should be interrupted and resumed at the same dose level once the nex block of treatment is started. If neutropaenia and/or thrombocytopaenia&nbsp;persist&nbsp;and&nbsp;the&nbsp;next&nbsp;block&nbsp;of&nbsp;treatment&nbsp;is&nbsp;delayedanother&nbsp;7&nbsp;days,&nbsp;a&nbsp;bone&nbsp;marrow assessment should be performed to assess cellularity and percentage of blasts. If marrow cellularity is &lt;10%, treatment with Dasatinib Tablets should be interrupted until&nbsp;ANC &gt;500/&mu;L (0.5 x 10<sup>9</sup>/L), at which time treatment may be resumed at full dose. If marrow cellularity is &gt;10%, resumption of treatment with Dasatinib Tablets may be considered.</p><p><u>Non-haematologic&nbsp;adverse&nbsp;reactions</u></p><p>If&nbsp;a&nbsp;moderate,&nbsp;grade&nbsp;2,&nbsp;non-haematologic&nbsp;adverse&nbsp;reaction&nbsp;develops&nbsp;with&nbsp;dasatinib,&nbsp;treatment&nbsp;should be interrupted until the adverse reaction has resolved or returned to baseline. The same dose should be resumed if this is the first occurrence and the dose should be reduced if this is a recurrent adverse&nbsp;reaction.&nbsp;If&nbsp;a&nbsp;severe&nbsp;grade&nbsp;3or&nbsp;4,&nbsp;nonhaematologic&nbsp;adverse&nbsp;reaction&nbsp;develops&nbsp;with dasatinib, treatment must be withheld until the adverse reaction has resolved. Thereafter, treatment can&nbsp;be&nbsp;resumed&nbsp;as&nbsp;appropriate&nbsp;at&nbsp;a&nbsp;reduced&nbsp;dose&nbsp;depending&nbsp;in&nbsp;theinitial&nbsp;severity&nbsp;of&nbsp;the&nbsp;adverse reaction. For patients with chronic phase CML who received 100 mg once daily, dose reduction to 80 mg once daily with further reduction from 80 mg once daily to 50 mg once daily, if needed, isrecommended.&nbsp;For&nbsp;patients&nbsp;with&nbsp;advanced&nbsp;phase&nbsp;CML&nbsp;or&nbsp;Ph+&nbsp;ALL&nbsp;who&nbsp;received&nbsp;140&nbsp;mg&nbsp;once daily, dose reduction to 100 mg once daily with further reduction from 100 mg once daily to 50 mg once&nbsp;daily,&nbsp;if&nbsp;needed,&nbsp;isrecommended.&nbsp;In&nbsp;CML-CP&nbsp;paediatric&nbsp;patients&nbsp;with&nbsp;non-haematologic adverse reactions, the dose reduction recommendations for haematologic adverse reactions that are described&nbsp;above&nbsp;should&nbsp;be&nbsp;followed.&nbsp;In&nbsp;Ph+&nbsp;ALLpaediatric&nbsp;patients&nbsp;with&nbsp;non-haematologic&nbsp;adverse reactions,&nbsp;if&nbsp;needed,&nbsp;one&nbsp;level&nbsp;of&nbsp;dose&nbsp;reduction&nbsp;should&nbsp;befollowed,&nbsp;according&nbsp;to&nbsp;the&nbsp;dose&nbsp;reduction recommendations for haematologic adverse reactions that are described above.</p><p><u>Pleural&nbsp;effusion</u></p><p>If a pleural effusion is diagnosed, dasatinib should be interrupted until patient is examined, asymptomatic or&nbsp;hasreturned&nbsp;to&nbsp;baseline.&nbsp;If&nbsp;the&nbsp;episode&nbsp;does not&nbsp;improve within&nbsp;approximately&nbsp;one week, a course of diuretics or corticosteroids or both concurrently should be considered (see sections 4.4 and 4.8). Following resolution of the first episode, reintroduction of dasatinib at the same dose level should be considered. Following resolution of a subsequent episode, dasatinib at one dose level reduction should be reintroduced. Following resolution of a severe (grade 3 or 4) episode, treatment can be&nbsp;resumed as&nbsp;appropriate at&nbsp;a&nbsp;reduced dose depending&nbsp;on&nbsp;the initial severity of the adverse reaction.</p><p><u>Dose&nbsp;reduction&nbsp;for&nbsp;concomitant&nbsp;use&nbsp;of&nbsp;strong&nbsp;CYP3A4&nbsp;inhibitors</u></p><p>The concomitant use of strong CYP3A4 inhibitors and grapefruit juice with Dasatinib Tablets should be avoided (see section 4.5). If possible, an alternative concomitant medication with no or minimal enzyme inhibition potential should be selected. If Dasatinib Tablets must be administered with a strong CYP3A4 inhibitor, consider a dose decrease to:</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->40&nbsp;mg&nbsp;daily&nbsp;for&nbsp;patients&nbsp;taking&nbsp;Dasatinib&nbsp;Tablets&nbsp;140&nbsp;mg&nbsp;tablet&nbsp;daily.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->20&nbsp;mg&nbsp;daily&nbsp;for&nbsp;patients&nbsp;taking&nbsp;Dasatinib&nbsp;Tablets&nbsp;100&nbsp;mg&nbsp;tablet&nbsp;daily.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->20&nbsp;mg&nbsp;daily&nbsp;for&nbsp;patients&nbsp;taking&nbsp;Dasatinib&nbsp;Tablets&nbsp;70&nbsp;mg&nbsp;tablet&nbsp;daily.</p><p>For patients taking Dasatinib Tablets 60 mg or 40 mg daily, consider interrupting the dose of Dasatinib&nbsp;Tablets until the CYP3A4 inhibitor is discontinued, or switching to a lower dose with the powder for oral suspension formulation (see Summary of Product Characteristics for Dasatinib Tablets powder for oral suspension). Allow a washout period of approximately 1 week after the inhibitor is stopped before reinitiating Dasatinib Tablets.</p><p>These reduced doses of Dasatinib Tablets are predicted to adjust the area under the curve (AUC) to the range observed without CYP3A4 inhibitors; however, clinical data are not available with these dose adjustments in patients receiving strong CYP3A4 inhibitors. If Dasatinib Tablets is not tolerated after&nbsp;dose&nbsp;reduction,&nbsp;either discontinue the&nbsp;strong&nbsp;CYP3A4&nbsp;inhibitor or&nbsp;interrupt&nbsp;Dasatinib Tablets until the inhibitor is discontinued. Allow a washout period of approximately 1 week after the inhibitor is stopped before the Dasatinib Tablets dose is increased.</p><p><strong><u>Special&nbsp;populations</u></strong></p><p><em><u>Elderly</u></em></p><p>No&nbsp;clinically&nbsp;relevant&nbsp;age-related&nbsp;pharmacokinetic&nbsp;differences&nbsp;have&nbsp;been&nbsp;observed&nbsp;in&nbsp;these patients. No specific dose recommendation is necessary in elderly.</p><p><em><u>Hepatic&nbsp;impairmen</u></em><em>t</em></p><p>Patients with mild, moderate or severe hepatic impairment may receive the recommended starting dose. However, Dasatinib Tablets should be used with caution in patients with hepatic impairment (see section 5.2).</p><p><em><u>Renal&nbsp;impairmen</u></em><em>t</em></p><p>No clinical studies were conducted with Dasatinib Tablets in patients with decreased renal function (the study in patients with newly diagnosed chronic phase CML excluded patients with serum creatinine concentration &gt; 3 times the upper limit of the normal range, and studies in patients with chronic phase CML with resistance or intolerance to prior imatinib therapy excluded patients with serum creatinine concentration &gt; 1.5 times the upper limit of the normal range). Since the renal clearance of&nbsp;dasatinib and&nbsp;its metabolites is &lt; 4%,&nbsp;a&nbsp;decrease&nbsp;in total body&nbsp;clearance is not expected in patients with renal insufficiency.</p><p><u>Method&nbsp;of&nbsp;administration</u></p><p>Dasatinib&nbsp;Tablets&nbsp;must&nbsp;be&nbsp;administered&nbsp;orally.</p><p>The film-coated tablets must not be crushed, cut or chewed in order to maintain dosing consistency and minimise the risk of dermal exposure; they must be swallowed whole. Film-coated tablets should not be dispersed as the exposure in patients receiving a dispersed tablet is lower than in&nbsp;those swallowing a whole tablet. Dasatinib Tablets powder for oral suspension is also available for paediatric Ph+ CML-CP and Ph+ ALL patients, and adult CML-CP patients, who cannot swallow&nbsp;tablets.</p><p>Dasatinib Tablets can be taken with or without a meal and should be taken consistently either in the morning or&nbsp;in the evening (see section 5.2).&nbsp;Dasatinib&nbsp;Tablets should not be taken with grapefruit or grapefruit juice (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Clinically&nbsp;relevant&nbsp;interactions</u></p><p>Dasatinib is a substrate and an inhibitor of cytochrome P450 (CYP) 3A4. Therefore, there is a potential for interaction with other concomitantly administered medicinal products that are metabolised primarily by or modulate the activity of CYP3A4 (see section 4.5).</p><p>Concomitant use of dasatinib and medicinal products or substances that potently inhibit CYP3A4 (e.g. Ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, telithromycin, grapefruit juice)&nbsp;&nbsp;may&nbsp;&nbsp;increase&nbsp;&nbsp;exposure&nbsp;&nbsp;to&nbsp;&nbsp;dasatinib.&nbsp;&nbsp;Therefore,&nbsp;&nbsp;in&nbsp;&nbsp;patients&nbsp;&nbsp;receiving&nbsp;&nbsp;dasatinib,&nbsp;coadministration&nbsp;of&nbsp;a&nbsp;potent&nbsp;CYP3A4&nbsp;inhibitor&nbsp;is&nbsp;not&nbsp;recommended&nbsp;(see&nbsp;section&nbsp;4.5).</p><p>Concomitant use of dasatinib and medicinal products that induce CYP3A4 (e.g. Dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or herbal preparations containing&nbsp;<em>Hypericum perforatum</em>, also known as St. John&#39;s Wort) may substantially reduce exposure to dasatinib, potentially increasing the risk of therapeutic failure. Therefore, in patients receiving dasatinib, coadministration&nbsp;of&nbsp;alternative medicinal products with&nbsp;less potential for&nbsp;CYP3A4&nbsp;induction&nbsp;should be selected (see section 4.5).</p><p>Concomitant use of dasatinib and a CYP3A4 substrate may increase exposure to the CYP3A4 substrate. Therefore, caution is warranted when dasatinib is coadministered with CYP3A4 substrates of narrow therapeutic index, such as astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot alkaloids (ergotamine, dihydroergotamine) (see section 4.5).</p><p>The concomitant use of dasatinib and a histamine-2 (H2) antagonist (e.g. famotidine), proton pump inhibitor (e.g. omeprazole), or aluminium hydroxide/magnesium hydroxide may reduce the exposure to dasatinib. Thus, H2&nbsp;antagonists and proton pump inhibitors are not recommended and aluminium&nbsp;hydroxide/magnesium&nbsp;hydroxideproducts should be&nbsp;administered up&nbsp;to&nbsp;2&nbsp;hours&nbsp;prior&nbsp;to, or 2 hours following the administration of dasatinib (see section 4.5).</p><p><u>Special&nbsp;populations</u></p><p>Based on the findings from a single-dose pharmacokinetic study, patients with mild, moderate or severe hepatic impairment may&nbsp;receive the recommended starting dose&nbsp;(see section 5.2). Due to the limitations of this clinical study, caution is recommended when administering dasatinib to patients with hepatic impairment.</p><p><u>Important&nbsp;adverse&nbsp;reactions</u></p><p><em><u>Myelosuppression</u></em></p><p>Treatment with dasatinib is associated with anaemia, neutropaenia and thrombocytopaenia. Their occurrence is earlier and more frequent in patients with advanced phase CML or Ph+ ALL than in chronic phase CML. In adult patients with advanced phase CML&nbsp;or Ph+&nbsp;ALL&nbsp;treated with dasatinib as monotherapy, complete blood counts (CBCs) should be performed weekly for the first 2 months, and then monthly thereafter, or as clinically indicated. In adult and paediatric patients with chronic phase CML, complete blood counts should be performed every 2 weeks for 12 weeks, then every 3 months thereafter or as clinically indicated. In paediatric patients with Ph+ ALL treated with dasatinib in combination with chemotherapy, CBCs should be performed prior to the start of each block of chemotherapy and as clinically indicated. During the consolidation blocks of chemotherapy, CBCs should be performed every 2 days until recovery (see sections 4.2 and 4.8). Myelosuppression is generally reversible and usually managed by withholding dasatinib&nbsp;temporarily or by dose reduction.</p><p><em><u>Bleeding</u></em></p><p>In patients with chronic phase CML (n=548), 5 patients (1%) receiving dasatinib had grade 3 or 4 haemorrhage. In clinical studies in patients with advanced phase CML receiving the recommended dose of Dasatinib Tablets (n=304), severe central nervous system (CNS) haemorrhage occurred in 1% of patients. One case was fatal and was associated with Common&nbsp;Toxicity&nbsp;Criteria (CTC) grade 4 thrombocytopaenia. Grade 3 or 4 gastrointestinal haemorrhage occurred in 6% of patients with advanced&nbsp;phase&nbsp;CML&nbsp;and&nbsp;generally&nbsp;required&nbsp;treatment&nbsp;interruptionsand&nbsp;transfusions.&nbsp;Other&nbsp;grade&nbsp;3 or 4 haemorrhage occurred in 2% of patients with advanced phase CML. Most bleeding related adverse reactions in these patients were typically associated with grade 3 or 4 thrombocytopaenia (see section 4.8). Additionally,&nbsp;<em>in vitro&nbsp;</em>and&nbsp;<em>in vivo&nbsp;</em>platelet assays suggest that Dasatinib Tablets treatment reversibly affects platelet activation.</p><p>Caution should be exercised if patients are required to take medicinal products that inhibit platelet function or anticoagulants.</p><p><u>Fluid&nbsp;retention</u></p><p>Dasatinib is associated with fluid retention. In the Phase III clinical study in patients with newly diagnosed chronic phase CML, grade 3 or 4 fluid retention was reported in 13 patients (5%) in the dasatinib-treatment group and in 2 patients (1%) in the imatinib-treatment group after a minimum&nbsp;of&nbsp;60&nbsp;months&nbsp;follow-up&nbsp;(see&nbsp;section&nbsp;4.8).In&nbsp;all&nbsp;Dasatinib&nbsp;Tablets&nbsp;treated&nbsp;patients&nbsp;with&nbsp;chronic&nbsp;phase CML, severe fluid retention occurred in 32 patients (6%) receiving Dasatinib Tablets at the recommended dose (n=548). In clinical studies in patients with advanced phase CML or Ph+ ALL receiving Dasatinib Tablets at the recommended dose (n=304), grade 3 or 4 fluid retention was reported in 8% of patients, including grade 3 or 4 pleural and pericardial effusion reported in 7% and 1% of patients, respectively. In these patients grade 3 or 4 pulmonary oedema and pulmonary hypertension were each reported in 1% of patients.</p><p>Patients who develop symptoms suggestive of pleural effusion such as dyspnoea or dry cough should be evaluated by chest X-ray. Grade 3 or 4 pleural effusion may require thoracocentesis and oxygen therapy. Fluid retention adverse reactions were typically managed by supportive care measures&nbsp;that&nbsp;include&nbsp;diuretics&nbsp;and&nbsp;short&nbsp;courses&nbsp;ofsteroids&nbsp;(see&nbsp;sections&nbsp;4.2&nbsp;and&nbsp;4.8).&nbsp;Patients&nbsp;aged 65 years and older are more likely than younger patients to experience pleural effusion, dyspnoea, cough, pericardial effusion and congestive heart failure, and should be monitored closely.</p><p><u>Pulmonary&nbsp;arterial&nbsp;hypertension&nbsp;(PAH)</u></p><p>PAH (pre-capillary pulmonary arterial hypertension confirmed by right heart catheterization) has been reported in association with dasatinib treatment (see section 4.8). In these cases, PAH was reported after initiation of dasatinib therapy, including after more than one year of treatment.</p><p>Patients&nbsp;should&nbsp;be&nbsp;evaluated&nbsp;for&nbsp;signs&nbsp;and&nbsp;symptoms&nbsp;of&nbsp;underlying&nbsp;cardiopulmonary&nbsp;disease&nbsp;prior&nbsp;to initiating dasatinib therapy. An echocardiography should be performed at treatment initiation in every&nbsp;patientpresenting&nbsp;symptoms&nbsp;of&nbsp;cardiac&nbsp;disease&nbsp;and&nbsp;considered&nbsp;in&nbsp;patients&nbsp;with&nbsp;risk&nbsp;factors&nbsp;for cardiac or pulmonary disease. Patients who develop dyspnoea and fatigue after initiation of therapy should&nbsp;be&nbsp;evaluated&nbsp;for&nbsp;commonetiologies&nbsp;including&nbsp;pleural&nbsp;effusion,&nbsp;pulmonary&nbsp;oedema,&nbsp;anaemia, or lung infiltration. In accordance with recommendations for management of nonhaematologic adverse reactions (see section 4.2) the dose of dasatinib should be reduced or therapy interrupted during this evaluation. If no explanation is found, or if there is no improvement with dose reduction or interruption, the diagnosis of PAH should be considered. The diagnostic approach should follow standard practice guidelines. If PAH is confirmed, dasatinib should be permanently discontinued. Follow up should be performed according to standard practice guidelines. Improvements in haemodynamic and clinical parameters have been observed in dasatinib-treated patients with PAH following cessation of dasatinib therapy.</p><p><u>QT&nbsp;Prolongation</u></p><p>In vitro data suggest that dasatinib has the potential to prolong cardiac ventricular repolarisation&nbsp;(QT Interval) (see section 5.3). In 258 dasatinib-treated patients and 258 imatinib-treated patients with a minimum of 60 months follow-up in the Phase III study in newly diagnosed chronic phase CML, 1 patient (&lt; 1%) in each group had QTc prolongation reported as an adverse reaction. The median changes in QTcF from baseline were 3.0 msec in dasatinib-treated patients compared to 8.2 msec in imatinib-treated patients. One patient (&lt; 1%) in each group experienced a QTcF &gt; 500 msec. In 865 patients with leukaemia treated with dasatinib in Phase II clinical studies, the mean changes from baseline in Qtc interval using Fridericia&#39;s method (QTcF) were 4 - 6 msec; the upper 95% confidence intervals for all mean changes from baseline were &lt; 7 msec (see section 4.8).</p><p>Of the&nbsp;2,182 patients with resistance or intolerance to prior imatinib therapy&nbsp;who received dasatinib in clinical studies, 15 (1%) had QTc prolongation reported as an adverse reaction. Twenty-one of these patients (1%) experienced a QTcF &gt; 500 msec.</p><p>Dasatinib should be&nbsp;administered with&nbsp;caution&nbsp;to&nbsp;patients who&nbsp;have or&nbsp;may&nbsp;develop&nbsp;prolongation&nbsp;of QTc.&nbsp;Theseinclude&nbsp;patients&nbsp;with hypokalaemia or&nbsp;hypomagnesaemia, patients with&nbsp;congenital long QT&nbsp;syndrome, patients taking antiarrhythmic medicinal products or other medicinal products which lead to QT prolongation, and cumulative high dose anthracycline therapy. Hypokalaemia or hypomagnesaemia should be corrected prior to dasatinib administration.</p><p><u>Cardiac&nbsp;adverse&nbsp;reactions</u></p><p>Dasatinib was studied in a randomised clinical study of 519 patients with newly diagnosed CML&nbsp;in chronic phase which included patients with prior cardiac disease. The cardiac adverse reactions of congestive heart failure/cardiac dysfunction, pericardial effusion, arrhythmias, palpitations, QT prolongation&nbsp;and&nbsp;myocardialinfarction&nbsp;(including&nbsp;fatal)&nbsp;were&nbsp;reported&nbsp;in&nbsp;patients&nbsp;taking&nbsp;dasatinib.</p><p>Cardiac adverse reactions were more frequent in patients with risk factors or a history of cardiac disease. Patients with risk factors (e.g. hypertension, hyperlipidaemia, diabetes) or a history of cardiac disease (e.g. prior percutaneous coronary intervention, documented coronary artery disease) should be monitored carefully for clinical signs or symptoms consistent with cardiac dysfunction such as chest pain, shortness of breath, and diaphoresis.</p><p>If these clinical signs or symptoms develop, physicians are advised to interrupt dasatinib administration and consider the need for alternative CML-specific treatment. After resolution, a functional assessment should be performed prior to resuming treatment with dasatinib. Dasatinib may&nbsp;be&nbsp;resumed&nbsp;at&nbsp;the&nbsp;original&nbsp;dose&nbsp;formild/moderate&nbsp;adverse&nbsp;reactions&nbsp;(&le;&nbsp;grade&nbsp;2)&nbsp;and&nbsp;resumed&nbsp;at a dose level reduction for severe adverse reactions (&ge; grade 3) (see section 4.2). Patients continuing treatment should be monitored periodically.</p><p>Patients with uncontrolled or significant cardiovascular disease were not included in the clinical&nbsp;studies.</p><p><u>Thrombotic&nbsp;microangiopathy&nbsp;(TMA)</u></p><p>BCR-ABL tyrosine kinase inhibitors have been associated with thrombotic microangiopathy (TMA), including individual case reports for Dasatinib Tablets (see section 4.8). If laboratory or clinical&nbsp;findings&nbsp;associated withTMA&nbsp;occur in a patient&nbsp;receiving Dasatinib&nbsp;Tablets, treatment with Dasatinib&nbsp;Tablets&nbsp;should&nbsp;be&nbsp;discontinued&nbsp;andthorough&nbsp;evaluation&nbsp;for&nbsp;TMA,&nbsp;including&nbsp;ADAMTS13 activity and anti-ADAMTS13-antibody determination, should be completed. If anti-ADAMTS13- antibody&nbsp;is elevated&nbsp;in&nbsp;conjunction&nbsp;with&nbsp;low&nbsp;ADAMTS13&nbsp;activity,treatment&nbsp;with&nbsp;Dasatinib&nbsp;Tablets should not be resumed.</p><p><u>Hepatitis&nbsp;B&nbsp;reactivation</u></p><p>Reactivation of hepatitis B in patients who are chronic carriers of this virus has occurred after these patients received BCR-ABL&nbsp;tyrosine kinase inhibitors. Some cases resulted in acute hepatic failure or fulminant hepatitis leading to liver transplantation or a fatal outcome.</p><p>Patients should be tested for HBV infection before initiating treatment with Dasatinib Tablets. Experts in liver disease and in the treatment of hepatitis B should be consulted before treatment is initiated in patients with positive hepatitis B serology (including those with active disease) and for patients who test positive for HBV infection during treatment. Carriers of HBV who require treatment with Dasatinib Tablets should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy (see section 4.8).</p><p>&nbsp;</p><p><u>Effects&nbsp;on&nbsp;growth&nbsp;and&nbsp;development&nbsp;in&nbsp;paediatric&nbsp;patients</u></p><p>In&nbsp;paediatric&nbsp;trials&nbsp;of&nbsp;Dasatinib&nbsp;Tablets&nbsp;in&nbsp;imatinib-resistant/intolerant&nbsp;Ph+&nbsp;CML-CP&nbsp;paediatric&nbsp;patients and treatment-naive Ph+ CML-CP paediatric patients after at least 2 years of treatment, treatment-related adverse events associated with bone growth and development were reported in 6 (4.6%) patients, one of which was severe in intensity (Growth Retardation Grade 3). These 6 cases included cases of epiphyses delayed fusion, osteopaenia,&nbsp;rowth retardation, and gynecomastia (see section 5.1). These results are difficult to interpret in the context of chronic diseases such as CML, and require long-term follow-up.</p><p>In paediatric trials of Dasatinib Tablets in combination with chemotherapy in newly diagnosed Ph+ ALL paediatric patients after a maximum of 2 years of treatment, treatment-related adverse events associated with bone growth and development were reported in 1 (0.6%) patient. This case was a Grade 1 osteopenia.</p><p><u>Excipients</u></p><p><em><u>Lactose</u></em></p><p>This medicinal product contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take&nbsp;this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Active&nbsp;substances&nbsp;that&nbsp;may&nbsp;increase&nbsp;dasatinib&nbsp;plasma&nbsp;concentrations</u></p><p><em>In vitro&nbsp;</em>studies indicate that dasatinib is a CYP3A4 substrate. Concomitant use of dasatinib and medicinal products or substances which potently inhibit CYP3A4 (e.g. ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, telithromycin, grapefruit juice) may increase exposure to dasatinib. Therefore, in patients receiving dasatinib, systemic administration of a potent CYP3A4 inhibitor is not recommended (see section 4.2).</p><p>At clinically relevant concentrations, binding of dasatinib to plasma proteins is approximately 96% on the basis of&nbsp;<em>in vitro&nbsp;</em>experiments. No studies have been performed to evaluate dasatinib interaction with other protein-bound medicinal products. The potential for displacement and its clinical relevance are unknown.</p><p><u>Active&nbsp;substances&nbsp;that&nbsp;may&nbsp;decrease&nbsp;dasatinib&nbsp;plasma&nbsp;concentrations</u></p><p>When dasatinib was administered following 8 daily evening administrations of 600 mg rifampicin,&nbsp;a potent CYP3A4 inducer, the AUC of dasatinib was decreased by 82%. Other medicinal products that induce CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, phenobarbital or herbal preparations containing&nbsp;<em>Hypericum perforatum</em>, also known as St. John&acute;s Wort) may also increase metabolism and decrease dasatinib plasma concentrations. Therefore, concomitant use of potent&nbsp;CYP3A4&nbsp;inducers&nbsp;with&nbsp;dasatinib&nbsp;is&nbsp;notrecommended.&nbsp;In&nbsp;patients&nbsp;in&nbsp;whom rifampicin or other CYP3A4 inducers are indicated, alternative medicinal products with less&nbsp;enzyme&nbsp;induction&nbsp;potential&nbsp;should&nbsp;be&nbsp;used.&nbsp;Concomitant&nbsp;use&nbsp;of&nbsp;dexamethasone,&nbsp;a&nbsp;weakCYP3A4&nbsp;inducer, with dasatinib is allowed; dasatinib&nbsp;AUC is predicted to decrease approximately 25% with concomitant use of dexamethasone, which is not likely to be clinically meaningful.</p><p><u>Histamine-2&nbsp;antagonists&nbsp;and&nbsp;proton&nbsp;pump&nbsp;inhibitors</u></p><p>Long-term suppression of gastric acid secretion by H2&nbsp;antagonists or proton pump inhibitors (e.g. famotidine and omeprazole) is likely&nbsp;to reduce dasatinib exposure. In a single-dose study&nbsp;in healthy subjects, the administration of famotidine 10 hours prior to a single dose of Dasatinib Tablets reduced dasatinib exposure by 61%. In a study of 14 healthy subjects, administration of a single 100-mg dose of Dasatinib Tablets 22 hours following a 4-day, 40-mg omeprazole dose at steady state reduced the AUC of dasatinib by 43% and the Cmax&nbsp;of dasatinib by 42%. The use of antacids should be considered in place of H2&nbsp;antagonists or proton pump inhibitors in patients receiving Dasatinib Tablets therapy (see section 4.4).</p><p><u>Antacids</u></p><p>Non-clinical data demonstrate that the solubility of dasatinib is pH-dependent. In healthy subjects, the concomitant use&nbsp;of aluminium&nbsp;hydroxide/magnesium hydroxide antacids with Dasatinib&nbsp;Tablets reduced the AUC of a single dose of Dasatinib Tablets by 55% and the Cmax&nbsp;by 58%. However, when antacids were administered 2 hours prior to a single dose of Dasatinib Tablets, no relevant changes in dasatinib concentration or exposure were observed. Thus, antacids may be administered up to 2 hours prior to or 2 hours following Dasatinib Tablets (see section 4.4).</p><p><u>Active&nbsp;substances&nbsp;that&nbsp;may&nbsp;have&nbsp;their&nbsp;plasma&nbsp;concentrations&nbsp;altered&nbsp;by&nbsp;dasatinib</u></p><p>Concomitant use of dasatinib and a CYP3A4 substrate may increase exposure to the CYP3A4&nbsp;substrate. In a study in healthy subjects, a single 100 mg dose of dasatinib increased&nbsp;AUC and Cmax&nbsp;exposure to simvastatin, a known CYP3A4 substrate, by 20 and 37% respectively. It cannot be excluded that the effect is larger after multiple doses of dasatinib. Therefore, CYP3A4 substrates known to have a narrow therapeutic index (e.g. astemizole, terfenadine, cisapride, pimozide, quinidine,&nbsp;bepridil&nbsp;or&nbsp;ergot alkaloids&nbsp;[ergotamine,&nbsp;dihydroergotamine])&nbsp;should&nbsp;be administered&nbsp;with caution in patients receiving dasatinib (see section 4.4).</p><p>In&nbsp;vitro&nbsp;data&nbsp;indicate&nbsp;a&nbsp;potential&nbsp;risk&nbsp;for&nbsp;interaction&nbsp;with&nbsp;CYP2C8&nbsp;substrates,&nbsp;such&nbsp;as&nbsp;glitazones.&nbsp;<u>Paediatric population</u></p><p>Interaction&nbsp;studies&nbsp;have&nbsp;only&nbsp;been&nbsp;performed&nbsp;in&nbsp;adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women&nbsp;of&nbsp;childbearing&nbsp;potential/contraception&nbsp;in&nbsp;males&nbsp;and&nbsp;females</u></p><p>Both&nbsp;sexually&nbsp;active&nbsp;men&nbsp;and&nbsp;women&nbsp;of&nbsp;childbearing&nbsp;potential&nbsp;should&nbsp;use&nbsp;effective&nbsp;methods&nbsp;of contraception during treatment.</p><p><u>Pregnancy</u></p><p>Based&nbsp;on&nbsp;human&nbsp;experience,&nbsp;dasatinib&nbsp;is&nbsp;suspected&nbsp;to&nbsp;cause&nbsp;congenital&nbsp;malformations&nbsp;including&nbsp;neural tube defects, and harmful pharmacological effects on the foetus when administered during pregnancy. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>Dasatinib Tablets should not be used during pregnancy unless the clinical condition of the woman requirestreatment&nbsp;with dasatinib. If&nbsp;Dasatinib&nbsp;Tablets&nbsp;is&nbsp;used&nbsp;during pregnancy, the&nbsp;patient must be informed of the potential risk to the foetus.</p><p><u>Breast-feeding</u></p><p>There is insufficient/limited information on the excretion of dasatinib in human or animal breast milk. Physico-chemical and available pharmacodynamic/toxicological data on dasatinib point to excretion in breast milk and a risk to the suckling child cannot be excluded.</p><p>Breast-feeding&nbsp;should&nbsp;be&nbsp;stopped&nbsp;during&nbsp;treatment&nbsp;with&nbsp;Dasatinib&nbsp;Tablets.&nbsp;<u>Fertility</u></p><p>In animal studies, the fertility of male and female rats was not affected by treatment with dasatinib (see section 5.3). Physicians and other healthcare providers should counsel male patients of appropriate age about possible effects of Dasatinib Tablets on fertility, and this counseling may&nbsp;include consideration of semen deposition.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dasatinib Tablets has minor influence on the ability to drive and use machines.</p><p>Patients should be advised that they may experience adverse reactions such as dizziness or blurred vision during treatment with dasatinib.</p><p>Therefore, caution should be recommended when driving a car or&nbsp;operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary&nbsp;of the&nbsp;safety&nbsp;profile</u></p><p>The data described below reflect the exposure to Dasatinib Tablets as single-agent therapy at all doses tested in clinical studies (N=2,900), including 324 adult patients with newly diagnosed chronic phase CML, 2,388 adult patients with imatinibresistant or -intolerant chronic or advanced phase CML or Ph+ ALL, and 188 paediatric patients.</p><p>In the 2,712 adult patients with either chronic phase CML, advanced phase CML or Ph+&nbsp;ALL, the median duration of therapy was 19.2 months (range 0 to 93.2 months). In a randomized trial in patients with newly diagnosed chronic phase CML, the median duration of therapy was approximately 60 months. The median duration of therapy in 1,618 adult patients with chronic phase&nbsp;CML&nbsp;was 29&nbsp;months (range 0&nbsp;to 92.9 months).&nbsp;The median duration of&nbsp;therapy&nbsp;in 1,094 adult patients with advanced phase CML or Ph+ ALL was 6.2 months (range 0 to 93.2 months).&nbsp;Among 188 patients in paediatric studies, the median duration of therapy was 26.3 months (range 0 to 99.6 months). In the subset of 130 chronic phase CML Dasatinib Tablets-treated paediatric patients, the median duration of therapy was 42.3 months (range 0.1 to 99.6 months).</p><p>The majority of Dasatinib Tablets-treated patients experienced adverse reactions at some time. In the overall population of 2,712 Dasatinib Tablets-treated adult subjects, 520 (19%) experienced adverse reactions leading to treatment discontinuation.</p><p>The overall safety profile of Dasatinib Tablets in the paediatric Ph+ CML-CP population was similar to that of the adult population, regardless of formulation, with the exception of no reported pericardial effusion, pleural effusion, pulmonary oedema, or pulmonary hypertension in the paediatric population. Of the 130 Dasatinib Tablets-treated paediatric subjects with CML-CP, 2 (1.5%) experienced adverse reactions leading to treatment discontinuation.</p><p><u>Tabulated&nbsp;list&nbsp;of&nbsp;adverse&nbsp;reactions</u></p><p>The following adverse reactions, excluding laboratory abnormalities, were reported in patients treated with Dasatinib Tablets used as single-agent therapy in clinical studies and post-marketing experience (Table 5). These reactions are presented by system organ class and by frequency. Frequencies are defined as: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); not known (cannot be estimated from available post-marketing data).</p><p>Within&nbsp;each&nbsp;frequency&nbsp;grouping,&nbsp;adverse&nbsp;reactions are&nbsp;presented&nbsp;in&nbsp;order&nbsp;of&nbsp;decreasing&nbsp;seriousness.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table&nbsp;5:&nbsp;Tabulated&nbsp;summary&nbsp;of&nbsp;adverse&nbsp;reactions</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections&nbsp;and&nbsp;infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very</em><em>&nbsp;</em><em>common</em></p></td><td style="vertical-align:top"><p>infection&nbsp;(including&nbsp;bacterial,&nbsp;viral,&nbsp;fungal,&nbsp;non-specified)</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>pneumonia&nbsp;(including&nbsp;bacterial,&nbsp;viral,&nbsp;and&nbsp;fungal),&nbsp;upper&nbsp;respiratory&nbsp;tract&nbsp;infection/ inflammation, herpes virus infection (including cytomegalovirus &ndash; CMV), enterocolitis infection, sepsis (including uncommon cases with fatal outcomes)</p></td></tr><tr><td style="vertical-align:top"><p><em>Not&nbsp;known</em></p></td><td style="vertical-align:top"><p>hepatitis&nbsp;B&nbsp;reactivation</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood&nbsp;and&nbsp;lymphatic&nbsp;system&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very</em><em>&nbsp;</em><em>common</em></p></td><td style="vertical-align:top"><p>myelosuppression&nbsp;(including&nbsp;anaemia,&nbsp;neutropaenia,&nbsp;thrombocytopaenia)</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>febrile&nbsp;neutropaenia</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>lymphadenopathy,&nbsp;lymphopaenia</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top"><p>aplasia&nbsp;pure red&nbsp;cell</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune&nbsp;system&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>hypersensitivity&nbsp;(including&nbsp;erythema&nbsp;nodosum)</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top"><p>anaphylactic&nbsp;shock</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Endocrine&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>hypothyroidism</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top"><p>hyperthyroidism,&nbsp;thyroiditis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism&nbsp;and&nbsp;nutrition&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>appetite&nbsp;disturbances<sup>a</sup>,&nbsp;hyperuricaemia</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>tumour&nbsp;lysis&nbsp;syndrome,&nbsp;dehydration,&nbsp;hypoalbuminemia,&nbsp;hypercholesterolemia</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top"><p>diabetes&nbsp;mellitus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>depression,&nbsp;insomnia</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>anxiety,&nbsp;confusional&nbsp;state,&nbsp;affect&nbsp;lability,&nbsp;libido&nbsp;decreased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous&nbsp;system&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very</em><em>&nbsp;</em><em>common</em></p></td><td style="vertical-align:top"><p>headache</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>neuropathy&nbsp;(including&nbsp;peripheral&nbsp;neuropathy),&nbsp;dizziness,&nbsp;dysgeusia,&nbsp;somnolence</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>CNS&nbsp;bleeding<sup>*b</sup>,&nbsp;syncope,&nbsp;tremor,&nbsp;amnesia,&nbsp;balance&nbsp;disorder</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top"><p>cerebrovascular&nbsp;accident,&nbsp;transient&nbsp;ischaemic&nbsp;attack,&nbsp;convulsion,&nbsp;optic&nbsp;neuritis, VIIth nerve paralysis, dementia, ataxia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>visual&nbsp;disorder&nbsp;(including&nbsp;visual&nbsp;disturbance,&nbsp;vision&nbsp;blurred,&nbsp;and&nbsp;visual&nbsp;acuity reduced), dry eye</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>visual&nbsp;impairment,&nbsp;conjunctivitis,&nbsp;photophobia,&nbsp;lacrimation&nbsp;increased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear&nbsp;and&nbsp;labyrinth&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>tinnitus</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>hearing&nbsp;loss,&nbsp;vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>congestive&nbsp;heart&nbsp;failure/cardiac&nbsp;dysfunction*<sup>c</sup>,&nbsp;pericardial&nbsp;effusion*,&nbsp;arrhythmia (including tachycardia), palpitations</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>myocardial infarction (including fatal outcome)*, electrocardiogram QT prolonged*, pericarditis, ventricular arrhythmia (including ventricular tachycardia),&nbsp;angina&nbsp;pectoris,&nbsp;cardiomegaly,&nbsp;electrocardiogram&nbsp;T&nbsp;wave&nbsp;abnormal, troponin increased</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top"><p>cor pulmonale, myocarditis, acute coronary syndrome, cardiac arrest, electrocardiogram&nbsp;PR&nbsp;prolongation,&nbsp;coronary&nbsp;artery&nbsp;disease,&nbsp;pleuropericarditis</p></td></tr><tr><td style="vertical-align:top"><p><em>Unknown</em></p></td><td style="vertical-align:top"><p>atrial&nbsp;fibrillation/atrial&nbsp;flutter</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular</strong><strong>&nbsp;</strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very</em><em>&nbsp;</em><em>common</em></p></td><td style="vertical-align:top"><p>Haemorrhage<sup>*d</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>hypertension,&nbsp;flushing</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>hypotension,&nbsp;thrombophlebitis,&nbsp;thrombosis</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top"><p>deep&nbsp;vein&nbsp;thrombosis,&nbsp;embolism,&nbsp;livedo&nbsp;reticularis</p></td></tr><tr><td style="vertical-align:top"><p><em>Not&nbsp;known</em></p></td><td style="vertical-align:top"><p>thrombotic&nbsp;microangiopathy</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory,&nbsp;thoracic&nbsp;and&nbsp;mediastinal&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very</em><em>&nbsp;</em><em>common</em></p></td><td style="vertical-align:top"><p>pleural&nbsp;effusion*,&nbsp;dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>pulmonary&nbsp;oedema*,&nbsp;pulmonary&nbsp;hypertension*,&nbsp;lung&nbsp;infiltration,&nbsp;pneumonitis,&nbsp;cough</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>pulmonary&nbsp;arterial&nbsp;hypertension,&nbsp;bronchospasm,&nbsp;asthma</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top"><p>pulmonary&nbsp;embolism,&nbsp;acute&nbsp;respiratory&nbsp;distress&nbsp;syndrome</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:1398px"><tbody><tr><td style="vertical-align:top"><p><em>Not&nbsp;known</em></p></td><td style="vertical-align:top; width:1292px"><p>interstitial&nbsp;lung&nbsp;disease</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1395px"><p><strong>Gastrointestinal&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very</em><em>&nbsp;</em><em>common</em></p></td><td style="vertical-align:top; width:1292px"><p>diarrhoea,&nbsp;vomiting,&nbsp;nausea,&nbsp;abdominal&nbsp;pain</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top; width:1292px"><p>gastrointestinal bleeding*, colitis (including neutropaenic colitis), gastritis, mucosal&nbsp;inflammation&nbsp;(including&nbsp;mucositis/stomatitis),&nbsp;dyspepsia,&nbsp;abdominal distension, constipation, oral soft tissuedisorder</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top; width:1292px"><p>pancreatitis (including acute pancreatitis), upper gastrointestinal ulcer, oesophagitis,&nbsp;ascites*,&nbsp;anal&nbsp;fissure,&nbsp;dysphagia,&nbsp;gastroesophageal&nbsp;reflux&nbsp;disease</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top; width:1292px"><p>protein-losing&nbsp;gastroenteropathy,&nbsp;ileus,&nbsp;anal&nbsp;fistula</p></td></tr><tr><td style="vertical-align:top"><p><em>Not&nbsp;known</em></p></td><td style="vertical-align:top; width:1292px"><p>fatal&nbsp;gastrointestinal&nbsp;haemorrhage*</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1395px"><p><strong>Hepatobiliary&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top; width:1292px"><p>hepatitis,&nbsp;cholecystitis,&nbsp;cholestasis</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1395px"><p><strong>Skin&nbsp;and&nbsp;subcutaneous&nbsp;tissue&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very</em><em>&nbsp;</em><em>common</em></p></td><td style="vertical-align:top; width:1292px"><p>skin&nbsp;rash<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top; width:1292px"><p>alopecia,&nbsp;dermatitis&nbsp;(including&nbsp;eczema),&nbsp;pruritus,&nbsp;acne,&nbsp;dry&nbsp;skin,&nbsp;urticaria,&nbsp;hyperhidrosis</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top; width:1292px"><p>neutrophilic&nbsp;dermatosis,&nbsp;photosensitivity,&nbsp;pigmentation&nbsp;disorder,&nbsp;panniculitis,&nbsp;skin ulcer, bullousconditions, nail disorder, palmar-plantar erythrodysesthesia syndrome, hair disorder</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top; width:1292px"><p>leukocytoclastic&nbsp;vasculitis,&nbsp;skin&nbsp;fibrosis</p></td></tr><tr><td style="vertical-align:top"><p><em>Not&nbsp;known</em></p></td><td style="vertical-align:top; width:1292px"><p>Stevens-Johnson&nbsp;syndrome<sup>f</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1395px"><p><strong>Musculoskeletal&nbsp;and&nbsp;connective&nbsp;tissue&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very</em><em>&nbsp;</em><em>common</em></p></td><td style="vertical-align:top; width:1292px"><p>musculoskeletal&nbsp;pain<sup>g</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top; width:1292px"><p>arthralgia,&nbsp;myalgia,&nbsp;muscular&nbsp;weakness,&nbsp;musculoskeletal&nbsp;stiffness,&nbsp;muscle&nbsp;spasm</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top; width:1292px"><p>rhabdomyolysis,&nbsp;osteonecrosis,&nbsp;muscle&nbsp;inflammation,&nbsp;tendonitis,&nbsp;arthritis</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top; width:1292px"><p>epiphyses&nbsp;delayed&nbsp;fusion<sup>h</sup>,&nbsp;growth&nbsp;retardation<sup>h</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1395px"><p><strong>Renal&nbsp;and&nbsp;urinary&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top; width:1292px"><p>renal&nbsp;impairment&nbsp;(including&nbsp;renal&nbsp;failure),&nbsp;urinary&nbsp;frequency,&nbsp;proteinuria</p></td></tr><tr><td style="vertical-align:top"><p><em>Not&nbsp;known</em></p></td><td style="vertical-align:top; width:1292px"><p>nephrotic&nbsp;syndrome</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1395px"><p><strong>Pregnancy,&nbsp;puerperium&nbsp;and&nbsp;perinatal&nbsp;conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top; width:1292px"><p>abortion</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1395px"><p><strong>Reproductive&nbsp;system&nbsp;and&nbsp;breast&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top; width:1292px"><p>gynecomastia,&nbsp;menstrual&nbsp;disorder</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1395px"><p><strong>General&nbsp;disorders&nbsp;and&nbsp;administration&nbsp;site&nbsp;conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very</em><em>&nbsp;</em><em>common</em></p></td><td style="vertical-align:top; width:1292px"><p>peripheral&nbsp;oedema<sup>i</sup>,&nbsp;fatigue,&nbsp;pyrexia,&nbsp;face&nbsp;oedema<sup>j</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top; width:1292px"><p>asthenia,&nbsp;pain,&nbsp;chest&nbsp;pain,&nbsp;generalised&nbsp;oedema<sup>*k</sup>,&nbsp;chills</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top; width:1292px"><p>malaise,&nbsp;other&nbsp;superficial&nbsp;oedemal</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top; width:1292px"><p>gait&nbsp;disturbance</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1395px"><p><strong>Investigations</strong></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:1399px"><tbody><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top; width:1310px"><p>weight&nbsp;decreased,&nbsp;weight&nbsp;increased</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top; width:1310px"><p>blood&nbsp;creatine&nbsp;phosphokinase&nbsp;increased,&nbsp;gamma-glutamyltransferase&nbsp;increased</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:1396px"><p><strong>Injury,&nbsp;poisoning,&nbsp;and&nbsp;procedural&nbsp;complications</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top; width:1310px"><p>contusion</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;Includes&nbsp;decreased&nbsp;appetite,&nbsp;early&nbsp;satiety,&nbsp;increased&nbsp;appetite.</p><p><sup>b</sup>&nbsp;Includes central nervous system haemorrhage, cerebral haematoma, cerebral haemorrhage, extradural haematoma, haemorrhage intracranial, haemorrhagic stroke, subarachnoid haemorrhage, subdural haematoma, and subdural haemorrhage.</p><p><sup>c</sup>&nbsp;Includes brain natriuretic peptide increased, ventricular dysfunction, left ventricular dysfunction, right ventricular dysfunction, cardiac failure, cardiac failure acute, cardiac failure chronic, cardiac failure congestive, cardiomyopathy, congestive cardiomyopathy, diastolic dysfunction, ejection fraction decreased and ventricular failure, left ventricular failure, right ventricular failure, and ventricular hypokinesia.</p><p><sup>d</sup>&nbsp;Excludes gastrointestinal bleeding and CNS bleeding; these adverse reactions are reported under the gastrointestinal disorders system organ class and the nervous system disorders system organ class, respectively.</p><p><sup>e</sup>&nbsp;Includes drug eruption, erythema, erythema multiforme, erythrosis, exfoliative rash, generalised erythema, genital rash, heat rash, milia, miliaria, pustular psoriaisis, rash, rash erythematous, rash follicular, rash generalised, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular,&nbsp;rash&nbsp;vesicular,&nbsp;skin&nbsp;exfoliation,&nbsp;skinirritation,&nbsp;toxic&nbsp;skin&nbsp;eruption,&nbsp;urticaria&nbsp;vesiculosa,&nbsp;and vasculitic rash.</p><p><sup>f</sup>&nbsp;In&nbsp;the&nbsp;post-marketing&nbsp;setting,&nbsp;individual&nbsp;cases&nbsp;of&nbsp;Stevens-Johnson&nbsp;syndrome&nbsp;have&nbsp;been&nbsp;reported.&nbsp;It could not be determined whether these mucocutaneous adverse reactions were directly related to Dasatinib Tablets or to concomitant medicinal product.</p><p><sup>g</sup>&nbsp;Musculoskeletal&nbsp;pain&nbsp;reported&nbsp;during&nbsp;or&nbsp;after&nbsp;discontinuing&nbsp;treatment.</p><p><sup>h</sup>&nbsp;Frequency&nbsp;reported&nbsp;as&nbsp;common&nbsp;in&nbsp;paediatric&nbsp;studies.</p><p><sup>i</sup>&nbsp;Gravitational&nbsp;oedema,&nbsp;localised&nbsp;oedema,&nbsp;oedema&nbsp;peripheral.</p><p><sup>j</sup>&nbsp;Conjunctival oedema, eye oedema, eye swelling, eyelid oedema, face oedema, lip oedema,&nbsp;macular oedema, oedema mouth, orbital oedema, periorbital oedema, swelling face.</p><p><sup>k</sup>&nbsp;Fluid overload, fluid retention, gastrointestinal oedema, generalised oedema, peripheral swelling, oedema, oedema due to cardiac disease, perinephric effusion, post procedural oedema, visceral&nbsp;oedema.</p><p><sup>l</sup>&nbsp;Genital swelling, incision site oedema, oedema genital, penile oedema, penile swelling, scrotal oedema, skin swelling, testicular swelling, vulvovaginal swelling.</p><p>*&nbsp;For&nbsp;additional&nbsp;details,&nbsp;see&nbsp;section&nbsp;&quot;Description&nbsp;of&nbsp;selected&nbsp;adverse&nbsp;reactions.</p><p><u>Description&nbsp;of&nbsp;selected&nbsp;adverse&nbsp;reactions</u></p><p><em><u>Myelosuppression</u></em></p><p>Treatment with Dasatinib&nbsp;Tablets is associated with anaemia, neutropaenia and thrombocytopaenia. Their occurrence is earlier and more frequent in patients with advanced phase CML or Ph+ ALL than in chronic phase CML (see section 4.4).</p><p><em><u>Bleeding</u></em></p><p>Bleeding drug-related adverse reactions, ranging from petechiae and epistaxis to grade 3 or 4 gastrointestinal haemorrhage and CNS bleeding, were reported in patients taking Dasatinib Tablets (see section 4.4).</p><p><em><u>Fluid&nbsp;retention</u></em></p><p>Miscellaneous adverse reactions such as pleural effusion, ascites, pulmonary oedema and&nbsp;pericardial effusion with or without superficial oedema may be collectively described as &ldquo;fluid retention&rdquo;. In the newly diagnosed chronic phase CML&nbsp;study after a minimum of 60 months follow up, dasatinib-related fluid retention adverse reactions included pleural effusion (28%), superficial oedema (14%), pulmonary hypertension (5%), generalised oedema (4%), and pericardial effusion (4%). Congestive heart failure/cardiac dysfunction and pulmonary oedema were reported in &lt; 2%&nbsp;of patients.</p><p>The cumulative rate of dasatinib-related pleural effusion (all grades) over time was 10% at 12 months, 14% at 24 months, 19% at 36 months, 24% at 48 months and 28% at 60 months.&nbsp;A&nbsp;total of 46 dasatinib-treated patients had recurrent pleural effusions. Seventeen patients had 2 separate adverse reactions, 6 had 3 adverse reactions, 18 had 4 to 8 adverse reactions and 5 had &gt; 8 episodes of pleural effusions.</p><p>The median time to first dasatinib-related grade 1 or 2 pleural effusion was 114 weeks (range: 4 to 299 weeks). Less than 10% of patients with pleural effusion had severe (grade 3 or 4) dasatinib related pleural effusions. The median time to first occurrence of grade &ge; 3 dasatinib-related pleural effusion&nbsp;was&nbsp;175&nbsp;weeks&nbsp;(range:&nbsp;114&nbsp;to&nbsp;274weeks).&nbsp;The&nbsp;median&nbsp;duration&nbsp;of&nbsp;dasatinib-related&nbsp;pleural effusion (all grades) was 283 days (~40 weeks).</p><p>Pleural effusion was usually reversible and managed by interrupting Dasatinib Tablets treatment&nbsp;and using diuretics or other appropriate&nbsp;supportive care measures (see&nbsp;sections 4.2 and 4.4).&nbsp;Among dasatinib&nbsp;treatedpatients with&nbsp;drug-related&nbsp;pleural&nbsp;effusion&nbsp;(n=73),&nbsp;45&nbsp;(62%)&nbsp;had&nbsp;dose&nbsp;interruptions and 30 (41%) had dose reductions. Additionally, 34 (47%) received diuretics, 23 (32%) received corticosteroids, and 20 (27%) received both corticosteroids and diuretics. Nine (12%) patients underwent therapeutic thoracentesis.</p><p>Six&nbsp;percent of&nbsp;dasatinib-treated patients&nbsp;discontinued treatment due&nbsp;to drug-related pleural&nbsp;effusion. Pleuraleffusion&nbsp;did&nbsp;not&nbsp;impair&nbsp;the&nbsp;ability&nbsp;of&nbsp;patients&nbsp;to&nbsp;obtain&nbsp;a&nbsp;response.&nbsp;Among&nbsp;the&nbsp;dasatinib&nbsp;treated patients with pleural effusion, 96% achieved a cCCyR, 82% achieved a MMR, and 50% achieved a MR4.5 despite dose interruptions or dose adjustment.</p><p>See section 4.4 for further information on patients with chronic phase CML and advanced phase CML or Ph+ ALL.</p><p><em><u>Pulmonary&nbsp;arterial&nbsp;hypertension&nbsp;(PAH)</u></em></p><p>PAH (pre-capillary pulmonary arterial hypertension confirmed by right heart catheterization) has been reported in association with dasatinib exposure. In these cases, PAH was reported after initiation of dasatinib therapy, including after more than one year of treatment. Patients with PAH reported during dasatinib treatment were often taking concomitant medicinal products or had co- morbidities in addition to the underlying malignancy. Improvements in haemodynamic and clinical parameters have been observed in patients with PAH following discontinuation of dasatinib.</p><p><em><u>QT&nbsp;Prolongation</u></em></p><p>In the Phase III study in patients with newly diagnosed chronic phase CML, one patient (&lt; 1%) of the Dasatinib Tablets-treated patients had a QTcF &gt; 500 msec after a minimum of 12 months follow-up (see section 4.4). No additional patients were reported to have QTcF &gt; 500 msec after a minimum of 60 months follow-up.</p><p>In 5 Phase II clinical studies in patients with resistance or intolerance to prior imatinib therapy, repeated baseline and ontreatment ECGs were obtained at pre-specified time points and read centrally for 865 patients receiving Dasatinib Tablets 70 mg twice daily. QT interval was corrected for heart rate by Fridericia&#39;s method.&nbsp;At all post-dose time points on day 8, the mean changes from baseline in QTcF interval were 4 - 6 msec, with associated upper 95% confidence intervals &lt; 7 msec. Of the 2,182 patients with resistance or intolerance to prior imatinib therapy who received Dasatinib&nbsp;Tablets&nbsp;in clinical&nbsp;studies,&nbsp;15 (1%)&nbsp;had QTc&nbsp;prolongation reported as an adverse reaction. Twenty-one patients (1%) experienced a QTcF &gt; 500 msec (see section 4.4).</p><p><em><u>Cardiac&nbsp;adverse&nbsp;reactions</u></em></p><p>Patients with&nbsp;risk&nbsp;factors or&nbsp;a&nbsp;history&nbsp;of&nbsp;cardiac&nbsp;disease should&nbsp;be&nbsp;monitored&nbsp;carefully&nbsp;for&nbsp;signs or&nbsp;= symptoms consistent with cardiac dysfunction and should be evaluated and treated appropriately (see section 4.4).</p><p><u>Hepatitis&nbsp;B&nbsp;reactivation</u></p><p>Hepatitis B&nbsp;reactivation&nbsp;has been reported in&nbsp;association with&nbsp;BCR-ABL&nbsp;TKIs.&nbsp;Some cases resulted in acute hepatic failure or fulminant hepatitis leading to liver transplantation or a fatal outcome (see section 4.4).</p><p>In the Phase III dose-optimisation study in patients with chronic phase CML with resistance or intolerance to prior imatinib therapy (median duration of treatment of 30 months), the incidence of pleural effusion and congestive heart failure/cardiac dysfunction was lower in patients treated with&nbsp;Dasatinib&nbsp;Tablets&nbsp;100 mg once daily&nbsp;than in those treated with&nbsp;Dasatinib&nbsp;Tablets 70&nbsp;mg twice&nbsp;daily. Myelosuppression was also reported less frequently in the 100 mg once daily treatment group (see Laboratory test abnormalities below). The median duration of therapy in the 100 mg once daily group&nbsp;was&nbsp;37 months (range 1-91months). Cumulative rates&nbsp;of selected adverse&nbsp;reactions&nbsp;that&nbsp;were reported in the 100 mg once daily recommended starting dose are shown in Table 6a.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Table 6a: Selected adverse reactions reported in a phase 3 dose optimisation study (imatinib intolerant or resistant chronic phase CML)<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Minimum&nbsp;of&nbsp;2&nbsp;years follow up</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Minimum&nbsp;of&nbsp;5&nbsp;years follow up</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Minimum&nbsp;of&nbsp;7&nbsp;years follow up</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>All&nbsp;grades</strong></p></td><td style="vertical-align:top"><p><strong>Grade&nbsp;3/4</strong></p></td><td style="vertical-align:top"><p><strong>All&nbsp;grades</strong></p></td><td style="vertical-align:top"><p><strong>Grade&nbsp;3/4</strong></p></td><td style="vertical-align:top"><p><strong>All&nbsp;grades</strong></p></td><td style="vertical-align:top"><p><strong>Grade&nbsp;3/4</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Preferred&nbsp;term</strong></p></td><td colspan="6" style="vertical-align:top"><p>Percent&nbsp;(%) of&nbsp;patients</p></td></tr><tr><td style="vertical-align:top"><p><strong>Diarrhoea</strong></p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fluid&nbsp;retention</strong></p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>Superficial&nbsp;oedema</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Pleural&nbsp;effusion</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Generalised&nbsp;oedema</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Pericardial&nbsp;effusion</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Pulmonary&nbsp;hypertension</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Haemorrhage</strong></p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal&nbsp;bleeding</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;Phase 3 dose optimisation study results reported in recommended starting dose of 100 mg once daily (n=165) population.</p><p>&nbsp;</p><p>In the Phase III dose-optimisation study in patients with advanced phase CML and Ph+ ALL, the median duration of treatment was 14 months for accelerated phase CML, 3 months for myeloid&nbsp;blast CML, 4 months for lymphoid blast CML and 3 months for Ph+ ALL. Selected adverse reactions that were reported in the recommended starting dose of 140 mg once daily are shown in Table 6b.&nbsp;A&nbsp;70 mg twice daily regimen was also studied. The 140 mg once daily regimen showed a comparable efficacy profile to the 70 mg twice daily regimen but a more favourable safety profile.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;6b:&nbsp;Selected&nbsp;adverse&nbsp;reactions&nbsp;reported&nbsp;in&nbsp;phase&nbsp;III&nbsp;dose-optimisation&nbsp;study: Advanced phase CML and Ph+ ALL<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>140&nbsp;mg&nbsp;once&nbsp;daily n = 304</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>All&nbsp;grades</strong></p></td><td style="vertical-align:top"><p><strong>Grade&nbsp;3/4</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Preferred&nbsp;term</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Percent&nbsp;(%)&nbsp;of&nbsp;patients</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Diarrhoea</strong></p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fluid&nbsp;retention</strong></p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>Superficial&nbsp;oedema</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>&lt;&nbsp;1</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:792px"><tbody><tr><td style="vertical-align:top; width:319px"><p>Pleural&nbsp;effusion</p></td><td style="vertical-align:top; width:236px"><p>20</p></td><td style="vertical-align:top; width:234px"><p>6</p></td></tr><tr><td style="vertical-align:top; width:319px"><p>Generalised&nbsp;oedema</p></td><td style="vertical-align:top; width:236px"><p>2</p></td><td style="vertical-align:top; width:234px"><p>0</p></td></tr><tr><td style="vertical-align:top; width:319px"><p>Congestive&nbsp;heart&nbsp;failure&nbsp;/cardiac&nbsp;dysfunction<sup>b</sup></p></td><td style="vertical-align:top; width:236px"><p>1</p></td><td style="vertical-align:top; width:234px"><p>0</p></td></tr><tr><td style="vertical-align:top; width:319px"><p>Pericardial&nbsp;effusion</p></td><td style="vertical-align:top; width:236px"><p>2</p></td><td style="vertical-align:top; width:234px"><p>1</p></td></tr><tr><td style="vertical-align:top; width:319px"><p>Pulmonary&nbsp;oedema</p></td><td style="vertical-align:top; width:236px"><p>1</p></td><td style="vertical-align:top; width:234px"><p>1</p></td></tr><tr><td style="vertical-align:top; width:319px"><p><strong>Haemorrhage</strong></p></td><td style="vertical-align:top; width:236px"><p>23</p></td><td style="vertical-align:top; width:234px"><p>8</p></td></tr><tr><td style="vertical-align:top; width:319px"><p>Gastrointestinal&nbsp;bleeding</p></td><td style="vertical-align:top; width:236px"><p>8</p></td><td style="vertical-align:top; width:234px"><p>6</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>a</sup>&nbsp;Phase&nbsp;3&nbsp;dose&nbsp;optimisation&nbsp;study&nbsp;results&nbsp;reported&nbsp;at&nbsp;the&nbsp;recommended&nbsp;starting&nbsp;dose&nbsp;of&nbsp;140&nbsp;mg&nbsp;once daily (n=304) population at 2 year final study follow up.</p><p><sup>b</sup>&nbsp;Includes ventricular dysfunction, cardiac failure, cardiac failure congestive, cardiomyopathy, congestive cardiomyopathy, diastolic dysfunction, ejection fraction decreased, and ventricular&nbsp;failure.</p><p>In addition, there were two studies in a total of 161 paediatric patients with Ph+ ALL in which Dasatinib Tablets was administered in combination with chemotherapy. In the pivotal study, 106 paediatric patients received Dasatinib Tablets in combination with chemotherapy on a continuous dosing regimen. In a supportive study, of 55 paediatric patients, 35 received Dasatinib Tablets in combination with chemotherapy on a discontinuous dosing regimen (two weeks on treatment followed by one to two weeks off) and 20 received Dasatinib Tablets in combination with chemotherapy on a continuous dosing regimen.&nbsp;Among the 126 Ph+&nbsp;ALL&nbsp;paediatric patients treated with Dasatinib Tablets on a continuous dosing regimen, the median duration of therapy was 23.6 months (range 1.4 to 33 months).</p><p>Of the 126 Ph+ ALL paediatric patients on a continuous dosing regimen, 2 (1.6%) experienced adverse reactions leading to treatment discontinuation. Adverse reactions reported in these two paediatric studies at a frequency of &ge;10% in patients on a continuous dosing regimen are shown in Table 7. Of note, pleural effusion was reported in 7 (5.6%) patients in this group, and is therefore not included in the table.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 7: Adverse reactions reported in &ge;10% of paediatric patients with Ph+ ALL treated with Dasatinib Tablets on a continuous dosing regimen in combination with chemotherapy&nbsp;(N=126)<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Percent&nbsp;(%)&nbsp;of&nbsp;patients</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Preferred&nbsp;term</strong></p></td><td style="vertical-align:top"><p><strong>All&nbsp;grades</strong></p></td><td style="vertical-align:top"><p><strong>Grade&nbsp;3/4</strong></p></td></tr><tr><td style="vertical-align:top"><p>Febrile&nbsp;neutropaenia</p></td><td style="vertical-align:top"><p>27.0</p></td><td style="vertical-align:top"><p>26.2</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>20.6</p></td><td style="vertical-align:top"><p>5.6</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>20.6</p></td><td style="vertical-align:top"><p>4.8</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal&nbsp;pain</p></td><td style="vertical-align:top"><p>14.3</p></td><td style="vertical-align:top"><p>3.2</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>12.7</p></td><td style="vertical-align:top"><p>4.8</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:1248px"><tbody><tr><td style="vertical-align:top; width:550px"><p>Pyrexia</p></td><td style="vertical-align:top; width:350px"><p>12.7</p></td><td style="vertical-align:top; width:345px"><p>5.6</p></td></tr><tr><td style="vertical-align:top; width:550px"><p>Headache</p></td><td style="vertical-align:top; width:350px"><p>11.1</p></td><td style="vertical-align:top; width:345px"><p>4.8</p></td></tr><tr><td style="vertical-align:top; width:550px"><p>Decreased&nbsp;appetite</p></td><td style="vertical-align:top; width:350px"><p>10.3</p></td><td style="vertical-align:top; width:345px"><p>4.8</p></td></tr><tr><td style="vertical-align:top; width:550px"><p>Fatigue</p></td><td style="vertical-align:top; width:350px"><p>10.3</p></td><td style="vertical-align:top; width:345px"><p>0</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>a</sup>&nbsp;In the pivotal study, among 106 total patients, 24 patients received the powder for oral suspension at least once, 8 of whom received the powder for oral suspension formulation exclusively.</p><p><em><u>Laboratory&nbsp;test&nbsp;abnormalities</u></em><em>&nbsp;Haematology</em></p><p>In the Phase III newly diagnosed chronic phase CML study, the following grade 3 or 4 laboratory abnormalities were reported after a minimum of 12 months follow-up in patients taking Dasatinib Tablets: neutropaenia (21%), thrombocytopaenia (19%), and anaemia (10%). After a minimum of 60 months follow-up, the cumulative rates of neutropaenia, thrombocytopaenia, and anaemia were 29%, 22% and 13%, respectively.</p><p>In Dasatinib Tablets-treated patients with newly diagnosed chronic phase CML who experienced grade 3 or 4 myelosuppression, recovery generally occurred following brief dose interruptions and/or reductions and permanent discontinuation of treatment occurred in 1.6% of patients after a minimum of 12 months follow-up.After a minimum of 60 months follow-up the cumulative rate of permanent discontinuation due to grade 3 or 4 myelosuppression was 2.3%.</p><p>In patients with CML with resistance or intolerance to prior imatinib therapy, cytopaenias (thrombocytopaenia, neutropaenia, and anaemia) were a consistent finding. However, the occurrence of cytopaenias was also clearly dependent on the stage of the disease. The frequency of grade 3 and 4 haematological abnormalities is presented in Table. 8.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Table&nbsp;8:&nbsp;CTC&nbsp;grades&nbsp;3/4&nbsp;haematological&nbsp;laboratory&nbsp;abnormalities&nbsp;in&nbsp;clinical&nbsp;studies&nbsp;inpatients with resistance or intolerance to prior imatinib therapy<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Chronic&nbsp;phase (n= 165)<sup>b</sup></p></td><td style="vertical-align:top"><p>Accelerated&nbsp;phase (n= 157)<sup>c</sup></p></td><td style="vertical-align:top"><p>Myeloid&nbsp;blast&nbsp;phase (n= 74)<sup>c</sup></p></td><td style="vertical-align:top"><p>Lymphoid blast phase&nbsp;and&nbsp;Ph+&nbsp;ALL (n= 168)<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>Percent&nbsp;(%)&nbsp;of&nbsp;patients</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Haematology parameters</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Neutropaenia</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>58</p></td><td style="vertical-align:top"><p>77</p></td><td style="vertical-align:top"><p>76</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopaenia</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>63</p></td><td style="vertical-align:top"><p>78</p></td><td style="vertical-align:top"><p>44</p></td></tr><tr><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>74</p></td><td style="vertical-align:top"><p>44</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;Phase&nbsp;3&nbsp;dose&nbsp;optimisation&nbsp;study&nbsp;results&nbsp;reported&nbsp;at&nbsp;2&nbsp;year&nbsp;study&nbsp;follow&nbsp;up.</p><p><sup>b</sup>&nbsp;CA180-034&nbsp;study&nbsp;results&nbsp;in&nbsp;recommended&nbsp;starting&nbsp;dose&nbsp;of&nbsp;100&nbsp;mg&nbsp;once&nbsp;daily.</p><p><sup>c</sup>&nbsp;CA180-035&nbsp;study&nbsp;results&nbsp;in&nbsp;recommended&nbsp;starting&nbsp;dose&nbsp;of&nbsp;140&nbsp;mg&nbsp;once&nbsp;daily.</p><p>CTC&nbsp;grades:&nbsp;neutropaenia&nbsp;(Grade&nbsp;3&nbsp;&ge;&nbsp;0.5&ndash;&nbsp;&lt;&nbsp;1.0&nbsp;&times;&nbsp;109/l,&nbsp;Grade&nbsp;4&nbsp;&lt;&nbsp;0.5&nbsp;&times;&nbsp;10<sup>9</sup>/l);&nbsp;thrombocytopaenia&nbsp;(Grade&nbsp;3&nbsp;&ge; 25&nbsp;&ndash; &lt;&nbsp;50&nbsp;&times;&nbsp;10<sup>9</sup>/l,&nbsp;Grade&nbsp;4&nbsp;&lt;&nbsp;25 &times; 10<sup>9</sup>/l);&nbsp;anaemia&nbsp;(haemoglobin&nbsp;Grade&nbsp;3&nbsp;&ge; 65 &ndash;&nbsp;&lt;&nbsp;80&nbsp;g/l,Grade 4&nbsp;&lt;&nbsp;65&nbsp;g/l).</p><p>Cumulative grade 3 or 4 cytopaenias among patients treated with 100 mg once daily&nbsp;were similar at 2&nbsp;and&nbsp;5years&nbsp;including:&nbsp;neutropaenia&nbsp;(35%&nbsp;vs.&nbsp;36%),&nbsp;thrombocytopaenia&nbsp;(23%&nbsp;vs.&nbsp;24%)&nbsp;and&nbsp;anaemia&nbsp;(13%&nbsp;vs.&nbsp;13%).</p><p>In patients who experienced grade 3 or 4 myelosuppression, recovery generally occurred following brief dose interruptions and/or reductions and permanent discontinuation of treatment occurred in 5% of patients. Most patients continued treatment without further evidence of myelosuppression.</p><p><em>Biochemistry</em></p><p>In the newly&nbsp;diagnosed chronic phase CML&nbsp;study, grade 3 or 4 hypophosphataemia was reported in 4% of Dasatinib Tabletstreated patients, and grade 3 or 4 elevations of transaminases, creatinine, and bilirubin were reported in &le; 1% of patients after a minimum of 12 months follow-up. After a minimum of 60 months follow-up the cumulative rate of grade 3 or 4 hypophosphataemia was 7%, grade 3 or 4 elevations of creatinine and bilirubin was 1% and grade 3 or 4 elevations of transaminases remained 1%. There were no discontinuations of Dasatinib Tablets therapy due to these biochemical laboratory parameters.</p><p><em>2&nbsp;year&nbsp;follow-up</em></p><p>Grade 3 or 4 elevations of transaminases or bilirubin were reported in 1% of patients with chronic phase CML (resistant or intolerant to imatinib), but elevations were reported with an increased frequency of 1 to 7% of patients with advanced phase CML and Ph+&nbsp;ALL. It was usually managed with dose reduction or interruption. In the Phase III dose-optimisation study&nbsp;in chronic phase CML, grade 3 or 4 elevations of transaminases or bilirubin were reported in &le; 1% of patients with similar low incidence in the four treatment groups. In the Phase III dose-optimisation study in advanced phase&nbsp;CML&nbsp;and Ph+ALL, grade 3 or 4 elevations of transaminases or bilirubin were reported in 1% to 5% of patients across treatment groups.</p><p>Approximately 5% of the Dasatinib Tablets-treated patients who had normal baseline levels experienced grade 3 or 4 transient hypocalcaemia at some time during the course of the study. In general, there was no association of decreased calcium with clinical symptoms. Patients developing grade 3 or 4 hypocalcaemia often had recovery with oral calcium supplementation. Grade 3 or 4 hypocalcaemia, hypokalaemia, and hypophosphataemia were reported in patients with all phases of CML but were reported with an increased frequency in patients with myeloid or lymphoid blast phase CML and Ph+ ALL. Grade 3 or 4 elevations in creatinine were reported in &lt; 1% of patients with chronic phase CML&nbsp;and were reported with an increased frequency&nbsp;of 1 to 4% of patients with advanced phase CML.</p><p><u>Paediatric&nbsp;population</u></p><p>The safety profile of Dasatinib Tablets administered as single-agent therapy in paediatric patients with Ph+ CML-CP was comparable to the safety profile in adults. The safety profile of Dasatinib Tablets administered in combination with chemotherapy in paediatric patients with Ph+ ALL was consistent with the known safety profile of Dasatinib Tablets in adults and the expected effects of chemotherapy, with the exception of&nbsp;a&nbsp;lower pleural effusion rate in&nbsp;paediatric patients as compared to adults.</p><p>In&nbsp;the paediatric CML&nbsp;studies, the rates of&nbsp;laboratory abnormalities were consistent with&nbsp;the known profile for laboratory parameters in adults.</p><p>In the paediatric&nbsp;ALL&nbsp;studies, the rates of laboratory abnormalities were consistent with the known profile for laboratory parameters in adults, within the context of an acute leukaemia patient receiving a background chemotherapy regimen.</p><p><u>Special&nbsp;population</u></p><p>While the safety profile of Dasatinib Tablets in elderly was similar to that in the younger&nbsp;population, patients aged 65 years and older are more likely to experience the commonly reported adverse reactions such as fatigue, pleural effusion, dyspnoea, cough, lower gastrointestinal haemorrhage, and appetite disturbance and more likely to experience less frequently reported adverse reactions such as abdominal distention, dizziness, pericardial effusion, congestive heart failure, and weight decrease and should be monitored closely (see section 4.4).</p><p>Reporting&nbsp;of&nbsp;suspected&nbsp;adverse&nbsp;reactions</p><p><strong>To&nbsp;reports&nbsp;any&nbsp;side&nbsp;effect(s):</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals&nbsp;are&nbsp;asked&nbsp;to&nbsp;report&nbsp;anysuspected&nbsp;adverse&nbsp;reactions&nbsp;to&nbsp;the&nbsp;competent&nbsp;authority&nbsp;in&nbsp;Saudi Arabia as per details below:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->The&nbsp;National&nbsp;Pharmacovigilance&nbsp;and Drug&nbsp;Safety&nbsp;Centre&nbsp;(NPC)</p><p>o &nbsp; Fax:&nbsp;+966-11-205-7662</p><p>o&nbsp; Call&nbsp;NPC&nbsp;at&nbsp;+966-11-2038222,&nbsp;Exts:&nbsp;2317-2356-2353-2354-2334-2340.</p><p><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;<!--[endif]-->Toll&nbsp;free&nbsp;phone:&nbsp;8002490000</p><p><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;<!--[endif]-->E-mail:&nbsp;npc.drug@sfda.gov.sa</p><p><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;<!--[endif]-->Website:&nbsp;www.sfda.gov.sa/npc</p><p>To&nbsp;report&nbsp;the&nbsp;Adverse&nbsp;event&nbsp;in&nbsp;other&nbsp;GCC&nbsp;States&nbsp;-&nbsp;Please&nbsp;contact&nbsp;the&nbsp;relevant&nbsp;competent&nbsp;authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Experience with overdose of Dasatinib Tablets in clinical studies is limited to isolated cases.</p><p>The highest&nbsp;overdose&nbsp;of280&nbsp;mg&nbsp;per&nbsp;day&nbsp;for&nbsp;one&nbsp;week&nbsp;was&nbsp;reported&nbsp;in&nbsp;two&nbsp;patients&nbsp;and&nbsp;both&nbsp;developed&nbsp;a significant decrease in platelet counts. Since dasatinib is associated with grade 3 or 4 myelosuppression&nbsp;(see&nbsp;section&nbsp;4.4),patients&nbsp;who&nbsp;ingest&nbsp;more&nbsp;than&nbsp;the&nbsp;recommended&nbsp;dose&nbsp;should&nbsp;be closely monitored for myelosuppression and given appropriate supportive treatment.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic&nbsp;group:&nbsp;antineoplastic&nbsp;agents,&nbsp;protein&nbsp;kinase&nbsp;inhibitors,&nbsp;ATC&nbsp;code:&nbsp;L01XE06&nbsp;<u>Pharmacodynamics</u></p><p>Dasatinib&nbsp;inhibits&nbsp;the&nbsp;activity&nbsp;of&nbsp;the&nbsp;BCR-ABL&nbsp;kinase&nbsp;and&nbsp;SRC&nbsp;family&nbsp;kinases&nbsp;along&nbsp;with&nbsp;a&nbsp;number of other selected oncogenic kinases including c-KIT, ephrin (EPH) receptor kinases, and PDGF&beta; receptor. Dasatinib is a potent, subnanomolar inhibitor of the BCR-ABL kinase with potency at concentration&nbsp;of&nbsp;0.6-0.8&nbsp;nM.&nbsp;It&nbsp;binds&nbsp;toboth&nbsp;the&nbsp;inactive&nbsp;and&nbsp;active&nbsp;conformations&nbsp;of&nbsp;the&nbsp;BCR-ABL&nbsp;enzyme.</p><p><u>Mechanism&nbsp;of&nbsp;action</u></p><p><em>In vitro</em>, dasatinib&nbsp;is active in&nbsp;leukaemic&nbsp;cell&nbsp;lines representing&nbsp;variants of imatinib-sensitive&nbsp;and resistant disease. These non-clinical studies show that dasatinib can overcome imatinib resistance resulting from BCR-ABL overexpression, BCRABL kinase domain mutations, activation of alternate signalling pathways involving the SRC family kinases (LYN, HCK), and multidrug resistance gene overexpression. Additionally, dasatinib inhibits SRC family kinases at subnanomolar concentrations.</p><p>In vivo, in separate experiments using murine models of CML, dasatinib prevented the progression of&nbsp;chronicCML&nbsp;to&nbsp;blast&nbsp;phase&nbsp;and&nbsp;prolonged&nbsp;the&nbsp;survival&nbsp;of&nbsp;mice&nbsp;bearing&nbsp;patient-derived&nbsp;CML&nbsp;cell lines grown at various sites, including the central nervous system.</p><p><u>Clinical efficacy and&nbsp;safety</u></p><p>In&nbsp;the&nbsp;Phase&nbsp;I&nbsp;study,&nbsp;haematologic&nbsp;and&nbsp;cytogenetic&nbsp;responses&nbsp;were&nbsp;observed&nbsp;in&nbsp;all&nbsp;phases&nbsp;of&nbsp;CML and in Ph+ALL&nbsp;in the first 84 patients treated and followed for up to 27 months. Responses were durable across all phases of CML and Ph+ ALL.</p><p>Four&nbsp;single-arm,&nbsp;uncontrolled,&nbsp;open-label&nbsp;Phase&nbsp;II&nbsp;clinical&nbsp;studies&nbsp;were&nbsp;conducted&nbsp;to&nbsp;determine&nbsp;the safety and efficacy of dasatinib in patients with CML in chronic, accelerated, or myeloid blast phase, who were either resistant or intolerant to imatinib. One randomised non-comparative study was conducted in chronic phase patients who failed initial treatment with 400 or 600 mg imatinib. The&nbsp;starting&nbsp;dose&nbsp;was&nbsp;70&nbsp;mg&nbsp;dasatinib&nbsp;twicedaily.&nbsp;Dose&nbsp;modifications&nbsp;were&nbsp;allowed&nbsp;for&nbsp;improving activity or management of toxicity (see section 4.2).</p><p>Two randomised, open-label Phase III studies were conducted to evaluate the efficacy of dasatinib administered once daily compared with dasatinib administered twice daily. In addition, one open label, randomised, comparative Phase III study was conducted in adult patients with newly diagnosed chronic phase CML.</p><p>The&nbsp;efficacy&nbsp;of&nbsp;dasatinib&nbsp;is&nbsp;based&nbsp;on&nbsp;haematological&nbsp;and&nbsp;cytogenetic response&nbsp;rates.</p><p>Durability of response and estimated survival rates provide additional evidence of dasatinib clinical&nbsp;benefit.</p><p>A&nbsp;total&nbsp;of&nbsp;2,712&nbsp;patients&nbsp;were&nbsp;evaluated&nbsp;in&nbsp;clinical&nbsp;studies;&nbsp;of&nbsp;these&nbsp;23%&nbsp;were&nbsp;&ge;&nbsp;65&nbsp;years&nbsp;of&nbsp;age&nbsp;and 5% were &ge; 75 years of age.</p><p><em><u>Chronic&nbsp;phase&nbsp;CML&nbsp;-&nbsp;Newly&nbsp;diagnosed</u></em></p><p>An&nbsp;international open-label, multicentre, randomised, comparative Phase&nbsp;III&nbsp;study&nbsp;was&nbsp;conducted in adult patients with newly&nbsp;diagnosed chronic phase CML. Patients were randomised to receive either Dasatinib Tablets 100 mg once daily or imatinib 400 mg once daily. The primary endpoint was the rate of confirmed complete cytogenetic response (cCCyR) within 12 months. Secondary endpoints included time in cCCyR (measure of durability of response), time to cCCyR, major molecular response (MMR) rate, time to MMR, progression free survival (PFS) and overall survival (OS). Other relevant efficacy results included CCyR and complete molecular response (CMR) rates.&nbsp;The study is ongoing.</p><p>A total of 519 patients were randomised to a treatment group: 259 to Dasatinib Tablets and 260 to imatinib. Baseline characteristics were&nbsp;well&nbsp;balanced between the two treatment groups with&nbsp;respect to age (median age was46 years for the Dasatinib&nbsp;Tablets group and 49 years for the imatinib group with&nbsp;10% and 11% of patients 65 years of age or older, respectively), gender (women 44% and 37%, respectively), and race (Caucasian 51% and 55%; Asian 42% and 37%, respectively). At baseline, the distribution of Hasford Scores was similar in the Dasatinib Tablets and imatinib treatment&nbsp;groups&nbsp;(low&nbsp;risk:&nbsp;33%&nbsp;and&nbsp;34%;&nbsp;intermediate&nbsp;risk&nbsp;48%&nbsp;and&nbsp;47%;&nbsp;highrisk:&nbsp;19%&nbsp;and&nbsp;19%,&nbsp;respectively).</p><p>With a minimum of 12 months follow-up, 85% of patients randomised to the Dasatinib Tablets group&nbsp;and&nbsp;81%&nbsp;ofpatients&nbsp;randomised&nbsp;to&nbsp;the&nbsp;imatinib&nbsp;group&nbsp;were&nbsp;still&nbsp;receiving&nbsp;first-line&nbsp;treatment. Discontinuation within 12 months due to disease progression occurred in 3% of Dasatinib Tablets- treated patients and 5% of imatinib-treated patients.</p><p>With a minimum of 60 months follow-up, 60% of patients randomised to the Dasatinib Tablets group&nbsp;and&nbsp;63%&nbsp;of&nbsp;patientsrandomised&nbsp;to&nbsp;the&nbsp;imatinib&nbsp;group&nbsp;were&nbsp;still&nbsp;receiving&nbsp;first-line&nbsp;treatment. Discontinuation&nbsp;within&nbsp;60&nbsp;months&nbsp;due&nbsp;to&nbsp;diseaseprogression&nbsp;occurred&nbsp;in&nbsp;11%&nbsp;of&nbsp;Dasatinib&nbsp;Tablets- treated patients and 14% of imatinib-treated patients.</p><p>Efficacy&nbsp;results&nbsp;are&nbsp;presented&nbsp;in&nbsp;Table&nbsp;9.&nbsp;A&nbsp;statistically&nbsp;significantly&nbsp;greater&nbsp;proportion&nbsp;of&nbsp;patients&nbsp;in the Dasatinib Tablets group achieved a cCCyR compared with patients in the imatinib group within the&nbsp;first&nbsp;12&nbsp;months oftreatment. Efficacy of&nbsp;Dasatinib&nbsp;Tablets was consistently&nbsp;demonstrated across different subgroups, including age, gender, and baseline Hasford score.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table&nbsp;9:&nbsp;Efficacy&nbsp;results&nbsp;from&nbsp;a&nbsp;phase&nbsp;3&nbsp;study&nbsp;of&nbsp;newly&nbsp;diagnosed&nbsp;patients&nbsp;with&nbsp;chronic&nbsp;phase&nbsp;CML</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dasatinib</strong><strong>&nbsp;</strong><strong>Tablets&nbsp;</strong><strong>n= 259</strong></p></td><td style="vertical-align:top"><p><strong>imatinib&nbsp;</strong><strong>n= 260</strong></p></td><td style="vertical-align:top"><p><strong>p-value</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Response&nbsp;rate&nbsp;(95%&nbsp;CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Cytogenetic&nbsp;response</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>within&nbsp;12&nbsp;months</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>cCCyR<sup>a</sup></p></td><td style="vertical-align:top"><p>76.8%&nbsp;(71.2&ndash;81.8)</p></td><td style="vertical-align:top"><p>66.2%&nbsp;(60.1&ndash;71.9)</p></td><td style="vertical-align:top"><p>p&lt;&nbsp;0.007*</p></td></tr><tr><td style="vertical-align:top"><p>cCCyR<sup>b</sup></p></td><td style="vertical-align:top"><p>85.3% (80.4-89.4)</p></td><td style="vertical-align:top"><p>73.5% (67.7-78.7)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>within&nbsp;24&nbsp;months</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>cCCyR<sup>a</sup></p></td><td style="vertical-align:top"><p>80.3%</p></td><td style="vertical-align:top"><p>74.2%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>cCCyR<sup>b</sup></p></td><td style="vertical-align:top"><p>87.3%</p></td><td style="vertical-align:top"><p>82.3%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>within&nbsp;36&nbsp;months</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>cCCyR<sup>a</sup></p></td><td style="vertical-align:top"><p>82.6%</p></td><td style="vertical-align:top"><p>77.3%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>cCCyR<sup>b</sup></p></td><td style="vertical-align:top"><p>88.0%</p></td><td style="vertical-align:top"><p>83.5%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>within&nbsp;48&nbsp;months</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>cCCyR<sup>a</sup></p></td><td style="vertical-align:top"><p>82.6%</p></td><td style="vertical-align:top"><p>78.5%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>cCCyR<sup>b</sup></p></td><td style="vertical-align:top"><p>87.6%</p></td><td style="vertical-align:top"><p>83.8%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>within&nbsp;60&nbsp;months</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>cCCyR<sup>a</sup></p></td><td style="vertical-align:top"><p>83.0%</p></td><td style="vertical-align:top"><p>78.5%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>cCCyR<sup>b</sup></p></td><td style="vertical-align:top"><p>88.0%</p></td><td style="vertical-align:top"><p>83.8%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Major&nbsp;molecular&nbsp;response<sup>c</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>12&nbsp;months</strong></p></td><td style="vertical-align:top"><p>52.1%&nbsp;(45.9&ndash;58.3</p></td><td style="vertical-align:top"><p>33.8%&nbsp;(28.1&ndash;39.9)</p></td><td style="vertical-align:top"><p>p&lt;&nbsp;0.00003*</p></td></tr><tr><td style="vertical-align:top"><p><strong>24&nbsp;months</strong></p></td><td style="vertical-align:top"><p>64.5% (58.3-70.3)</p></td><td style="vertical-align:top"><p>50% (43.8-56.2)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>36&nbsp;months</strong></p></td><td style="vertical-align:top"><p>69.1% (63.1-74.7)</p></td><td style="vertical-align:top"><p>56.2% (49.9-62.3)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>48&nbsp;months</strong></p></td><td style="vertical-align:top"><p>75.7% (70.0-80.8)</p></td><td style="vertical-align:top"><p>62.7% (56.5-68.6)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>60&nbsp;months</strong></p></td><td style="vertical-align:top"><p>76.4% (70.8-81.5)</p></td><td style="vertical-align:top"><p>64.2% (58.1-70.1)</p></td><td style="vertical-align:top"><p>p=0.0021</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:662px"><tbody><tr><td style="vertical-align:top; width:220px"><p>&nbsp;</p></td><td style="vertical-align:top; width:341px"><p><strong>Hazard&nbsp;ratio&nbsp;(HR)</strong></p></td><td style="vertical-align:top; width:100px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>&nbsp;</p></td><td style="vertical-align:top; width:341px"><p><strong>within&nbsp;12&nbsp;months&nbsp;(99.99%&nbsp;CI)</strong></p></td><td style="vertical-align:top; width:100px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>Time-to&nbsp;cCCyR</p></td><td style="vertical-align:top; width:341px"><p>1.55 (1.0-2.3)</p></td><td style="vertical-align:top; width:100px"><p>p&lt;&nbsp;0.0001*</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>Time-to&nbsp;MMR</p></td><td style="vertical-align:top; width:341px"><p>2.01 (1.2-3.4)</p></td><td style="vertical-align:top; width:100px"><p>p&lt;&nbsp;0.0001*</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>Durability&nbsp;of&nbsp;cCCyR</p></td><td style="vertical-align:top; width:341px"><p>0.7 (0.4-1.4)</p></td><td style="vertical-align:top; width:100px"><p>p&lt;&nbsp;0.035</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>&nbsp;</p></td><td style="vertical-align:top; width:341px"><p><strong>within&nbsp;24&nbsp;months&nbsp;(95%&nbsp;CI)</strong></p></td><td style="vertical-align:top; width:100px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>Time-to&nbsp;cCCyR</p></td><td style="vertical-align:top; width:341px"><p>1.49 (1.22-1.82)</p></td><td style="vertical-align:top; width:100px"><p>-</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>Time-to&nbsp;MMR</p></td><td style="vertical-align:top; width:341px"><p>1.69 (1.34-2.12)</p></td><td style="vertical-align:top; width:100px"><p>-</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>Durability&nbsp;of&nbsp;cCCyR</p></td><td style="vertical-align:top; width:341px"><p>0.77 (0.55-1.10)</p></td><td style="vertical-align:top; width:100px"><p>-</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>&nbsp;</p></td><td style="vertical-align:top; width:341px"><p><strong>within&nbsp;36&nbsp;months&nbsp;(95%&nbsp;CI)</strong></p></td><td style="vertical-align:top; width:100px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>Time-to&nbsp;cCCyR</p></td><td style="vertical-align:top; width:341px"><p>1.48 (1.22-1.80)</p></td><td style="vertical-align:top; width:100px"><p>-</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>Time-to&nbsp;MMR</p></td><td style="vertical-align:top; width:341px"><p>1.59 (1.28-1.99)</p></td><td style="vertical-align:top; width:100px"><p>-</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>Durability&nbsp;of&nbsp;cCCyR</p></td><td style="vertical-align:top; width:341px"><p>0.77 (0.53-1.11)</p></td><td style="vertical-align:top; width:100px"><p>-</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>&nbsp;</p></td><td style="vertical-align:top; width:341px"><p><strong>within&nbsp;48&nbsp;months&nbsp;(95%&nbsp;CI)</strong></p></td><td style="vertical-align:top; width:100px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>Time-to&nbsp;cCCyR</p></td><td style="vertical-align:top; width:341px"><p>1.45 (1.20-1.77)</p></td><td style="vertical-align:top; width:100px"><p>-</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>Time-to&nbsp;MMR</p></td><td style="vertical-align:top; width:341px"><p>1.55 (1.26-1.91)</p></td><td style="vertical-align:top; width:100px"><p>-</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>Durability&nbsp;of&nbsp;cCCyR</p></td><td style="vertical-align:top; width:341px"><p>0.81 (0.56-1.17)</p></td><td style="vertical-align:top; width:100px"><p>-</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>&nbsp;</p></td><td style="vertical-align:top; width:341px"><p><strong>within&nbsp;60&nbsp;months&nbsp;(95%&nbsp;CI)</strong></p></td><td style="vertical-align:top; width:100px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>Time-to&nbsp;cCCyR</p></td><td style="vertical-align:top; width:341px"><p>1.46 (1.20-1.77)</p></td><td style="vertical-align:top; width:100px"><p>p=0.0001</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>Time-to&nbsp;MMR</p></td><td style="vertical-align:top; width:341px"><p>1.54 (1.25-1.89)</p></td><td style="vertical-align:top; width:100px"><p>p&lt;0.0001</p></td></tr><tr><td style="vertical-align:top; width:220px"><p>Durability&nbsp;of&nbsp;cCCyR</p></td><td style="vertical-align:top; width:341px"><p>0.79 (0.55-1.13)</p></td><td style="vertical-align:top; width:100px"><p>p=0.1983</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;Confirmed&nbsp;complete&nbsp;cytogenetic&nbsp;response&nbsp;(cCCyR)&nbsp;is&nbsp;defined&nbsp;as&nbsp;a&nbsp;response&nbsp;noted&nbsp;on&nbsp;two consecutive occasions (at least 28 days apart).</p><p><sup>b</sup>&nbsp;Complete&nbsp;cytogenetic&nbsp;response&nbsp;(CCyR)&nbsp;is&nbsp;based&nbsp;on&nbsp;a&nbsp;single&nbsp;bone&nbsp;marrow cytogenetic&nbsp;evaluation.</p><p><sup>c</sup>&nbsp;Major molecular&nbsp;response&nbsp;(at&nbsp;any time)&nbsp;was&nbsp;defined&nbsp;as&nbsp;BCR ABL ratios&nbsp;&le; 0.1%&nbsp;by RQ&nbsp;PCR&nbsp;in peripheralblood&nbsp;samples&nbsp;standardised&nbsp;on&nbsp;the&nbsp;International&nbsp;scale.&nbsp;These&nbsp;are&nbsp;cumulative rates representing minimum follow up for the timeframe specified.</p><p>*Adjusted for Hasford Score and indicated statistical significance at a pre-defined nominal level of&nbsp;significance.</p><p>CI&nbsp;=&nbsp;confidence&nbsp;interval</p><p>After 60 months of follow-up, median time to cCCyR was 3.1 months in the Dasatinib Tablets group and 5.8 months in the imatinib group in patients with a confirmed CCyR. Median time to MMR after 60&nbsp;months&nbsp;of follow-up was 9.3&nbsp;months in the Dasatinib&nbsp;Tablets&nbsp;group and 15.0&nbsp;months in the imatinib group in patients with a MMR.&nbsp;These results are consistent with those seen at 12, 24 and 36 months.</p><p>&nbsp;</p><p>The time to MMR is displayed graphically in Figure 1. The time to MMR was consistently shorter in dasatinib-treated patients compared with imatinib-treated patients.</p><p><strong>Figure&nbsp;1:&nbsp;Kaplan-Meier estimate&nbsp;of&nbsp;time&nbsp;to&nbsp;major&nbsp;molecular&nbsp;response&nbsp;(MMR)</strong></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="481" height="366" src="blob:https://sdi.sfda.gov.sa/fcbc1c33-47fc-4eec-ae95-5656f2c051c6" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>The rates of cCCyR in the Dasatinib Tablets and imatinib treatment groups, respectively, within 3 months (54% and 30%), 6 months (70% and 56%), 9 months (75% and 63%), 24 months (80% and</p><p>74%), 36 months (83% and 77%), 48 months (83% and 79%) and 60 months (83% and 79%) were consistent&nbsp;withthe&nbsp;primary&nbsp;endpoint.&nbsp;The&nbsp;rates&nbsp;of&nbsp;MMR&nbsp;in&nbsp;the&nbsp;Dasatinib&nbsp;Tablets&nbsp;and&nbsp;imatinib treatment&nbsp;groups,&nbsp;respectively,within&nbsp;3&nbsp;months&nbsp;(8%&nbsp;and&nbsp;0.4%),&nbsp;6&nbsp;months&nbsp;(27%&nbsp;and&nbsp;8%),&nbsp;9&nbsp;months</p><p>(39%&nbsp;and&nbsp;18%),&nbsp;12&nbsp;months&nbsp;(46%&nbsp;and&nbsp;28%),&nbsp;24&nbsp;months&nbsp;(64%&nbsp;and&nbsp;46%)&nbsp;,&nbsp;36&nbsp;months&nbsp;(67%&nbsp;and</p><p>55%),&nbsp;48&nbsp;months&nbsp;(73%&nbsp;and&nbsp;60%)&nbsp;and&nbsp;60&nbsp;months&nbsp;(76%&nbsp;and&nbsp;64%)were&nbsp;also&nbsp;consistent&nbsp;with&nbsp;the primary endpoint.</p><p>MMR&nbsp;rates&nbsp;by&nbsp;specific&nbsp;time&nbsp;point&nbsp;are&nbsp;displayed&nbsp;graphically&nbsp;in&nbsp;Figure&nbsp;2.&nbsp;Rates&nbsp;of&nbsp;MMR&nbsp;were consistently higher in dasatinib-treated patients compared with imatinib-treated patients.</p><p>&nbsp;</p><p><strong>Figure 2: MMR rates over time - all randomised patients in a phase 3 study of newly diagnosed patients with chronic phase CML</strong></p><p><img width="475" height="293" style="text-align: unset;" src="blob:https://sdi.sfda.gov.sa/d59fc0a3-5765-4029-8991-066eb3978e02" /></p><p>&nbsp;</p><p>The proportion of patients achieving BCR-ABL ratio of &le;0.01% (4-log reduction) at any time was higher in the Dasatinib Tablets group compared to the imatinib group (54.1% versus 45%). The proportion of patients achieving BCR-ABL ratio of &le;0.0032% (4.5-log reduction) at any time was higher in the Dasatinib Tablets group compared to the imatinib group (44% versus 34%).</p><p>MR4.5 rates over time are displayed graphically in Figure 3. Rates of MR4.5 over time were consistently higher in dasatinib-treated patients compared with imatinib-treated patients.</p><p>&nbsp;</p><p><strong>Figure 3: MR4.5 rates over time - all randomised patients in a phase 3 study of newly diagnosed patients with chronic phase CML</strong></p><p><img width="424" height="252" src="blob:https://sdi.sfda.gov.sa/d59befda-99fe-40e2-954c-93836642ee83" /></p><p>&nbsp;</p><p>The rate of MMR at any time in each risk group determined by Hasford score was higher in the Dasatinib Tablets group compared with the imatinib group (low risk: 90% and 69%; intermediate risk: 71% and 65%; high risk: 67% and 54%, respectively).</p><p>In an additional analysis, more dasatinib-treated patients (84%) achieved early molecular response (defined as BCRABL levels &le; 10% at 3 months) compared with imatinib-treated patients (64%). Patients achieving early molecular response had a lower risk of transformation, higher rate of progression-free survival (PFS) and higher rate of overall survival (OS), as shown in Table 10.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;10:&nbsp;Dasatinib&nbsp;patients&nbsp;with&nbsp;BCR-ABL&nbsp;&le;&nbsp;10%&nbsp;and&nbsp;&gt;&nbsp;10%&nbsp;at&nbsp;3&nbsp;months</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Dasatinib&nbsp;N&nbsp;=&nbsp;235</strong></p></td><td style="vertical-align:top"><p><strong>Patients&nbsp;with&nbsp;BCR-ABL</strong></p><p><strong>&le;&nbsp;10%&nbsp;at&nbsp;3&nbsp;months</strong></p></td><td style="vertical-align:top"><p><strong>Patients&nbsp;with&nbsp;BCR-ABL</strong></p><p><strong>&gt; 10%&nbsp;at&nbsp;3&nbsp;months</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number&nbsp;of&nbsp;patients&nbsp;(%)</p></td><td style="vertical-align:top"><p>198&nbsp;(84.3)</p></td><td style="vertical-align:top"><p>37&nbsp;(15.7)</p></td></tr><tr><td style="vertical-align:top"><p>Transformation&nbsp;at&nbsp;60&nbsp;months,&nbsp;n/N&nbsp;(%)</p></td><td style="vertical-align:top"><p>6/198&nbsp;(3.0)</p></td><td style="vertical-align:top"><p>5/37&nbsp;(13.5)</p></td></tr><tr><td style="vertical-align:top"><p>Rate&nbsp;of&nbsp;PFS&nbsp;at 60&nbsp;months&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>92.0% (89.6,&nbsp;95.2)</p></td><td style="vertical-align:top"><p>73.8% (52.0,&nbsp;86.8)</p></td></tr><tr><td style="vertical-align:top"><p>Rate&nbsp;of&nbsp;OS at&nbsp;60 months&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>93.8% (89.3,&nbsp;96.4)</p></td><td style="vertical-align:top"><p>80.6% (63.5,&nbsp;90.2)</p></td></tr></tbody></table><p>&nbsp;</p><p>The OS rate by&nbsp;specific time point is displayed graphically&nbsp;in Figure 4.&nbsp;Rate of&nbsp;OS&nbsp;was consistently higher in dasatinib treated patients who achieved BCR-ABL level &le; 10% at 3 months than those who did not.</p><p>&nbsp;</p><p><img width="478" height="282" src="blob:https://sdi.sfda.gov.sa/7c68a404-a648-411b-8224-0f324ea2fa76" /></p><p>&nbsp;</p><p>Disease progression was defined as increasing white blood cells despite appropriate therapeutic management,&nbsp;lossof&nbsp;CHR,&nbsp;partial&nbsp;CyR or&nbsp;CCyR,&nbsp;progression&nbsp;to&nbsp;accelerated&nbsp;phase&nbsp;or&nbsp;blast&nbsp;phase,&nbsp;or death. The estimated 60-month PFS rate was 88.9% (CI: 84% - 92.4%) for both the dasatinib and imatinib treatment groups. At 60 months, transformation to accelerated or blast phase occurred in fewer dasatinib-treated patients (n=8; 3%) compared with imatinib-treated patients (n=15; 5.8%). The estimated 60-month survival rates for dasatinib and imatinib-treated patients were 90.9% (CI: 86.6% - 93.8%) and 89.6% (CI: 85.2% - 92.8%), respectively. There was no difference in OS (HR 1.01,&nbsp;95%&nbsp;CI: 0.58-&nbsp;1.73,&nbsp;p=&nbsp;0.9800)&nbsp;and&nbsp;PFS&nbsp;(HR&nbsp;1.00,&nbsp;95%&nbsp;CI: 0.58-1.72,&nbsp;p&nbsp;=&nbsp;0.9998)&nbsp;between&nbsp;dasatinib&nbsp;and&nbsp;imatinib.</p><p>In patients who report disease progression or discontinue dasatinib or imatinib therapy, BCR-ABL sequencing was performed on blood samples from patients where these are available. Similar rates of mutation were observed in both the treatment arms. The mutations detected among the dasatinib treated patients were T315I, F317I/L and V299L.&nbsp;A&nbsp;different spectrum of mutation was detected in the imatinib treatment arm. Dasatinib does not appear to be active against the T315I mutation,&nbsp;based on&nbsp;<em>in vitro&nbsp;</em>data.</p><p><em><u>Chronic&nbsp;phase&nbsp;CML&nbsp;-&nbsp;Resistance&nbsp;or&nbsp;intolerance&nbsp;to&nbsp;prior&nbsp;imatinib&nbsp;therapy</u></em></p><p>Two clinical studies were conducted in patients resistant or intolerant to imatinib; the primary efficacy endpoint in these studies was Major Cytogenetic Response (McyR).</p><p><em>Study&nbsp;1</em></p><p>An open-label, randomised, non-comparative multicentre study was conducted in patients who failed initial treatment with 400 or 600 mg imatinib.&nbsp;They&nbsp;were randomised (2:1) to either dasatinib (70 mg twice daily) or imatinib (400 mg twice daily). Crossover to the alternative treatment arm&nbsp;was allowed if patients showed evidence of disease progression or intolerance that could not be managed by&nbsp;dose&nbsp;modification.The&nbsp;primary&nbsp;endpoint&nbsp;was&nbsp;MCyR at&nbsp;12&nbsp;weeks.&nbsp;Results&nbsp;are available for 150 patients: 101 were randomised to dasatinib and 49 to imatinib (all imatinib-resistant).</p><p>The median time from diagnosis to randomisation was 64 months in the dasatinib group and 52 months in&nbsp;theimatinib&nbsp;group.&nbsp;All&nbsp;patients&nbsp;were&nbsp;extensively&nbsp;pretreated.&nbsp;Prior&nbsp;complete&nbsp;haematologic response (CHR)&nbsp;to imatinib was achieved&nbsp;in 93%&nbsp;of&nbsp;the&nbsp;overall patient&nbsp;population.&nbsp;A&nbsp;prior&nbsp;McyR to imatinib was achieved in 28% and 29% of the patients in the dasatinib and imatinib arms,&nbsp;respectively.</p><p>Median duration of treatment was 23 months for dasatinib (with 44% of patients treated for &gt; 24 months to date) and 3 months for imatinib (with 10% of patients treated for &gt; 24 months to date). Ninety-three percent of patients in the dasatinib arm and 82% of patients in the imatinib arm achieved a CHR prior to crossover.</p><p>At 3 months, a MCyR occurred more often in the dasatinib arm (36%) than in the imatinib arm (29%). Notably, 22% of patients reported a complete cytogenetic response (CCyR) in the dasatinib arm while only 8% achieved a CCyR in the imatinib arm. With longer treatment and follow-up (median&nbsp;of&nbsp;24&nbsp;months),&nbsp;MCyR&nbsp;was&nbsp;achieved&nbsp;in53%&nbsp;of&nbsp;the&nbsp;dasatinibtreated&nbsp;patients&nbsp;(CCyR&nbsp;in&nbsp;44%) and 33% of the imatinib-treated patients (CCyR in 18%) prior to crossover. Among patients who had received imatinib 400 mg prior to study entry, MCyR was achieved in 61% of patients in the dasatinib arm and 50% in the imatinib arm.</p><p>Based on the Kaplan-Meier estimates, the proportion of patients who maintained MCyR for 1 year was&nbsp;92%&nbsp;(95%CI:&nbsp;[85%-100%])&nbsp;for&nbsp;dasatinib&nbsp;(CCyR&nbsp;97%,&nbsp;95%&nbsp;CI:&nbsp;[92%-100%])&nbsp;and&nbsp;74%&nbsp;(95%</p><p>CI: [49%-100%]) for imatinib (CcyR 100%).&nbsp;The proportion of patients who maintained MCyR for 18&nbsp;monthswas&nbsp;90%&nbsp;(95%&nbsp;CI:&nbsp;[82%-98%])&nbsp;for&nbsp;dasatinib&nbsp;(CCyR&nbsp;94%,&nbsp;95%&nbsp;CI:&nbsp;[87%-100%])&nbsp;and</p><p>74%&nbsp;(95%&nbsp;CI:&nbsp;[49%-100%])&nbsp;for&nbsp;imatinib&nbsp;(CCyR&nbsp;100%).</p><p>Based on the Kaplan-Meier estimates, the proportion of patients who had progression-free survival (PFS) for 1 year was 91% (95% CI: [85%-97%]) for dasatinib and 73% (95% CI: [54%-91%]) for imatinib. The proportion of patients who had PFS at 2 years was 86% (95% CI: [78%-93%]) for dasatinib and 65% (95% CI: [43%-87%]) for imatinib.</p><p>A total of 43% of the patients in the dasatinib arm, and 82% in the imatinib arm had treatment failure, defined as disease progression or cross-over to the other treatment (lack of response, intolerance of study medicinal product, etc.).</p><p>The rate&nbsp;of major molecular response&nbsp;(defined as&nbsp;BCR-ABL/control&nbsp;transcripts &le;&nbsp;0.1%&nbsp;by&nbsp;RQ-PCR in peripheral blood samples) prior to crossover was 29% for dasatinib and 12% for imatinib.</p><p><em>Study&nbsp;2</em></p><p>An open-label, single-arm, multicentre study was conducted in patients resistant or intolerant to imatinib (i.e. Patients who experienced significant toxicity during treatment with imatinib that precluded further treatment).</p><p>A total of 387 patients received dasatinib 70 mg twice daily (288 resistant and 99 intolerant). The median time from&nbsp;diagnosis to start of treatment was 61 months.&nbsp;The majority&nbsp;of the patients (53%) had received prior imatinib treatment for more than 3 years. Most resistant patients (72%) had received &gt; 600 mg imatinib. In addition to imatinib, 35% of patients had received prior cytotoxic chemotherapy, 65% had received prior interferon, and 10% had received a prior stem cell&nbsp;transplant. Thirty-eight percent of patients had baseline mutations known to confer imatinib resistance. Median duration of treatment on dasatinib was 24 months with 51% of patients treated for &gt; 24 months to date. Efficacy results are reported in Table 11. MCyR was achieved in 55% of imatinib-resistant patients and 82% of imatinib-intolerant patients. With a minimum of 24 months follow-up, 21 of the 240 patients who had achieved a MCyR had progressed and the median duration of MCyR had not been reached.</p><p>Based on the Kaplan-Meier estimates, 95% (95% CI: [92%-98%]) of the patients maintained McyR for&nbsp;1&nbsp;year&nbsp;and 88%&nbsp;(95%&nbsp;CI:&nbsp;[83%-93%])&nbsp;maintained MCyR for&nbsp;2&nbsp;years.&nbsp;The&nbsp;proportion of&nbsp;patients who maintained CCyR for 1 year was 97% (95% CI: [94%-99%]) and for 2 years was 90% (95% CI: [86%-95%]). Forty-two percent of the imatinib-resistant patients with no prior MCyR to imatinib (n= 188) achieved a MCyR with dasatinib.</p><p>There were 45 different BCR-ABL mutations in 38% of patients enrolled in this study. Complete haematologic response or MCyR was achieved in patients harbouring a variety of BCR-ABL mutations associated with imatinib resistance except T315I. The rates of MCyR at 2 years were similar whether patients had any baseline BCR-ABL mutation, P-loop mutation, or no mutation (63%, 61% and 62%, respectively).</p><p>Among imatinib-resistant patients, the estimated rate of PFS was 88% (95% CI: [84%-92%]) at 1 year and 75% (95% CI: [69%-81%]) at 2 years. Among imatinib-intolerant patients, the estimated rate of PFS was 98% (95% CI: [95%-100%]) at 1 year and 94% (95% CI: [88%-99%]) at 2 years. The rate of major molecular response at 24 months was 45% (35% for imatinib-resistant patients and 74% for imatinibintolerant patients).</p><p><em><u>Accelerated&nbsp;phase&nbsp;CML</u></em></p><p>An open-label, single-arm, multicentre study was conducted in patients intolerant or resistant to imatinib. A total of 174 patients received dasatinib 70 mg twice daily (161 resistant and 13 intolerant to imatinib). The median time from diagnosis to start of treatment was 82 months.&nbsp;Median&nbsp;duration&nbsp;of&nbsp;treatment&nbsp;on&nbsp;dasatinib&nbsp;was&nbsp;14&nbsp;monthswith&nbsp;31%&nbsp;of&nbsp;patients&nbsp;treated&nbsp;for&nbsp;&gt;&nbsp;24months to date. The rate of major molecular response (assessed in 41 patients with a CcyR) was 46% at 24 months. Further efficacy results are reported in Table 11.</p><p><em><u>Myeloid&nbsp;blast&nbsp;phase&nbsp;CML</u></em></p><p>An open-label, single-arm, multicentre study was conducted in patients intolerant or resistant to imatinib.&nbsp;A&nbsp;total of 109 patients received dasatinib 70 mg twice daily&nbsp;(99 resistant and 10 intolerant to imatinib). The median time from diagnosis to start of treatment was 48 months. Median duration of treatment on dasatinib was 3.5 months with 12% of patients treated for &gt; 24 months to date.&nbsp;The rate of major molecular response (assessed in 19 patients with a CCyR) was 68% at 24 months. Further efficacy results are reported in Table 11.</p><p><em><u>Lymphoid&nbsp;blast&nbsp;phase&nbsp;CML&nbsp;and&nbsp;Ph+&nbsp;ALL</u></em></p><p>An open-label, single-arm, multicentre study was conducted in patients with lymphoid blast phase CML or Ph+ ALL who were resistant or intolerant to prior imatinib therapy. A total of 48 patients with lymphoid blast CML received dasatinib 70 mg twice daily (42 resistant and 6 intolerant to imatinib). The median time from diagnosis to start of treatment was 28 months. Median duration of treatment on dasatinib was 3 months with 2% treated for &gt; 24 months to date. The rate of major molecular response (all 22 treated patients with a CCyR) was 50% at 24 months. In addition, 46 patients with Ph+ ALL received dasatinib 70 mg twice daily (44 resistant and 2 intolerant to imatinib). The median time from diagnosis to start of treatment was 18 months. Median duration of treatmenton&nbsp;dasatinib&nbsp;was&nbsp;3&nbsp;months&nbsp;with&nbsp;7%&nbsp;of&nbsp;patients&nbsp;treated&nbsp;for&nbsp;&gt;&nbsp;24&nbsp;months&nbsp;to&nbsp;date.&nbsp;The&nbsp;rate&nbsp;of major molecular response (all 25 treated patients with a CcyR) was 52% at 24 months. Further efficacy results are reported in Table 11. Of note, major haematologic responses (MaHR) were achieved quickly (most within 35 days of first dasatinib administration for patients with lymphoid blast CML, and within 55 days for patients with Ph+&nbsp;ALL).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="6" style="vertical-align:top"><p><strong>Table&nbsp;11:&nbsp;Efficacy&nbsp;in&nbsp;phase&nbsp;II&nbsp;Dasatinib&nbsp;Tablets&nbsp;single-arm&nbsp;clinical&nbsp;studies<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Chronic&nbsp;</strong><strong>(n=&nbsp;387)</strong></p></td><td style="vertical-align:top"><p><strong>Accelerated&nbsp;</strong><strong>(n= 174)</strong></p></td><td style="vertical-align:top"><p><strong>Myeloid&nbsp;blast (n= 109)</strong></p></td><td style="vertical-align:top"><p><strong>Lymphoid</strong><strong>&nbsp;</strong><strong>blast&nbsp;</strong><strong>(n= 48)</strong></p></td><td style="vertical-align:top"><p><strong>Ph+</strong><strong>&nbsp;</strong><strong>ALL&nbsp;</strong><strong>(n= 46)</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Haematologic&nbsp;response&nbsp;rate<sup>b</sup>&nbsp;(%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>MaHR&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>n/a</p></td><td style="vertical-align:top"><p><strong>64% (57-72)</strong></p></td><td style="vertical-align:top"><p><strong>33%&nbsp;(24-43)</strong></p></td><td style="vertical-align:top"><p><strong>35%&nbsp;(22-51)</strong></p></td><td style="vertical-align:top"><p><strong>41%&nbsp;(27-57)</strong></p></td></tr><tr><td style="vertical-align:top"><p>CHR&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p><strong>91%&nbsp;(88-94)</strong></p></td><td style="vertical-align:top"><p>50% (42-58)</p></td><td style="vertical-align:top"><p>26% (18-35)</p></td><td style="vertical-align:top"><p>29% (17-44)</p></td><td style="vertical-align:top"><p>35% (21-50)</p></td></tr><tr><td style="vertical-align:top"><p>NEL&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>n/a</p></td><td style="vertical-align:top"><p>14% (10-21)</p></td><td style="vertical-align:top"><p>7% (3-14)</p></td><td style="vertical-align:top"><p>6% (1-17)</p></td><td style="vertical-align:top"><p>7% (1-18)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Duration&nbsp;of&nbsp;MaHR&nbsp;(%;&nbsp;Kaplan-Meier&nbsp;estimates)</strong></p></td></tr><tr><td style="vertical-align:top"><p>1&nbsp;year</p></td><td style="vertical-align:top"><p>n/a</p></td><td style="vertical-align:top"><p>79% (71-87)</p></td><td style="vertical-align:top"><p>71% (55-87)</p></td><td style="vertical-align:top"><p>29% (3-56)</p></td><td style="vertical-align:top"><p>32% (8-56)</p></td></tr><tr><td style="vertical-align:top"><p>2&nbsp;year</p></td><td style="vertical-align:top"><p>n/a</p></td><td style="vertical-align:top"><p>60% (50-70)</p></td><td style="vertical-align:top"><p>41% (21-60)</p></td><td style="vertical-align:top"><p>10% (0-28)</p></td><td style="vertical-align:top"><p>24% (2-47)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Cytogenetic</strong><strong>&nbsp;</strong><strong>response<sup>c</sup></strong><strong>&nbsp;</strong><strong>(%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>MCyR&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p><strong>62%&nbsp;(57-67)</strong></p></td><td style="vertical-align:top"><p>40% (33-48)</p></td><td style="vertical-align:top"><p>34% (25-44)</p></td><td style="vertical-align:top"><p>52% (37-67)</p></td><td style="vertical-align:top"><p>57% (41-71)</p></td></tr><tr><td style="vertical-align:top"><p>CCyR&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>54% (48-59)</p></td><td style="vertical-align:top"><p>33% (26-41)</p></td><td style="vertical-align:top"><p>27% (19-36)</p></td><td style="vertical-align:top"><p>46% (31-61)</p></td><td style="vertical-align:top"><p>54% (39-69)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:848px"><tbody><tr><td colspan="6" style="vertical-align:top; width:845px"><p><strong>Survival&nbsp;(%;&nbsp;Kaplan-Meier&nbsp;estimates)</strong></p></td></tr><tr><td style="vertical-align:top; width:104px"><p>Progression-Free1 year</p></td><td style="vertical-align:top; width:128px"><p>&nbsp;</p><p>91% (88-94)</p></td><td style="vertical-align:top; width:156px"><p>&nbsp;</p><p>64% (57-72)</p></td><td style="vertical-align:top; width:163px"><p>&nbsp;</p><p>35% (25-45)</p></td><td style="vertical-align:top; width:170px"><p>&nbsp;</p><p>14% (3-25)</p></td><td style="vertical-align:top; width:126px"><p>&nbsp;</p><p>21% (9-34)</p></td></tr><tr><td style="vertical-align:top; width:104px"><p>2&nbsp;year</p></td><td style="vertical-align:top; width:128px"><p>80% (75-84)</p></td><td style="vertical-align:top; width:156px"><p>46% (38-54)</p></td><td style="vertical-align:top; width:163px"><p>20%&nbsp;(11-29)</p></td><td style="vertical-align:top; width:170px"><p>5% (0-13)</p></td><td style="vertical-align:top; width:126px"><p>12% (2-23)</p></td></tr><tr><td style="vertical-align:top; width:104px"><p>Overall1 year</p></td><td style="vertical-align:top; width:128px"><p>&nbsp;</p><p>97% (95-99)</p></td><td style="vertical-align:top; width:156px"><p>&nbsp;</p><p>83% (77-89)</p></td><td style="vertical-align:top; width:163px"><p>&nbsp;</p><p>48% (38-59)</p></td><td style="vertical-align:top; width:170px"><p>&nbsp;</p><p>30% (14-47)</p></td><td style="vertical-align:top; width:126px"><p>&nbsp;</p><p>35% (20-51)</p></td></tr><tr><td style="vertical-align:top; width:104px"><p>2&nbsp;year</p></td><td style="vertical-align:top; width:128px"><p>94% (91-97)</p></td><td style="vertical-align:top; width:156px"><p>72% (64-79)</p></td><td style="vertical-align:top; width:163px"><p>38% (27-50)</p></td><td style="vertical-align:top; width:170px"><p>26% (10-42)</p></td><td style="vertical-align:top; width:126px"><p>31% (16-47)</p></td></tr></tbody></table><p>&nbsp;</p><p>Data&nbsp;described&nbsp;in&nbsp;this&nbsp;table&nbsp;are&nbsp;from&nbsp;studies&nbsp;using&nbsp;a&nbsp;starting&nbsp;dose&nbsp;of&nbsp;70&nbsp;mg&nbsp;twice&nbsp;daily.&nbsp;See&nbsp;section&nbsp;4.2&nbsp;for&nbsp;the&nbsp;recommended&nbsp;starting&nbsp;dose.</p><p><sup>a</sup>&nbsp;Numbers&nbsp;in&nbsp;bold&nbsp;font&nbsp;are&nbsp;the&nbsp;results&nbsp;of&nbsp;primary&nbsp;endpoints.</p><p><sup>b</sup>&nbsp;Haematologic response criteria (all responses confirmed after 4 weeks): Major haematologic response (MaHR) = complete haematologic response (CHR) + no evidence of leukaemia (NEL).</p><p>CHR (chronic CML): WBC &le; institutional ULN, platelets &lt; 450,000/mm<sup>3</sup>, no blasts or promyelocytes in peripheral blood, &lt; 5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood &lt; 20%, and no extramedullary involvement.</p><p>CHR (advanced CML/Ph+ ALL): WBC &le; institutional ULN, ANC &ge; 1,000/mm<sup>3</sup>, platelets &ge; 100,000/mm<sup>3</sup>, no blasts or promyelocytes in peripheral blood, bone marrow blasts &le; 5%, &lt; 5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood &lt; 20%, and no extramedullary involvement.</p><p>NEL: same criteria as for CHR but ANC &ge; 500/mm<sup>3</sup>&nbsp;and &lt; 1,000/mm<sup>3</sup>, or platelets &ge; 20,000/mm<sup>3</sup>&nbsp;and &le; 100,000/mm<sup>3</sup>.</p><p><sup>c</sup>&nbsp;Cytogenetic response criteria: complete (0% Ph+ metaphases) or partial (&gt; 0%-35%). MCyR (0% 35%) combines both complete and partial responses.</p><p>n/a&nbsp;=&nbsp;not&nbsp;applicable; CI&nbsp;=&nbsp;confidence interval;&nbsp;ULN&nbsp;=&nbsp;upper&nbsp;limit&nbsp;of&nbsp;normal&nbsp;range.</p><p>The outcome of patients with bone marrow transplantation after dasatinib treatment has not been fully evaluated.</p><p><em><u>Phase III&nbsp;clinical studies in patients with CML&nbsp;in&nbsp;chronic, accelerated, or myeloid blast&nbsp;phase, and</u></em><em>&nbsp;<u>Ph+ ALL who were resistant or intolerant to imatinib</u></em></p><p>Two randomised, open-label studies were conducted to evaluate the efficacy of dasatinib administered once&nbsp;dailycompared with dasatinib administered twice&nbsp;daily. Results described below are based on a minimum of 2 years and 7 years follow-up after the start of dasatinib therapy.</p><p><em>Study&nbsp;1</em></p><p>In the study in chronic phase CML, the primary endpoint was MCyR in imatinib-resistant patients. The main secondary endpoint was MCyR by total daily dose level in the imatinib-resistant patients. Other secondary endpoints included duration of MCyR, PFS, and overall survival. A total of 670 patients,&nbsp;of&nbsp;whom&nbsp;497&nbsp;wereimatinib-resistant,&nbsp;were&nbsp;randomised&nbsp;to&nbsp;the&nbsp;dasatinib&nbsp;100&nbsp;mg&nbsp;once&nbsp;daily,&nbsp;140 mg once daily, 50 mg twice daily, or 70 mg twice daily group. The median duration of treatment for all patients still on therapy with a minimum of 5 years of follow-up (n=205) was 59 months (range 28-66 months). Median duration of treatment for all patients at 7 years of follow-up was 29.8 months (range &lt; 1-92.9 months).</p><p>Efficacy was achieved across all dasatinib treatment groups with the once daily schedule demonstrating comparable efficacy (non-inferiority) to the twice daily schedule on the primary efficacy endpoint (difference in MCyR 1.9%; 95% confidence interval [-6.8% - 10.6%]); however, the 100 mg once daily regimen demonstrated improved safety and tolerability. Efficacy results are presented in Tables 12 and 13.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table&nbsp;12:&nbsp;Efficacy&nbsp;of&nbsp;Dasatinib&nbsp;Tablets&nbsp;in&nbsp;phase&nbsp;III&nbsp;dose-optimization&nbsp;study:&nbsp;imatinibresistant or intolerant chronic phase CML&nbsp;(2-year results)<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All&nbsp;patients</strong></p></td><td style="vertical-align:top"><p><strong>n=167</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Imatinib-resistant&nbsp;patients</strong></p></td><td style="vertical-align:top"><p><strong>n=124</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Haematologic&nbsp;response&nbsp;rate</strong><strong>b&nbsp;</strong><strong>(%)&nbsp;(95%&nbsp;CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>CHR</p></td><td style="vertical-align:top"><p><strong>92%&nbsp;(86&ndash;95</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cytogenetic&nbsp;response</strong><strong>c&nbsp;</strong><strong>(%)&nbsp;(95%&nbsp;CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>MCyR</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>All&nbsp;patients</p></td><td style="vertical-align:top"><p><strong>63%&nbsp;(56&ndash;71)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Imatinib-resistant&nbsp;patients</p></td><td style="vertical-align:top"><p><strong>59%&nbsp;(50&ndash;68)</strong></p></td></tr><tr><td style="vertical-align:top"><p>CCyR</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>All&nbsp;patients</p></td><td style="vertical-align:top"><p><strong>50%&nbsp;(42&ndash;58)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Imatinib-resistant&nbsp;patients</p></td><td style="vertical-align:top"><p><strong>44%&nbsp;(35&ndash;53)</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Major&nbsp;molecular&nbsp;response&nbsp;in&nbsp;patients&nbsp;achieving&nbsp;CCyR</strong><strong>d&nbsp;</strong><strong>(%)&nbsp;(95%&nbsp;CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>All&nbsp;patients</p></td><td style="vertical-align:top"><p><strong>69%&nbsp;(58&ndash;79)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Imatinib-resistant&nbsp;patients</p></td><td style="vertical-align:top"><p><strong>72%&nbsp;(58&ndash;83)</strong></p></td></tr></tbody></table><p><sup>a</sup>&nbsp;Results&nbsp;reported&nbsp;in&nbsp;recommended&nbsp;starting&nbsp;dose&nbsp;of&nbsp;100&nbsp;mg&nbsp;once&nbsp;daily.</p><p><sup>b</sup>&nbsp;Haematologic response criteria (all responses confirmed after 4 weeks): Complete haematologic response (CHR) (chronic CML): WBC &le; institutional ULN, platelets &lt;450,000/mm<sup>3</sup>, no blasts or promyelocytes in peripheral blood, &lt;5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood &lt;20%, and no extramedullary involvement.</p><p><sup>c</sup>&nbsp;Cytogenetic response criteria: complete (0% Ph+ metaphases) or partial (&gt;0%&ndash;35%). MCyR (0% 35%) combines both complete and partial responses.</p><p><sup>d</sup>&nbsp;Major&nbsp;molecular&nbsp;response&nbsp;criteria:&nbsp;Defined&nbsp;as&nbsp;BCR-ABL/control&nbsp;transcripts&nbsp;&le;0.1%&nbsp;by&nbsp;RQ-PCR&nbsp;in peripheral blood samples.</p><p><strong>Table&nbsp;13:&nbsp;Long&nbsp;term&nbsp;efficacy&nbsp;of&nbsp;Dasatinib&nbsp;Tablets&nbsp;in&nbsp;phase&nbsp;3&nbsp;dose&nbsp;optimisation&nbsp;study: imatinib resistant or intolerant chronic phase CML patients<sup>a</sup></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>Minimum&nbsp;follow-up&nbsp;period</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>1&nbsp;year</strong></p></td><td style="vertical-align:top"><p><strong>2&nbsp;year</strong></p></td><td style="vertical-align:top"><p><strong>5&nbsp;year</strong></p></td><td style="vertical-align:top"><p><strong>7&nbsp;year</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Major&nbsp;molecular&nbsp;response</strong></p></td></tr><tr><td style="vertical-align:top"><p>All&nbsp;patients</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>37%&nbsp;(57/154)</p></td><td style="vertical-align:top"><p>44%&nbsp;(71/160)</p></td><td style="vertical-align:top"><p>46%&nbsp;(73/160)</p></td></tr><tr><td style="vertical-align:top"><p>Imatinib-resistant&nbsp;patients</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>35%&nbsp;(41/117)</p></td><td style="vertical-align:top"><p>42%&nbsp;(50/120)</p></td><td style="vertical-align:top"><p>43%&nbsp;(51/120)</p></td></tr><tr><td style="vertical-align:top"><p>Imatinib-intolerant&nbsp;patients</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>43%&nbsp;(16/37)</p></td><td style="vertical-align:top"><p>53%&nbsp;(21/40)</p></td><td style="vertical-align:top"><p>55%&nbsp;(22/40)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Progression-free</strong><strong>&nbsp;</strong><strong>survival<sup>b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>All&nbsp;patients</p></td><td style="vertical-align:top"><p>90% (86,&nbsp;95)</p></td><td style="vertical-align:top"><p>80% (73,&nbsp;87)</p></td><td style="vertical-align:top"><p>51% (41,&nbsp;60)</p></td><td style="vertical-align:top"><p>42% (33,&nbsp;51)</p></td></tr><tr><td style="vertical-align:top"><p>Imatinib-resistant&nbsp;patients</p></td><td style="vertical-align:top"><p>88% (82,&nbsp;94)</p></td><td style="vertical-align:top"><p>77% (68,&nbsp;85)</p></td><td style="vertical-align:top"><p>49% (39,&nbsp;59)</p></td><td style="vertical-align:top"><p>39% (29,&nbsp;49)</p></td></tr><tr><td style="vertical-align:top"><p>Imatinib-intolerant&nbsp;patients</p></td><td style="vertical-align:top"><p>97% (92,&nbsp;100)</p></td><td style="vertical-align:top"><p>87% (76,&nbsp;99)</p></td><td style="vertical-align:top"><p>56% (37,&nbsp;76)</p></td><td style="vertical-align:top"><p>51% (32,&nbsp;67)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Overall&nbsp;survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>All&nbsp;patients</p></td><td style="vertical-align:top"><p>96% (93,&nbsp;99)</p></td><td style="vertical-align:top"><p>91% (86,&nbsp;96)</p></td><td style="vertical-align:top"><p>78% (72,&nbsp;85)</p></td><td style="vertical-align:top"><p>65% (56,&nbsp;72)</p></td></tr><tr><td style="vertical-align:top"><p>Imatinib-resistant&nbsp;patients</p></td><td style="vertical-align:top"><p>94% (90,&nbsp;98)</p></td><td style="vertical-align:top"><p>89% (84,&nbsp;95)</p></td><td style="vertical-align:top"><p>77% (69,&nbsp;85)</p></td><td style="vertical-align:top"><p>63% (53,&nbsp;71)</p></td></tr><tr><td style="vertical-align:top"><p>Imatinib-intolerant&nbsp;patients</p></td><td style="vertical-align:top"><p>100% (100,&nbsp;100)</p></td><td style="vertical-align:top"><p>95% (88,&nbsp;100)</p></td><td style="vertical-align:top"><p>82% (70,&nbsp;94)</p></td><td style="vertical-align:top"><p>70% (52,&nbsp;82)</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;Results&nbsp;reported&nbsp;in&nbsp;recommended&nbsp;starting&nbsp;dose&nbsp;of&nbsp;100&nbsp;mg&nbsp;once&nbsp;daily.</p><p><sup>b</sup>&nbsp;Progression was defined as increasing WBC count, loss of CHR or MCyR, &ge;30% increase in Ph+ metaphases, confirmed AP/BP disease or death. PFS was analysed on an intent-to-treat principle&nbsp;and patients were followed to events including subsequent therapy.</p><p>Based on the Kaplan-Meier estimates, the proportion of patients treated with dasatinib 100 mg once daily who maintained MCyR for 18 months was 93% (95% CI: [88%-98%]). Efficacy was also assessed&nbsp;in patients&nbsp;whowere intolerant&nbsp;to imatinib. In&nbsp;this&nbsp;population&nbsp;of&nbsp;patients&nbsp;who&nbsp;received&nbsp;100 mg once daily, MCyR was achieved in 77% and CCyR in 67%.</p><p><em>Study&nbsp;2</em></p><p>In the study in advanced phase CML&nbsp;and Ph+&nbsp;ALL, the primary endpoint was MaHR.&nbsp;A&nbsp;total of 61 patients were randomised to either the dasatinib 140 mg once daily or 70 mg twice daily group. Median duration of treatment was approximately 6 months (range 0.03-31 months).</p><p>The once daily schedule demonstrated comparable efficacy (non-inferiority) to the twice daily schedule on the primary efficacy endpoint (difference in MaHR 0.8%; 95% confidence interval [7.1% - 8.7%]); however, the 140 mg once daily regimen demonstrated improved safety and&nbsp;tolerability.</p><p>Response&nbsp;rates&nbsp;are&nbsp;presented&nbsp;in&nbsp;Table&nbsp;14.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Table&nbsp;14:&nbsp;Efficacy&nbsp;of&nbsp;Dasatinib&nbsp;Tablets&nbsp;in&nbsp;phase&nbsp;III&nbsp;dose-optimisation&nbsp;study:&nbsp;advanced&nbsp;phase CML and Ph+ ALL (2 year results)<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Accelerated&nbsp;</strong><strong>(n= 158)</strong></p></td><td style="vertical-align:top"><p><strong>Myeloid&nbsp;blast (n= 75)</strong></p></td><td style="vertical-align:top"><p><strong>Lymphoid</strong><strong>&nbsp;</strong><strong>blast&nbsp;</strong><strong>(n= 33)</strong></p></td><td style="vertical-align:top"><p><strong>Ph+ALL&nbsp;</strong><strong>(n= 40)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>MaHR<sup>b</sup></strong></p><p>(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>66%</p><p>(59-74)</p></td><td style="vertical-align:top"><p>28%</p><p>(18-40)</p></td><td style="vertical-align:top"><p>42%</p><p>(26-61)</p></td><td style="vertical-align:top"><p>38%</p><p>(23-54)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:841px"><tbody><tr><td style="vertical-align:top; width:85px"><p>CHR<sup>b</sup>(95%&nbsp;CI)</p></td><td style="vertical-align:top; width:193px"><p>47%</p><p>(40-56)</p></td><td style="vertical-align:top; width:197px"><p>17%</p><p>(10-28)</p></td><td style="vertical-align:top; width:213px"><p>21%</p><p>(9-39)</p></td><td style="vertical-align:top; width:152px"><p>33%</p><p>(19-49)</p></td></tr><tr><td style="vertical-align:top; width:85px"><p>NEL<sup>b</sup>(95%&nbsp;CI)</p></td><td style="vertical-align:top; width:193px"><p>19%</p><p>(13-26)</p></td><td style="vertical-align:top; width:197px"><p>11%</p><p>(5-20)</p></td><td style="vertical-align:top; width:213px"><p>21%</p><p>(9-39)</p></td><td style="vertical-align:top; width:152px"><p>5%</p><p>(1-17)</p></td></tr><tr><td style="vertical-align:top; width:85px"><p><strong>MCyR<sup>c</sup></strong></p><p>(95%&nbsp;CI)</p></td><td style="vertical-align:top; width:193px"><p>39%</p><p>(31-47)</p></td><td style="vertical-align:top; width:197px"><p>28%</p><p>(18-40)</p></td><td style="vertical-align:top; width:213px"><p>52%</p><p>(34-69)</p></td><td style="vertical-align:top; width:152px"><p>70%</p><p>(54-83)</p></td></tr><tr><td style="vertical-align:top; width:85px"><p>CCyR&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top; width:193px"><p>32%</p><p>(25-40)</p></td><td style="vertical-align:top; width:197px"><p>17%</p><p>(10-28)</p></td><td style="vertical-align:top; width:213px"><p>39%</p><p>(23-58)</p></td><td style="vertical-align:top; width:152px"><p>50%</p><p>(34-66)</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;Results&nbsp;reported&nbsp;in&nbsp;recommended&nbsp;starting&nbsp;dose&nbsp;of&nbsp;140&nbsp;mg&nbsp;once&nbsp;daily&nbsp;(see&nbsp;section&nbsp;4.2).</p><p><sup>b</sup>&nbsp;Haematologic response criteria (all responses confirmed after 4 weeks): Major haematologic response (MaHR) = complete haematologic response (CHR) + no evidence of leukaemia (NEL).</p><p>CHR: WBC &le; institutional ULN, ANC &ge; 1,000/mm<sup>3</sup>, platelets &ge; 100,000/mm<sup>3</sup>, no blasts or promyelocytes in peripheral blood, bone marrow blasts &le; 5%, &lt; 5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood &lt; 20%, and no extramedullary&nbsp;involvement.</p><p>NEL: same criteria as for CHR but ANC &ge; 500/mm<sup>3</sup>&nbsp;and &lt; 1,000/mm<sup>3</sup>, or platelets &ge; 20,000/mm<sup>3</sup>&nbsp;and &le; 100,000/mm<sup>3</sup>.</p><p><sup>c</sup>&nbsp;MCyR&nbsp;combines&nbsp;both&nbsp;complete&nbsp;(0%&nbsp;Ph+&nbsp;metaphases)&nbsp;and&nbsp;partial&nbsp;(&gt;&nbsp;0%-35%)&nbsp;responses. CI = confidence interval; ULN = upper limit of normal range.</p><p>In patients with accelerated phase CML treated with the 140 mg once daily regimen, the median duration of MaHR and the median overall survival was not reached and the median PFS was 25&nbsp;months.</p><p>In patients with myeloid blast phase CML&nbsp;treated with the 140 mg once daily regimen, the median duration of MaHR was 8 months, the median PFS was 4 months, and the median overall survival was 8 months. In patients with lymphoid blast phase CML treated with the 140 mg once daily regimen, the median duration of MaHR was 5 months, the median PFS was 5 months, and the median overall survival was 11 months.</p><p>In patients with Ph+ ALL treated with the 140 mg once daily regimen, the median duration of MaHR&nbsp;was&nbsp;5months&nbsp;the median&nbsp;PFS&nbsp;was&nbsp;4&nbsp;months,&nbsp;and&nbsp;the&nbsp;median&nbsp;overall&nbsp;survival was&nbsp;7&nbsp;months.&nbsp;<u>Paediatric population</u></p><p><em><u>Paediatric&nbsp;patients&nbsp;with&nbsp;CML</u></em></p><p>Among 130 patients with chronic phase CML (CML-CP) treated in two paediatric studies, a Phase&nbsp;I, open-label, nonrandomized dose-ranging trial and a Phase II, open-label, nonrandomized trial, 84 patients (exclusively from the Phase II trial) were newly diagnosed with CML-CP and 46 patients (17 from the Phase I trial and 29 from the Phase II trial) were resistant or intolerant to previous treatment with imatinib. Ninety-seven of the 130 paediatric patients with CML-CP were treated&nbsp;with&nbsp;Dasatinib&nbsp;Tablets&nbsp;tablets&nbsp;60&nbsp;mg/m2&nbsp;once&nbsp;daily&nbsp;(maximum&nbsp;dose&nbsp;of100&nbsp;mg&nbsp;once&nbsp;daily&nbsp;for&nbsp;patients with high BSA). Patients were treated until disease progression or unacceptable toxicity. Key efficacy endpoints were: complete cytogenetic response (CCyR), major cytogenetic response (MCyR) and major molecular response (MMR). Results are shown in Table 15.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Table&nbsp;15:&nbsp;Efficacy&nbsp;of&nbsp;Dasatinib&nbsp;Tablets&nbsp;in&nbsp;paediatric&nbsp;patients&nbsp;with&nbsp;CML-CP Cumulative response over time by minimum follow-up period</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>3&nbsp;months</strong></p></td><td style="vertical-align:top"><p><strong>6&nbsp;months</strong></p></td><td style="vertical-align:top"><p><strong>12&nbsp;months</strong></p></td><td style="vertical-align:top"><p><strong>24&nbsp;months</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>CCyR&nbsp;</strong><strong>(95%&nbsp;CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Newly&nbsp;diagnosed (N = 51)<sup>a</sup></p></td><td style="vertical-align:top"><p>43.1%</p><p>(29.3,&nbsp;57.8)</p></td><td style="vertical-align:top"><p>66.7%</p><p>(52.1,&nbsp;79.2)</p></td><td style="vertical-align:top"><p>96.1%</p><p>(86.5,&nbsp;99.5)</p></td><td style="vertical-align:top"><p>96.1%</p><p>(86.5,&nbsp;99.5)</p></td></tr><tr><td style="vertical-align:top"><p>Prior&nbsp;imatinib (N = 46)<sup>b</sup></p></td><td style="vertical-align:top"><p>45.7%</p><p>(30.9,&nbsp;61.0)</p></td><td style="vertical-align:top"><p>71.7%</p><p>(56.5,&nbsp;84.0)</p></td><td style="vertical-align:top"><p>78.3%</p><p>(63.6,&nbsp;89.1)</p></td><td style="vertical-align:top"><p>82.6%</p><p>(68.6,&nbsp;92.2)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>MCyR&nbsp;</strong><strong>(95%&nbsp;CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Newly&nbsp;diagnosed (N = 51)<sup>a</sup></p></td><td style="vertical-align:top"><p>60.8%</p><p>(46.1,&nbsp;74.2)</p></td><td style="vertical-align:top"><p>90.2%</p><p>(78.6,&nbsp;96.7)</p></td><td style="vertical-align:top"><p>98.0%</p><p>(89.6,&nbsp;100)</p></td><td style="vertical-align:top"><p>98.0%</p><p>(89.6,&nbsp;100)</p></td></tr><tr><td style="vertical-align:top"><p>Prior&nbsp;imatinib (N = 46)<sup>b</sup></p></td><td style="vertical-align:top"><p>60.9%</p><p>(45.4,&nbsp;74.9)</p></td><td style="vertical-align:top"><p>82.6%</p><p>(68.6,&nbsp;92.2)</p></td><td style="vertical-align:top"><p>89.1%</p><p>(76.4,&nbsp;96.4)</p></td><td style="vertical-align:top"><p>89.1%</p><p>(76.4,&nbsp;96.4)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>MMR&nbsp;</strong><strong>(95%&nbsp;CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Newly&nbsp;diagnosed (N = 51)<sup>a</sup></p></td><td style="vertical-align:top"><p>7.8%</p><p>(2.2,&nbsp;18.9)</p></td><td style="vertical-align:top"><p>31.4%</p><p>(19.1,&nbsp;45.9)</p></td><td style="vertical-align:top"><p>56.9%</p><p>(42.2,&nbsp;70.7)</p></td><td style="vertical-align:top"><p>74.5%</p><p>(60.4,&nbsp;85.7)</p></td></tr><tr><td style="vertical-align:top"><p>Prior&nbsp;imatinib (N = 46)<sup>b</sup></p></td><td style="vertical-align:top"><p>15.2%</p><p>(6.3,&nbsp;28.9)</p></td><td style="vertical-align:top"><p>26.1%</p><p>(14.3,&nbsp;41.1)</p></td><td style="vertical-align:top"><p>39.1%</p><p>(25.1,&nbsp;54.6)</p></td><td style="vertical-align:top"><p>52.2%</p><p>(36.9,&nbsp;67.1)</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;Patients from Phase II paediatric study of newly diagnosed CML-CP receiving oral tablet&nbsp;formulation</p><p><sup>b</sup>&nbsp;Patients from Phase I and Phase II paediatric studies of imatinib-resistant or intolerant CML-CP receiving oral tablet formulation</p><p>In the Phase I paediatric study, after a minimum of 7 years of follow-up among the 17 patients with imatinib-resistant or intolerant CML-CP, the median duration of PFS was 53.6 months and the rate of OS was 82.4%.</p><p>In the Phase II paediatric study, in patients receiving the tablet formulation, estimated 24-month PFS&nbsp;rate&nbsp;amongthe&nbsp;51&nbsp;patients&nbsp;with&nbsp;newly&nbsp;diagnosed&nbsp;CML-CP&nbsp;was&nbsp;94.0%&nbsp;(82.6,&nbsp;98.0),&nbsp;and&nbsp;81.7%</p><p>(61.4, 92.0) among the 29 patients with imatinib-resistant/intolerant CML-CP. After 24 months of follow-up, OS in newly diagnosed patients was 100%, and 96.6% in imatinib-resistant or intolerant&nbsp;patients.</p><p>In the Phase II paediatric study, 1 newly diagnosed patient and 2 imatinib-resistant or intolerant patients progressed to blast phase CML.</p><p>There&nbsp;were&nbsp;33&nbsp;newly&nbsp;diagnosed&nbsp;paediatric&nbsp;patients&nbsp;with&nbsp;CML-CP&nbsp;who&nbsp;received&nbsp;Dasatinib&nbsp;Tablets&nbsp;powder for oral suspension at a dose of 72 mg/m<sup>2</sup>. This dose represents 30% lower exposure compared to the recommended dose (see section 5.2. of Summary of Product Characteristics for Dasatinib Tablets powder for oral suspension). In these patients, CCyR and MMR were CCyR: 87.9% [95% CI: (71.8-96.6)] and MMR: 45.5% [95% CI: (28.1-63.6)] at 12 months.</p><p>Among dasatinib-treated CML-CP&nbsp;paediatric patients previously&nbsp;exposed to imatinib, the mutations detected at the end of treatment were: T315A, E255K and F317L. However, E255K and F317L were also detected prior to treatment. There were no mutations detected in newly diagnosed CML- CP patients at the end of treatment.</p><p><em><u>Paediatric&nbsp;patients&nbsp;with&nbsp;ALL</u></em></p><p>The efficacy of Dasatinib Tablets in combination with chemotherapy was evaluated in a pivotal study in paediatric patients over one year of age with newly diagnosed Ph+&nbsp;ALL.</p><p>In this multicenter, historically-controlled Phase II study of dasatinib added to standard chemotherapy, 106 paediatric patients with newly diagnosed Ph+ ALL, of whom 104 patients had confirmed&nbsp;Ph+&nbsp;ALL,&nbsp;receiveddasatinib&nbsp;at&nbsp;a&nbsp;daily&nbsp;dose&nbsp;of&nbsp;60&nbsp;mg/m<sup>2</sup>&nbsp;on&nbsp;a&nbsp;continuous&nbsp;dosing&nbsp;regimen for up to 24 months, in combination with chemotherapy. Eighty-two patients received dasatinib tablets exclusively and 24 patients received dasatinib powder for oral suspension at least once, 8 of whom received dasatinib powder for oral suspension exclusively. The backbone chemotherapy regimen was the same as used in the AIEOP-BFM ALL 2000 trial (chemotherapeutic standard multi-agent chemotherapy protocol). The primary efficacy endpoint was 3-year event-free survival (EFS), which was 65.5% (55.5, 73.7).</p><p>The minimal residual disease (MRD) negativity rate assessed by Ig/TCR rearrangement was 71.7% by the end of consolidation in all treated patients. When this rate was based on the 85 patients with evaluable Ig/TCR assessments, the estimate was 89.4%. The MRD negativity rates at the end of induction and consolidation as measured by flow cytometry were 66.0% and 84.0%, respectively.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The&nbsp;pharmacokinetics&nbsp;of&nbsp;dasatinib&nbsp;were&nbsp;evaluated&nbsp;in&nbsp;229&nbsp;adult&nbsp;healthy&nbsp;subjects&nbsp;and&nbsp;in&nbsp;84&nbsp;patients.</p><p>&nbsp;<strong><u>Absorption</u></strong></p><p>Dasatinib is rapidly absorbed in patients following oral administration, with peak concentrations between 0.5-3 hours. Following oral administration, the increase in the mean exposure (AUC&tau;) is approximately&nbsp;proportional&nbsp;tothe&nbsp;dose&nbsp;increment across doses ranging from&nbsp;25&nbsp;mg&nbsp;to 120&nbsp;mg twice daily. The overall mean terminal half-life of dasatinib is approximately 5-6 hours in patients.</p><p>Data from healthy subjects administered a single 100 mg dose of dasatinib 30 minutes following a high-fat meal indicated a 14% increase in the mean AUC of dasatinib. A low-fat meal 30 minutes prior to dasatinib resulted in a 21% increase in the mean AUC of dasatinib. The observed food effects&nbsp;do&nbsp;not&nbsp;represent&nbsp;clinically&nbsp;relevantchanges&nbsp;in&nbsp;exposure.&nbsp;</p><p>Dasatinib&nbsp;exposure&nbsp;variability&nbsp;is&nbsp;higher under fasted conditions (47% CV) compared to light-fat meal (39% CV) and high-fat meal (32% CV) conditions.</p><p>Based on the patient population PK analysis, variability in dasatinib exposure was estimated to be mainly due to interoccasion variability in bioavailability (44% CV) and, to a lesser extent, due to inter-individual variability in bioavailability and inter-individual variability in clearance (30% and 32% CV, respectively). The random inter-occasion variability in exposure is not expected to affect the cumulative exposure and efficacy or safety.</p><p><strong><u>Distribution</u></strong></p><p>In patients, dasatinib has a large apparent volume of distribution (2,505 L), coefficient of variation (CV% 93%), suggesting that the medicinal product is extensively distributed in the extravascular space. At clinically relevant concentrations of dasatinib, binding to plasma proteins was approximately 96% on the basis of&nbsp;<em>in vitro&nbsp;</em>experiments.</p><p><strong><u>Biotransformation</u></strong></p><p>Dasatinib is extensively metabolised in humans with multiple enzymes involved in the generation&nbsp;of the metabolites. In healthy subjects administered 100 mg of [<sup>14</sup>C]-labelled dasatinib, unchanged dasatinib represented 29% of circulating radioactivity in plasma. Plasma concentration and measured&nbsp;<em>in vitro&nbsp;</em>activity indicate that metabolites of dasatinib are unlikely to play a major role in the&nbsp;observed&nbsp;pharmacology&nbsp;of&nbsp;the&nbsp;product.CYP3A4&nbsp;is&nbsp;a&nbsp;major&nbsp;enzyme&nbsp;responsible&nbsp;for&nbsp;the metabolism of dasatinib.</p><p><strong><u>Elimination</u></strong></p><p>The mean terminal half-life of dasatinib is 3 hours to 5 hours. The mean apparent oral clearance is 363.8 L/hr (CV% 81.3%).</p><p>Elimination is predominantly in the faeces, mostly as metabolites. Following a single oral dose of [<sup>14</sup>C]-labelled dasatinib, approximately 89% of the dose was eliminated within 10 days, with 4% and 85% of the radioactivity recovered in the urine and faeces, respectively. Unchanged dasatinib accounted for 0.1% and 19% of the dose&nbsp;in urine and faeces, respectively, with the remainder of the dose as metabolites.</p><p><strong><u>Hepatic&nbsp;and&nbsp;renal&nbsp;impairment</u></strong></p><p>The&nbsp;effect&nbsp;of&nbsp;hepatic&nbsp;impairment&nbsp;on&nbsp;the&nbsp;single-dose&nbsp;pharmacokinetics&nbsp;of&nbsp;dasatinib&nbsp;was&nbsp;assessed&nbsp;in&nbsp;8 moderately hepatic-impaired subjects who received a 50 mg dose and 5 severely hepatic-impaired subjects who received a 20 mg dose compared to matched healthy subjects who received a 70 mg dose of dasatinib.&nbsp;The mean Cmax&nbsp;and&nbsp;AUC of dasatinib adjusted for the 70 mg dose were decreased by 47% and 8%, respectively, in subjects with moderate hepatic impairment compared to subjects with normal hepatic function. In severely hepatic-impaired subjects, the mean Cmax&nbsp;and AUC adjusted&nbsp;for&nbsp;the&nbsp;70&nbsp;mg&nbsp;dose&nbsp;were&nbsp;decreased&nbsp;by&nbsp;43%&nbsp;and&nbsp;28%,&nbsp;respectively,&nbsp;compared&nbsp;tosubjects&nbsp;with&nbsp;normal&nbsp;hepatic&nbsp;function&nbsp;(see&nbsp;sections&nbsp;4.2&nbsp;and&nbsp;4.4).</p><p>Dasatinib&nbsp;and&nbsp;its&nbsp;metabolites&nbsp;are&nbsp;minimally&nbsp;excreted&nbsp;via&nbsp;the&nbsp;kidney.</p><p><strong>&nbsp;<u>Paediatric population</u></strong></p><p>The pharmacokinetics of&nbsp;dasatinib have been evaluated in 104&nbsp;paediatric&nbsp;patients&nbsp;with leukaemia&nbsp;or solid tumours (72 who received the tablet formulation and 32 who received the powder for oral&nbsp;suspension).</p><p>In a paediatric pharmacokinetics study,&nbsp;dose-normalized dasatinib exposure (Cavg, Cmin&nbsp;and Cmax)&nbsp;appears similar between 21 patients with CP-CML and 16 patients with Ph+&nbsp;ALL.&nbsp;Pharmacokinetics&nbsp;of&nbsp;the&nbsp;tablet&nbsp;formulation&nbsp;ofdasatinib&nbsp;were&nbsp;evaluated&nbsp;for&nbsp;72&nbsp;paediatric&nbsp;patients with relapsed or refractory leukaemia or solid tumours at oral doses ranging from 60 to 120 mg/m<sup>2</sup>&nbsp;once daily and 50 to 110 mg/m<sup>2</sup>&nbsp;twice daily. Data was pooled across two studies and showed that&nbsp;dasatinib was rapidly absorbed. Mean Tmax&nbsp;was observed between 0.5 and 6 hours and mean half-&nbsp;life&nbsp;ranged&nbsp;from&nbsp;2&nbsp;to&nbsp;5&nbsp;hours&nbsp;across&nbsp;all&nbsp;dose&nbsp;levels&nbsp;and&nbsp;age&nbsp;groups.&nbsp;</p><p>Dasatinib&nbsp;PK&nbsp;showed&nbsp;dose proportionality with a dose-related increase in exposure observed in paediatric patients. There was no&nbsp;significantdifference&nbsp;of&nbsp;dasatinib&nbsp;PK&nbsp;between&nbsp;children&nbsp;and&nbsp;adolescents.&nbsp;The&nbsp;geometric&nbsp;means&nbsp;of dose-normalized&nbsp;dasatinibCmax,&nbsp;AUC&nbsp;(0-T),&nbsp;and&nbsp;AUC&nbsp;(INF)&nbsp;appeared&nbsp;to&nbsp;be&nbsp;similar&nbsp;between&nbsp;children and adolescents at different dose levels.&nbsp;A&nbsp;PPK model-based simulation predicted that the body weight tiered dosing recommendation described for the tablet, in section 4.2, is expected to&nbsp;provide similar exposure to a tablet dose of 60 mg/m<sup>2</sup>.</p><p>These data should be considered if patients are to switch from tablets to powder for oral suspension or vice versa.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The non-clinical safety profile of dasatinib was assessed in a battery of&nbsp;<em>in vitro&nbsp;</em>and&nbsp;<em>in vivo&nbsp;</em>studies&nbsp;in mice, rats, monkeys, and rabbits.</p><p>The primary toxicities occurred in the gastrointestinal, haematopoietic, and lymphoid systems. Gastrointestinal toxicity was dose-limiting in rats and monkeys, as the intestine was a consistent target organ. In rats, minimal to mild decreases in erythrocyte parameters were accompanied by bone marrow changes; similar changes occurred in monkeys at a lower incidence. Lymphoid toxicity in rats consisted of lymphoid depletion of the lymph nodes, spleen, and thymus, and decreased lymphoid organ weights. Changes in the gastrointestinal, haematopoietic and lymphoid systems were reversible following cessation of treatment.</p><p>Renal changes in monkeys treated for up to 9 months were limited to an increase in background kidney mineralisation. Cutaneous haemorrhage was observed in an acute, single-dose oral study in monkeys but was not observed in repeatdose studies in either monkeys or rats. In rats, dasatinib inhibited platelet aggregation&nbsp;<em>in vitro&nbsp;</em>and prolonged cuticle bleeding time&nbsp;<em>in vivo</em>, but did not&nbsp;invoke spontaneous haemorrhage.</p><p>Dasatinib activity&nbsp;<em>in vitro&nbsp;</em>in hERG and Purkinje fiber assays suggested a potential for prolongation of cardiac ventricular repolarisation (QT interval). However, in an&nbsp;<em>in vivo&nbsp;</em>single-dose study in conscious telemetered monkeys, there were no changes in QT interval or ECG wave form.</p><p>Dasatinib was not mutagenic in&nbsp;<em>in vitro&nbsp;</em>bacterial cell assays (Ames test) and was not genotoxic in&nbsp;an&nbsp;<em>in vivo&nbsp;</em>rat micronucleus study. Dasatinib was clastogenic&nbsp;<em>in vitro&nbsp;</em>to dividing Chinese Hamster Ovary (CHO) cells.</p><p>Dasatinib did not affect male or female fertility in a conventional rat fertility and early embryonic development study, but induced embryolethality at dose levels approximating human clinical exposures. In embryofoetal development studies, dasatinib likewise induced embryolethality with associated decreases in litter size in rats, as well as foetal skeletal alterations in both rats and&nbsp;rabbits. These effects occurred at doses that did not produce maternal toxicity, indicating that dasatinib is a selective reproductive toxicant from implantation through the completion of&nbsp;organogenesis.</p><p>In&nbsp;mice,&nbsp;dasatinib&nbsp;induced&nbsp;immunosuppression,&nbsp;which&nbsp;was&nbsp;dose-related&nbsp;and&nbsp;effectively&nbsp;managed&nbsp;by dose reduction and/or changes in dosing schedule. Dasatinib had phototoxic potential in an&nbsp;<em>in vitro&nbsp;</em>neutral red uptake phototoxicity assay in mouse fibroblasts. Dasatinib was considered to be non phototoxic&nbsp;<em>in&nbsp;vivo&nbsp;</em>after&nbsp;a&nbsp;single&nbsp;oraladministration&nbsp;to&nbsp;female&nbsp;hairless&nbsp;mice&nbsp;at&nbsp;exposures&nbsp;up&nbsp;to&nbsp;3-fold the human exposure following administration of the recommended therapeutic dose (based on&nbsp;AUC).</p><p>In a two-year carcinogenicity study, rats were administered oral doses of dasatinib at 0.3, 1, and 3&nbsp;mg/kg/day. The highest dose resulted in a plasma exposure (AUC) level generally equivalent to the human exposure at the recommended range of starting doses from 100 mg to 140 mg daily. A statistically significant increase in the combined incidence of squamous cell carcinomas and papillomas in the uterus and cervix of high-dose females and of prostate adenoma in low-dose&nbsp;males was noted. The relevance of the findings from the rat carcinogenicity study for humans is not&nbsp;known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet&nbsp;core:</u></p><p>Microcrystalline&nbsp;Cellulose&nbsp;PH&nbsp;101,&nbsp;Microcrystalline&nbsp;Cellulose&nbsp;PH&nbsp;102,&nbsp;Lactose&nbsp;monohydrate, Hydroxypropyl Cellulose, Croscarmellose sodium, Magnesium Stearate and Purifed water.</p><p><u>Tablet&nbsp;coat:</u></p><p>Opadry&nbsp;white&nbsp;03O18646&nbsp;(HPMC&nbsp;2910/Hypromellose,&nbsp;Titanium&nbsp;dioxide,&nbsp;Triethyl&nbsp;citrate.)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do&nbsp;not store&nbsp;above&nbsp;30&deg;C.</p><p>Keep&nbsp;out&nbsp;of&nbsp;the&nbsp;sight and&nbsp;reach&nbsp;of&nbsp;children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 blister Pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any&nbsp;unused&nbsp;medicinal product&nbsp;or&nbsp;waste material&nbsp;should&nbsp;be disposed&nbsp;of&nbsp;in&nbsp;accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadawi Biomedical Company, 
Sudair Industrial Zone,
Sudair, 
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>